


14TH EANO MEETING 2019

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

SEPTEMBER 19 - 22, 2019
LYON, FRANCE



POSTER LISTING - EANO 2019

TABLE OF CONTENTS

P01 Liquid biomarker	2
P02 Spinal tumors	2
P03 Patient-reported outcomes	2
P04 Low grade glioma	3
P05 Early clinical trials	5
P06 DIPG	6
P07 Metabolic pathways	7
P08 QoL / QoD	7
P09 Meningeoma	7
P10 Neuroimmunology	8
P11 Preclinical neuro-oncology	9
P12 Immunotherapy	15
P13 Omics in neuro-oncology	16
P14 Clinical neuro-oncology	18
AUTHOR INDEX	31

P01 Liquid biomarker

P01.01

The role of exosome miRNA between tumor cells and microglia during the progression of medulloblastoma

Q. Chang, L. Zhu, N. Li;

Dept. of Pathology, Peking University Health Science Center, Beijing, China.

P01.02

Serum-derived DNA methylation markers distinguish functional and invasiveness subtypes in patients harboring pituitary tumors

A. V. Castro, M. Wells, K. Asmaro, T. S. Sabedot, M. S. Mosella, T. M. Malta, K. Nelson, J. Snyder, A. deCarvalho, A. Mukherjee, D. Chitale, A. Robin, M. Rosenblum, T. Mikkelsen, L. M. Poisson, I. Lee, T. Walbert, A. Bhan, S. Kalkanis, J. Rock, H. Noushmehr;

Henry Ford Health System, Detroit, MI, United States.

P02 Spinal tumors

P02.01

Analysis of Multimodal Intraoperative Monitoring During Intramedullary Spinal Ependymoma Surgery

J. PARK, J. Kim, M. Shin, D. Choi;

The Catholic University of Korea, Incheon, Korea, Republic of.

P03 Patient-reported outcomes

P03.01

Secondary central nervous system lymphoma (SCNSL) in patient with non Hodgkin lymphoma (NHL) : a case report

E. Susanti, N. Suci Rahayu, M. Fuad;

dr. Zainoel Abidin General Hospital, Banda Aceh, Indonesia.

P03.02

Risk of leptomeningeal dissemination in patients treated with postoperative stereotactic radiotherapy of brain metastases

A. Mousli¹, B. Bihir², T. Gustin³, G. Koerts⁴, M. Mouchamps⁵, J. F. Daisne^{1,6};

¹Université Catholique de Louvain CHU-UCL-Namur site Sainte Elisabeth, Namur, Belgium, ²Université Catholique de Louvain, CHU-UCL-Namur site Godinne, Biostatistics Unit, Yvoir, Belgium, ³Université Catholique de Louvain, CHU-UCL-Namur site Godinne, Neurosurgery Dept, Yvoir, Belgium, ⁴Centre Hospitalier Régional Sambre et Meuse, Neurosurgery Dept, Namur, Belgium, ⁵CHC Saint-Joseph, Neurosurgery Dept, Liège, Belgium, ⁶Katholieke Universiteit Leuven, Universitaire Ziekenhuis Leuven, Radiation Oncology Dept, Leuven, Belgium.

P03.03

Dynamics of brain metastasis cavities between resection and adjuvant stereotactic radiotherapy and impact of the delay on local control

A. Mousli¹, B. Bihir², T. Gustin³, G. Koerts⁴, M. Mouchamps⁵, J. F. Daisne^{1,6};

¹Université Catholique de Louvain, CHU-UCL-Namur site Sainte Elisabeth, Radiation Oncology Dept, Namur, Belgium, ²Université Catholique de Louvain, CHU-UCL-Namur site Godinne, Biostatistics Unit, Yvoir, Belgium, ³Université Catholique de Louvain, CHU-UCL-Namur site Godinne, Neurosurgery Dept., Yvoir, Belgium, ⁴Centre Hospitalier Régional Sambre et Meuse, Neurosurgery Dept., Namur, Belgium, ⁵CHC Saint-Joseph, Neurosurgery Dept., Liège, Belgium, ⁶Katholieke Universiteit Leuven, Universitaire Ziekenhuis Leuven, Radiation Oncology Dept., Leuven, Belgium.

P03.04

Signaling questions assessing brain tumor patients' distress in clinical routine - a feasibility study

A. Hartoyo¹, K. Lichtenthaler¹, E. Kurz¹, T. Pantel¹, C. Richter¹, P. Scholz-Kreisel², F. Ringel³, N. Keric³, **M. Renovanz⁴**;

¹Department of Neurosurgery, University Medical Center Mainz, Mainz, Germany, ²Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany, ³Department of Neurosurgery, University Medical Center Mainz, Mainz, Germany, ⁴Interdisciplinary Division of Neurooncology, University Medical Center Tuebingen, Tuebingen, Germany.

P03.05

Could suspected Glioblastomas be Treated without Hystological Diagnosis?

K. Cortés Mateus¹, I. Valduvico Ruiz¹, E. Verger Fransoy¹, E. Pineda Losada¹, L. Oleaga Zufiria¹, T. Pujol Farre¹, J. González Sánchez¹, L. Pedrosa Eguílaz², F. Graus Ribas¹, T. Barreto Zambrano¹, D. Muñoz Guglielmetti¹, C. Castro Cuevas¹, E. Escudero López¹, A. Lloret Puerto¹, J. Sáez Beltrán¹, C. Camacho López¹, C. Conill Llobet¹, G. Oses González¹, S. Garrido Alcantud¹, M. Mollà Armada¹;

¹Hospital Clínico de Barcelona, Barcelona, Spain, ²Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

P03.06

Cavernous malformations of the brainstem: radiosurgical management with gamma knife

K. Abdel Karim^{1,2}, A. M. El-Shehaby^{3,2}, W. A. Reda^{3,2}, R. M. Emad Eldin^{4,2}, A. Nabee^{6,2}, S. Tawadros^{3,2}, P. Khalil⁶;

¹Clinical Oncology Department, Ain Shams University, Cairo, Egypt, ²Gamma Knife Center, Nasser Institute, Cairo, Egypt, ³Neurosurgery Department, Ain Shams University, Cairo, Egypt, ⁴Radiation Oncology Department, National Cancer Institute Cairo University, Cairo, Egypt, ⁵Neurosurgery Department, Benha University, Cairo, Egypt, ⁶Extended Modular Program, Ain Shams University, Cairo, Egypt.

P03.07

Radiosurgical management of trigeminal schwannomas: A single center experience

R. M. Emad Eldin^{1,2}, A. M. El-Shehaby^{3,2}, K. Abdel Karim^{4,2}, W. A. Reda^{3,2}, A. Nabee^{6,2}, S. Tawadros^{3,2};

¹National Cancer Institute, Cairo University, Cairo, Egypt, ²Gamma knife center, nasser institute, Cairo, Egypt, ³Neurosurgery Department, Ain Shams University, Cairo, Egypt, ⁴Clinical Oncology Department, Ain Shams University, Cairo, Egypt, ⁵Neurosurgery Department, Benha University, Benha, Egypt.

P03.08

Large cerebral arteriovenous malformations management with Volume-staged gamma knife radiosurgery

R. M. Emad Eldin^{1,2}, W. A. Reda^{3,2}, A. M. El-Shehaby^{3,2}, K. Abdel Karim^{4,2}, A. Nabee^{6,2}, S. Tawadros^{3,2};

¹National Cancer Institute, Cairo University, Cairo, Egypt, ²Gamma knife center, nasser institute, Cairo, Egypt, ³Neurosurgery Department, Ain Shams University, Cairo, Egypt, ⁴Clinical Oncology Department, Ain Shams University, Cairo, Egypt, ⁵Neurosurgery Department, Benha University, Benha, Egypt.

P03.09

Real world management and prognosis of glioma patients:SYSUCC report from China

D. Li, Y. Chen, C. Guo, Q. Yang, s. Wu, Y. Xia, J. Zeng, x. zhang, C. ke, K. Sai, J. Wang, y. mou, **Z. Chen**;
Sun Yat-sen University Cancer Center, Guangzhou, China.

P03.10

Analyzing the role of reoperation in high grade gliomas: a retrospective study

V. González, J. Ibáñez, J. Fuster, M. Brell;
Son Espases, Palma de Mallorca, Spain.

P03.11

Finding a predictive marker for compliance to TTFIELDS therapy - the comptune study

M. A. Proescholdt¹, A. Haj¹, C. Doenitz¹, A. Brawanski¹, A. Mühlberger², M. Schmidmeier²;

¹Department of Neurosurgery, Regensburg, Germany, ²Department of Clinical Psychology, Regensburg, Germany.

P03.12

Complete versus incomplete resection in newly diagnosed Glioblastoma: Impact on functional Outcome

M. A. Proescholdt, A. Haj, C. Doenitz, K. Schebesch, A. Brawanski;
Department of Neurosurgery, Regensburg, Germany.

P03.13

Evaluation of PIK3CA mutational status in glioma molecular subgroups

C. Brito¹, A. Azevedo^{2,3}, S. Esteves⁴, C. Martins¹, M. Mafra⁵, L. Roque¹, M. Pojo¹;

¹Unidade de Investigação em Patobiologia Molecular (UIPM), Lisboa, Portugal, ²Serviço de Neurologia do Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal, ³Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal, Portugal, ⁴Unidade de Investigação Clínica (UIC), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal, Portugal, ⁵Serviço de Anatomia Patológica do Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal, Portugal.

P03.14

New features of modern 3D conformal external radiotherapy (RT) of benign head tumors in children

F. Antonenko, **E. Slobina**, E. Abbasova, A. Smyslov, A. Dykina, N. Sidibe, S. Abdullaeva, V. Vasilyev;
Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation.

P04 Low grade glioma

P04.01

Return to work in patients with low grade glioma

I. Rydén;

Institute of Neuroscience and Physiology, Göteborg, Sweden.

P04.02

Postponing the medical treatment is possible in selected cases of diffuse low-grade glioma with foci of WHO grade III-IV after total or subtotal resection

A. Darlix¹, V. Rigau², J. Fraisse³, C. Gozè⁴, M. Fabbro⁵, H. Duffau⁶;

¹Institut du Cancer de Montpellier; INSERM U1051, Montpellier Neurosciences Institute, Montpellier, France, ²Department of Pathology, Montpellier University Hospital; INSERM U1051, Montpellier Neurosciences Institute, Montpellier, France, ³Biometrics Unit, Institut du Cancer de Montpellier, University of Montpellier, Montpellier, France, ⁴Pathology and Oncobiology Department, Laboratory of solid tumors biology, Montpellier University Hospital; INSERM U1051, Montpellier Neurosciences Institute, Montpellier, France, ⁵Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France, ⁶Department of Neurosurgery, Montpellier University Hospital; INSERM U1051, Montpellier Neurosciences Institute, Montpellier, France.

P04.03

Radiotherapy for subependymal giant cell astrocytoma: time to challenge a historical ban? Case report and review of the literature

R. Kamel, D. Van den Berge;

Universitair Ziekenhuis Brussel, Jette, Belgium.

P04.04

Different stages of astrocytoma in young adult patient

E. Susanti, R. Kamarlis, N. Suci Rahayu;

dr. Zainoel Abidin General Hospital, Banda Aceh, Indonesia.

P04.05

The Effects and Mechanism Involved in Paclitaxel combined with Shikonin on U87 Glioma Cells

J. SHI;

LiaoNing Cancer Hospital and Institutue, ShenYang, China.

P04.06

The incidence and impact of post-operative stroke in surgery for LGG

a. berger, G. Tzarfati, M. Costa, M. Serafimova, A. Korn, T. Alfasi, A. Kashinian, Z. Ram, **R. Grossman**;

Tel-Aviv Medical Center, Tel-Aviv, Israel.

P04.07

Correlation of ¹⁸F-fluorethyl-L-tyrosine (¹⁸F-FET) uptake in positron emission tomography (PET) and MRI growth rate in low-grade glioma

M. Mueller¹, M. Kamp¹, M. Sabel¹, G. Stoffels², N. Galldiks^{2,3}, K. Langer², M. Rapp¹;

¹Department of Neurosurgery University Medical Center Duesseldorf, Duesseldorf, Germany, ²Research Center Juelich, Institute of Neuroscience and Medicine (INM-3, -4), Juelich, Germany, ³Department of Neurology, University Hospital Cologne, Cologne, Germany.

P04.08

The role of SCN1A in glioblastomas and mixed neuronal glial tumors of pediatric age

L. Giunti¹, V. Cetica², V. De Gregorio³, D. Me², C. Barba², A. Buccoliero⁴, L. Genitor⁵, R. Guerrini², S. Giglio¹, I. Sard³, M. Guidi¹, **M. Censullo**¹;

¹Medical Genetics Unit, Meyer Children Hospital, Firenze, Italy, ²Child Neurology Unit, Meyer Children's University Hospital, Firenze, Italy, ³Neuro-Oncology Unit, Meyer Children's University Hospital, Firenze, Italy, ⁴Pathology Unit Meyer Children's University Hospital, Firenze, Italy, ⁵Neurosurgery Unit, Meyer Children's University Hospital, Firenze, Italy.

P04.09

Patterns of care and impact on survival of first salvage therapy in high-risk grade II gliomas following initial temozolomide

A. Pellerino¹, L. Bello², M. Conti Nibal², F. Bruno¹, F. Mo¹, E. Pronello¹, F. Franchino¹, R. Soffietti¹, R. Rudà¹;

¹Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy, ²Department of Neurosurgery, Humanitas Hospital, Milan, Italy.

P04.10

IDH-wildtype low grade gliomas: overall survival and prognostic indicators

G. Berzero^{1,2}, A. Di Stefano^{3,4}, S. Ronchi⁵, C. Villa⁶, Y. Marie⁴, K. Hoang-Xuan^{1,4}, J. Delattre^{1,4}, K. Mokhtari⁵, M. Sanson^{1,4};

¹APHP GH Pitié Salpêtrière, Service de Neurologie 2-Mazarin, Paris, France, ²Università degli studi di Pavia, Pavia, Italy, ³Department of Neurology, Foch Hospital, Suresnes, France, ⁴Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, Paris, France, ⁵APHP GH Pitié Salpêtrière, Laboratoire R Escourolle, Paris, France, ⁶Department of Pathology, Foch Hospital, Paris, France.

P04.11

Voxelwise correlation between vascular MRI parameters obtained with ASL and DSC is decreased in IDH-wt non-enhancing glioma

E. A. H. Warnert, F. Incekara, A. J. P. E. Vincent, J. W. Schouten, **M. J. van den Bent**, P. J. French, H. J. Dubbink, J. M. Kros, J. A. Hernandez-Tamames, M. Smits;

Erasmus MC, Rotterdam, Netherlands.

P04.12

Characteristics of IDH-mutant gliomas with non-canonical IDH mutations

L. Poetsch¹, C. Dehais², J. Fréne³, A. Siegfried⁴, S. Lacomme⁵, R. Seizeur⁶, D. Larrieu-Ciron⁴, D. Cappellen⁷, D. Loussouarn³, C. Ferec⁶, S. Eimer⁸, C. Carpentier², M. Sanson², J. Delattre², D. Figarella-Branger⁹, F. Ducray¹⁰, POLA network, **C. Bronnimann**¹;

¹CHU Saint André, BORDEAUX, France, ²APHP, Paris, France, ³Institut de Cancérologie de l'Ouest, Saint Herblain, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nancy, Nancy, France, ⁶CHU Brest, Brest, France, ⁷CHU Haut Leveque, PESSAC, France, ⁸CHU Pellegrin, BORDEAUX, France, ⁹CHU La Timone, Marseille, France, ¹⁰Hopital Neurologique, Lyon, France.

P04.13

Prognostic role of single stranded DNA binding protein 2 in IDH wild type lower grade glioma

Y. Chai, W. Liu, L. Hu, Y. Zhang, **P. Liang**;

School of Clinical Medicine, Tsinghua University, Department of Neurosurgery, Beijing, China.

P04.14

Loss of oligodendroglial features at recurrence in five diffuse low-grade glioma patients treated with repeated surgery

A. Darlix^{1,2}, H. Duffau^{3,2}, V. Rigau^{4,2}, C. Gozé^{5,2};

¹Institut du Cancer de Montpellier, University of Montpellier, Montpellier, France, ²Institute for Neuroscience of Montpellier, INSERM U1051, Team "Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors," Saint Eloi Hospital, Montpellier University Medical Center, Montpellier, France, ³Department of Neurosurgery, Gui de Chauliac Hospital, 80 avenue Augustin Fliche, Montpellier University Medical Center, Montpellier, France, ⁴Department of Pathology, Gui de Chauliac Hospital, 80 avenue Augustin Fliche, Montpellier University Medical Center, Montpellier, France, ⁵Tumor and Cell Biology Laboratory, Arnaud de Villeneuve Hospital, 371 Av. du Doyen Gaston Giraud, Montpellier University Medical Center, Montpellier, France.

P04.15

Impact of histone lysine methyltransferases SETDB1, SETD2, SUV39H1, MLL2, EZH2 and their corresponding histone marks in pediatric astrocytomas

A. Klonou¹, P. Korkolopoulou², A. N. Gargalionis¹, M. Themistocleous³, S. Sgouros⁴, A. G. Papavassiliou¹, C. Piperi¹;

¹Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Department of Pathology, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Neurosurgery, "Agia Sophia" Children's Hospital, Athens, Greece, ⁴Department of Neurosurgery, "Mitera" Children's Hospital, Athens, Greece.

P04.16

TP53 mutations in codon 273 is predictive of overall survival in astrocytoma patients

H. Noor, R. Rapkins, K. McDonald;

University of New South Wales, Sydney, Australia.

P04.17

Differential diagnosis of gliomas using Digital Holographic Microscopy

V. L. Calin¹, **G. E. D. Petrescu**², M. Mihailescu³, F. M. Brehar^{2,4}, M. Lisievici⁵, B. Comanescu⁶, N. Tarba³, M. R. Gorgan^{2,4}, T. Savopol¹, M. G. Moisescu¹;

¹Biophysics and Cellular Biotechnology Dept., "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, ²"Bagdasar-Arseni" Clinical Hospital, Neurosurgery Department, Bucharest, Romania, ³Physics Dept., Faculty of Applied Sciences, Politehnica University, Bucharest, Romania, ⁴"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania, ⁵"Bagdasar-Arseni" Clinical Hospital, Pathology Department, Bucharest, Romania, ⁶Optoelectronica S. A., Măgurele, Romania.

P04.18

Management of diffuse gliomas using hypnosis-aided awake surgery: oncological and functional preliminary results in a series of 16 cases

T. Picart, G. Pardey Bracho, R. Ameli, L. Berner, L. Thomas, S. Cartalat, J. Honnorat, F. Ducray, J. Guyotat;

Hospices Civils de Lyon - Hôpital Neurologique Pierre Wertheimer, Bron, France.

P04.19

Analysis of tumor immune microenvironment and immune checkpoint modulators across infantile and pediatric pilocytic astrocytomas to elucidate the role of immunotherapy in these tumors

K. Kaur, V. Suri, M. C. Sharma, A. Garg, A. Suri, C. Sarkar;

All India Institute of Medical Sciences, New Delhi, New Delhi, India.

P05 Early clinical trials

P05.01

the efficacy of donepezil on cognitive function in postoperative brain tumor patients

Y. Diansari^{1,2}, y. harun^{1,2}, s. marisdina^{1,2}, y. felistia^{1,2};

¹Neurology Department, Mohammad Hoesin Hospital, Palembang, Indonesia, ²Sriwijaya University, Palembang, Indonesia.

P05.02

A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon- α 2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001)

B. Gentner¹, F. Cicerò², F. DiMeco³, F. Legnani³, M. Eoli³, B. Pollo³, F. Farina², S. Mazzoleni⁴, C. Russo⁴, L. Naldini¹, **G. Finocchiaro³;**

¹San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy, ²Ospedale San Raffaele, Milan, Italy, ³Istituto Neurologico Carlo Besta, Milan, Italy, ⁴Genenta Science, Milan, Italy.

P05.03

OptimalTTF-1: Final results of a phase 1 study at first glioblastoma recurrence examining targeted craniotomy to enhance Tumor Treating Fields intensity

A. R. Korshøj¹, **N. Mikić**¹, S. Lukacova², J. C. H. Sørensen¹, F. L. Hansen¹, A. Thielscher³, S. O. S. Cortnum¹, T. L. Guldborg², Y. Ramshad-Lassen², C. Rahbek⁴, K. E. Severinsen⁵, G. von Oettingen¹;

¹Aarhus University Hospital, Dept. of Neurosurgery, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, ³The Technical University of Denmark, DTU Electro, Biomedical Engineering, Kgs. Lyngby, Denmark, ⁴Aarhus University Hospital, Dept. of Neuroradiology, Aarhus, Denmark, ⁵Aarhus University Hospital, Dept. of Neurology, Aarhus, Denmark.

P05.04

Phase 2 open-label study of maintenance treatment with ibrutinib following first line methotrexate-based immuno-chemotherapy in elderly patients with primary CNS lymphoma (PCNSL)

O. Bairey, A. Amiel, S. Yust-Katz, R. Gurion, **T. Siegal**;

Rabin Medical Center, Petach Tikva, Israel.

P05.05

Safety and feasibility of temporary blood-brain barrier disruption with the SonoCloud-1/3 implantable ultrasound device in recurrent glioblastoma

A. Idbaih¹, M. Canney², G. Bouchoux³, C. Desseaux², A. Vignot², C. Lafon⁴, J. Chapelon⁵, J. Delattre¹, L. Belin⁶, A. Carpentier⁷;

¹Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, F-75013, Paris, France, ²CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France, ³CarThera, Institut du Cerveau et de la Moelle épinière (ICM), Paris, France, ⁴LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, Lyon, France, ⁵LabTAU, INSERM, Centre Léon Bérard, Université Lyon 1, Univ Lyon, F-69003, Lyon, France, ⁶Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, INSERM, CIC-1421, Paris, France, ⁷Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires La Pitié-Salpêtrière, Service de Neurochirurgie and Sorbonne Université, UPMC Univ Paris 06, Paris, France.

P05.06

Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O₆-methylguanine-methyltransferase (MGMT) promoter status

P. Y. Wen¹, J. de Groot², J. D. Battiste³, S. A. Goldlust⁴, J. Garner⁵, J. Simpson⁶, A. Olivero⁶, T. Cloughesy⁷;

¹Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States, ²Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, ³Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, United States, ⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, United States, ⁵Kazia Therapeutics Limited, Sydney, Australia, ⁶Genentech Inc, South San Francisco, CA, United States, ⁷Department of Neurology, Ronald Reagan UCLA Medical Center University of California, Los Angeles, CA, United States.

P05.07

Effect of Tumor-Treating Fields plus Short-Course Radiation with or without Temozolomide in Elderly Patients with Glioblastoma (GERAS Trial)

S. J. Höne¹, J. Krisam², C. Jäkel¹, D. Schmitt¹, K. Lang¹, R. El Shafie¹, S. Adeberg¹, A. Unterberg³, S. Rieken¹, M. Kieser², J. Debus¹, D. Bernhardt¹;

¹Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, ²Institute of Medical Biometry and Informatics, Heidelberg University Hospital, Heidelberg, Germany, ³Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.

P05.08

High-grade gliomas and immunotherapeutic early phase clinical trials: a single-center experience

M. Simonelli¹, P. Persico², A. Dipasquale², E. Lorenz², L. Giordano², F. Pessina¹, P. Navarra², M. Scorsetti¹, L. Bello³, A. Santoro¹;

¹Humanitas Clinical and Research Center; Humanitas University, Rozzano (Milan), Italy, ²Humanitas Clinical and Research Center, Rozzano (Milan), Italy, ³Humanitas Clinical and Research Center; University of Milan, Rozzano (Milan), Italy.

P06 DIPG

P06.01

Delta24-ACT oncolytic adenovirus as a therapeutic approach for DIPG

V. Laspidea¹, M. Puigdelloses¹, M. García-Moure¹, I. Iñigo-Marco¹, J. Gallego¹, A. Patiño-García¹, J. Fueyo², C. Gomez-Manzano², **M. M. Alonso**¹;

¹University of Navarra, Pamplona, Spain, ²UT MD Anderson Cancer Center, Houston, TX, United States.

P06.02

Tumor Treating Fields therapy application in 3-year-old grade 4 glioma patient is feasible and safe

S. Kietz¹, M. Steir²;

¹Ped. Oncology, Giessen, Germany, ²Neurosurgery, Giessen, Germany.

P07 Metabolic pathways

P07.01

Functional role of N-Myc in SHH type TP53 mutated MB's metabolism

K. Yokogami;

Section of Neurosurgery, Department of Clinical Neuroscience, Faculty of Medicine, University of Miy, Miyazaki, Japan.

P07.02

Enhanced glycolysis in glioblastomas is associated with tumor cells migration

M. Ndiaye¹, C. Rébé^{1,2}, A. Ilie¹, L. Ménégaut², T. Pilot¹, F. Ghiringhelli^{1,2};

¹Centre Georges François Leclerc, Dijon, France, ²Inserm U1231, Dijon, France.

P08 QoL / QoD

P08.01

Impact of cannabis use on quality of life in patients with central nervous system tumors

J. E. Rodriguez Almaraz, N. A. Butowski, S. M. Chang, N. A. E. Oberheim-Bush, J. R. Clarke, J. W. Taylor, R. A. Buerki, M. S. Berger;

University of California, San Francisco, San Francisco, CA, United States.

P08.02

Israeli experience with Patient Reported Outcomes (PROs) in the field of neuro oncology - Quality of Life Assessment Metrics (QAM)

T. Wagner, E. Jan, S. Bley, R. Cohen, O. Furman, A. Talianski, L. Zach;

Sheba Medical Center, Ramat Gan, Israel.

P08.03

Separation and divorce after the diagnosis of child's brain tumor

I. Sardi, M. Censullo, M. Rousseau, M. Guidi, F. Giordano, C. Fonte, S. Farina, F. Carra, L. Genitori;

Neuro-Oncology Unit, Florence, Italy.

P08.04

Glioblastoma and Alzheimer pathology: lessons from a single case with practical implications and need for further research

J. Gállego Pérez-Larraya, I. Esparragosa, M. Puigdelloses, M. Idoate, M. Alonso;

Clínica Universidad de Navarra, Pamplona, Spain.

P08.05

Cognitive impairment in patients with newly-diagnosed high-grade gliomas

M. Ribeiro^{1,2}, T. Durand³, J. Jacob⁴, D. Psimaras¹, G. Noel⁴, L. Feuvret¹, K. Hoang-Xuan¹, M. Rousset⁵, O. Godefroy⁵, M. Bernier⁶, D. Ricard^{7,2};

¹Hôpital de la Pitié Salpêtrière, Paris, France, ²CNRS UMR 8257, Paris, France, ³Université Paris Descartes, Paris, France, ⁴Centre de lutte contre le cancer Paul Strauss, Strasbourg, France, ⁵Centre hospitalier universitaire d'Amiens, Amiens, France, ⁶Institut de radioprotection et de sûreté nucléaire, Fontenay-aux-Roses, France, ⁷Hôpital d'instruction des armées de Percy, Clamart, France.

P08.06

Clinical value scores for treatment of newly diagnosed glioblastoma with TTFields

J. Kelly¹, C. Proeschold²;

¹Novocure, Portsmouth, NH, United States, ²Novocure, Root, Switzerland.

P09 Meningeoma

P09.01

case series: meningioma in young adult male

Y. Diansari^{1,2}, N. karindang^{1,2}, d. angggraeni^{1,2};

¹Neurology Department, Mohammad Hoesin Hospital, Palembang, Indonesia, ²faculty of Medicine of Sriwijaya university, Palembang, Indonesia.

P09.02

Surgical treatment for intracranial meningiomas in elderly patients growing during follow-up study

M. Okuma;

Nakamura Memorial Hospital, Sapporo, Japan.

P09.03

Array-CGH analysis in meningiomas adds further information of biological behavior

C. Calatozzolo, A. Rizzo, V. Girgenti, A. Saladino, M. Patanè, F. Di Meco, B. Pollo, F. L. Sciacca;

Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano, Italy.

P09.04

Natural history of meningiomas: review with meta-analyses

S. Nakasu¹, Y. Nakasu²;

¹Kusatsu General Hospital, Kusatsu, Japan, ²Shiga University of Medical Science, Ohtsu, Japan.

P09.05

¹⁷⁷Lu-DOTATATE therapy in progressive meningioma

M. Mütter¹, W. Rolf², B. Zinnhardt², M. Schäfers², K. Rahbar², B. Brokinkel¹, W. Stummer¹;

¹University Hospital Münster, Dept. of Neurosurgery, Münster, Germany, ²University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany.

P09.06

Risk factors associated with Meningioma in a Cohort of 2 Million Israeli Adolescents

S. Yust-Katz¹, E. Derzane², L. Keinan³, A. Amiel¹, A. Honig⁴, Y. Laviv⁵, A. Kanner⁶, G. Twig⁴, **T. Siegal¹;**

¹Davidoff Cancer Center at Rabin Medical Center, Petach-Tikva, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³Ministry of Health, Tel Aviv, Israel, ⁴IDF, Ramat Gan, Israel, ⁵Neuro-Surgery Department at Rabin Medical Center, Petach-Tikva, Israel, ⁶Neuro-Surgery Department Rabin Medical Center, Petach-Tikva, Israel.

P09.07

Constitutive activation of the EGFR-STAT1 axis increases proliferation of meningioma tumour cells

C. O. Hanemann¹, S. Ferluga¹, D. Baiz¹, V. Sharma¹, C. L. Adams¹, K. Bassiri¹, J. Dunn¹, E. Ercolano¹, K. Kurian², D. A. Hilton³;

¹Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom, ²Department of Neuropathology, Pathology Sciences, Southmead Hospital, Bristol, United Kingdom, ³Cellular and Anatomical Pathology, Plymouth University Hospitals NHS Trust, Plymouth, United Kingdom.

P09.08

Increased incidence of intracranial meningiomas in patients with acromegaly

J. Engelhardt¹, M. Nunes¹, C. Pouchieu², F. San-Galli¹, E. Gimberty¹, J. Vignes¹, F. Laurent¹, J. Berge¹, I. Baldi², A. Tabarin¹, H. Loiseau¹;

¹CHU de Bordeaux, Bordeaux, France, ²Université de Bordeaux, Bordeaux, France.

P10 Neuroimmunology

P10.01

Anti-migration and anti-invasion effects of curcumin via suppression of fascin expression in glioblastoma cells

P. Ki-Su¹, S. Yoon¹, J. Hwang², H. Ahn²;

¹Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of, ²Kyungpook National University Hospital, Daegu, Korea, Republic of.

P10.02

Differentiating microglia and tumour associated macrophages in high grade glioma

Z. Woolf, M. Swanson, T. Park, A. Brooks, M. Dragunow;

The University of Auckland, Auckland, New Zealand.

P10.03

Immunological differences between patient-matched normal-derived and GBM-derived pericytes

J. Macapagal¹, A. Brooks^{2,3}, P. Schweder⁴, E. Mee⁴, R. Faull¹, T. I. H. Park¹, M. Dragunow¹;

¹Center for Brain Research, Auckland, New Zealand, ²Maurice Wilkins Centre, Auckland, New Zealand, ³Auckland Cytometry, Faculty of Science, Auckland, New Zealand, ⁴Department of Neurosurgery, Auckland City Hospital, Auckland, New Zealand.

P10.04

Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors

R. Velasco¹, A. Argyriou², J. Bruna¹, G. G. Anastopoulou³, M. Alemany¹, M. Simó¹, J. M. Piulats⁴, E. Nadal⁴, H. P. Kalofonos⁵;

¹Hospital Universitari de Bellvitge- ICO I Hospitalet, L'Hospitalet, Barcelona., Spain, ²Neurological Department, Saint Andrew's General Hospital of Patras, Saint Andrew's General Hospital of Patras, Greece, ³Department of Medicine-Oncology Unit, Saint Andrew's General Hospital of Patras, Saint Andrew's General Hospital of Patras, Greece, ⁴ICO I Hospitalet, L'Hospitalet, Barcelona., Spain, ⁵Department of Medicine-Oncology Unit, Saint Andrew's General Hospital of Patras, Greece.

P10.05

NKG2DL expression and dormancy in cerebral metastases: impact of chemotherapeutic treatment

C. Flueh, R. Hufnagel, M. Synowitz, J. Held-Feindt;

Klinik für Neurochirurgie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.

P10.06

Stiff limb syndrome associated to anti NMDA-R antibodies

C. Birzu¹, L. Jaume¹, S. Rostomashvili², J. Honnorat³, G. Berzero^{1,4}, D. Psimaras^{1,5};

¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2-Mazarin et Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CRICM), UMRs 975, Paris 75013, France; Inserm U 975, CNRS, UMR, Paris, France, ²Centre Hospitalier Interregional Robert Ballanger Aulnay Sous Bois, Aulnay sous Bois, France, ³Centre de Référence National pour les Syndromes Neurologiques Paraneoplasiques, Hôpital Neurologique, Lyon, France ; SynatAc Team, NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon, France, Lyon, France, ⁴IRCCS Mondino Foundation, Pavia, Italy, Pavia, Italy, ⁵Centre de Compétence des Syndromes Neurologiques Paraneoplasiques et Encéphalites Autoimmunes, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, Paris, France.

P11 Preclinical neuro-oncology

P11.01

TMZ-LEV- IFN cocktail regimen significantly inhibited the growth of glioma

X. Ni, Y. Qu, J. Wang, F. Chen, H. Cai, Y. Yu, Y. Yu, Z. Yu, Z. Cen, Z. Chen;

Department of Neurosurgery, Sun Yat-sen University Cancer Center, Guang zhou, China.

P11.02

Hypothermia effect on glioblastoma cell viability, proliferation and migration

C. Fulbert¹, C. Gaude¹, E. Sulpice², S. Chabardès^{1,3}, D. Ratel¹;

¹Univ. Grenoble Alpes, CEA, LETI, Clinatec, F-38000, Grenoble, France, ²Univ. Grenoble Alpes, CEA, INSERM, IRIG-BGE U1038, F-38000, Grenoble, France, ³Neurosurgery Department, CHU Grenoble Alpes, F-38000, Grenoble, France.

P11.03

Next generation sequencing-identified *IDH-1*, *ATRX*, *TP53* mutation and *MYCN* amplification in glioblastoma with primitive neuroectodermal tumor-like feature and extensive subarachnoid spread: a case report

K. Lee, C. Gheeyoung;

Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of.

P11.04

Study of molecular features of migrating human glioblastoma cells in vitro

G. Pavlova¹, D. Panteleev², S. Pavlova³, E. Savchenko⁴, L. Zakharova², A. Potapov⁵, A. Revishchin²;

¹Institute of Gene Biology, RAS;N.N. Burdenko Neurosurgery Research Institute; Sechenov First Moscow State Medical University, Moscow, Russian Federation, ²Institute of Gene Biology, RAS, Moscow, Russian Federation, ³Pirogov Russian National Research Medical University, Moscow, Russian Federation, ⁴Ltd Apto-Pharm, Moscow, Russian Federation, ⁵N.N. Burdenko Neurosurgery Research Institute, Moscow, Russian Federation.

P11.05

Reappraisal of CNS embryonal tumors, not otherwise specified and *RELA* fusion negative supratentorial ependymomas using immunohistochemistry and sequencing for *BCOR*

A. Nambirajan, N. Gurung, A. Sashidharan, A. Sharma, S. Kedia, A. Garg, V. Suri, C. Sarkar, M. Sharma;

All India Institute of Medical Sciences, New Delhi, India.

P11.06

Non epigenetic effect of vorinostat in glioblastoma cells

T. Perez, **R. Berges**, H. Maccario, D. Braguer, S. Honoré;

UMR 7051, Institut de Neurophysiopathologie (INP), Marseille, France.

P11.07

LAPTM5 functions as a tumor suppressor via CD40 - NF κ B pathway inhibition and represents a potential biomarker for temozolomide sensitivity in CD40 proficient glioblastoma

A. Berberich^{1,2}, F. Bartels^{1,2}, Z. Tang^{1,3}, S. Pusch¹, N. Huckle¹, T. Kessler^{1,2}, Z. Dong⁴, B. Wiestler⁵, F. Winkler^{1,2}, M. Platten^{1,6}, W. Wick^{1,2}, A. Abdollahi^{1,3}, D. Lemke^{1,2};

¹German Cancer Research Center, Heidelberg, Germany, ²Department of Neurology, University Hospital, Heidelberg, Germany, ³Division of Molecular & Translational Radiation Oncology, University hospital, Heidelberg, Germany, ⁴Tongji Hospital, Department of Neurosurgery, Wuhan, China, ⁵Department of Neuroradiology, Klinikum rechts der Isar der Technischen Universität, München, Germany, ⁶Department of Neurology, Medical Faculty Mannheim, Mannheim, Germany.

P11.08**Defining EGFR amplification status for clinical trial inclusion**

P. French¹, M. Eolf², J. Sepulveda³, I. de Heer¹, J. M. Kros¹, A. Walenkamp⁴, J. Frene⁵, E. Franceschi⁶, P. Clement⁷, M. Weller⁸, P. Ansell⁹, J. Looman⁹, E. Bain⁹, M. Morfouace¹⁰, T. Gorlia¹⁰, M. van den Bent¹;

¹Erasmus MC Hersentumorcentrum, Rotterdam, Netherlands, ²Carlo Besta, Milano, Italy, ³Univ Hospital, Madrid, Spain, ⁴UMCG, Groningen, Netherlands, ⁵Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France, ⁶Azienda USL/IRCCS Institute of Neurological Sciences, Bologna, Italy, ⁷UZ Leuven, Leuven, Belgium, ⁸University Hospital and University of Zurich, Zurich, Switzerland, ⁹AbbVie, North Chicago, IL, United States, ¹⁰EORTC HQ, Brussels, Belgium.

P11.09**Pan-RTK inhibition of sLRIG1 mediates AXL downregulation in Glioblastoma**

V. Neirinckx¹, A. Hau¹, A. Schuster¹, S. Fritah¹, A. Chevigné², M. H. H. Schmidt³, S. P. Niclou¹;

¹NorLux Neuro-Oncology Laboratory, Dept of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg, ²Immuno-pharmacology and interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg, Luxembourg, ³Molecular Signal Transduction Laboratories, Institute for Microscopic Anatomy and Neurobiology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

P11.10**The IFN γ pathway mediates brain metastasis formation of breast cancer**

R. Pedrosa¹, **J. M. Kros**¹, B. Schrijver², R. Marques³, P. Leenen², W. Dik², C. van Eijck¹, D. Mustafa¹;

¹TIP laboratory, Rotterdam, Netherlands, ²Dept. of Immunology, Erasmus MC, Rotterdam, Netherlands, ³Dept. of Urology, Erasmus MC, Rotterdam, Netherlands.

P11.11**Circulating Pro-Angiogenic Cells and Proteins in Patients with Glioma and Acute Myocardial Infarction: Differences in Neovascularization between Neoplasia and Tissue Regeneration**

K. Huizer¹, A. Sacchetti², W. Dik³, **J. M. Kros**¹, D. Mustafa¹;

¹TIP laboratory, Rotterdam, Netherlands, ²Dept. of Pathology, Erasmus MC, Rotterdam, Netherlands, ³Dept. of Immunology, Erasmus MC, Rotterdam, Netherlands.

P11.12**Periostin is expressed by pericytes and is crucial for angiogenesis in glioma**

k. Huizer¹, **J. M. Kros**¹, C. Zhu¹, I. Chiriff², B. Krist¹, C. Cheng², D. Mustafa¹;

¹TIP laboratory, Rotterdam, Netherlands, ²Lab for Experimental Cardiology, Erasmus MC, Rotterdam, Netherlands.

P11.13**Radiotherapy combined with a multimodal imaging approach in a glioblastoma preclinical model**

D. Salvatore^{1,2}, G. Shaw¹, J. Wright³, I. Teh³, J. Koch-Paszkowski³, L. Murray¹, A. Scarsbrook¹, J. Schneider³, L. Ottobrin⁴, S. Short¹;

¹Leeds Institute of Medical Research (LIMR), Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom, ²Department of Pathophysiology and Transplantation, University of Milan, Segrate, Milan, Italy, ³Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), School of Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Pathophysiology and Transplantation, University of Milan, Segrate-Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Milan, Italy.

P11.14**The addition of hyperbaric oxygen to the treatment of T98G glioblastoma cell cultures with selected CK2 inhibitor TDB enhances its anti-tumour effect**

E. Pucko, R. Ostrowski, M. Zielinska, E. Matyja;

Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.

P11.15**Exosomal MicroRNA expression profiling altered by high TRAP1 expression in glioblastoma**

J. Wu;

Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

P11.16**The stemness and invasiveness of glioblastoma tumorspheres were suppressed by combined treatment with 2'-hydroxycinnamaldehyde and temozolomide**

W. Kim;

Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Med, Seoul, Korea, Republic of.

P11.17**Splicing dysregulation drives glioblastoma malignancy: SRSF3 as a potential therapeutic target to impair glioblastoma progression**

A. C. Fuentes-Fayos^{1,2}, M. C. Vázquez-Borrego^{1,2}, J. M. Jiménez-Vacas^{1,2}, L. Bejarano³, C. Blanco-Acevedo^{1,4}, R. Sánchez-Sánchez^{1,5}, J. Solivera^{1,4}, M. A. Blasco³, J. P. Castaño^{1,2}, R. M. Luque^{1,2};

¹Maimonides Institute of Biomedical Research of Cordoba (IMIBIC)/Reina Sofia University Hospital (HURS), Cordoba, Spain, ²Department of Cell Biology, Physiology and Immunology, CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), University of Cordoba, Cordoba, Spain, ³Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, ⁴Neurology Service, Reina Sofia University Hospital (HURS), Cordoba, Spain, ⁵Pathology Service, Reina Sofia University Hospital (HURS), Cordoba, Spain.

P11.18

Tumor treating fields (TTFields) treatment of spinal cord metastases

A. Kinzel¹, O. Yesharim², A. Naveh², Z. Bomzon²;

¹Novocure GmbH, Root, Switzerland, ²Novocure Ltd., Haifa, Israel.

P11.19

Glioblastoma cancer stem cells proliferation and cell cycle arrest under TTFields influence

M. Mazzanti, I. Verduci, G. Cannavale, I. Pyromali, R. Poloni, D. Rampini;

Dept Bioscience, Milano, Italy.

P11.20

Assessing TTFields-response and associated gene expression in various human cancer cell lines

A. Kinzel¹, G. Lavy-Shaha², M. Gilad², R. Schneiderman², K. Gotlib², E. Zeev², Y. Porat², M. Munster², U. Weinberg², E. Kirson², Y. Palt²;

¹Novocure GmbH, Root D4, Switzerland, ²Novocure Ltd., Haifa, Israel.

P11.21

Treating numerous secondary tumors in the brain with tumor treating fields: Simulation study to identify optimal transducer array layout

A. Kinzel¹, O. Yesharim², A. Naveh², Z. Bomzon²;

¹Novocure GmbH, Root D4, Switzerland, ²Novocure Ltd., Haifa, Israel.

P11.22

Radiotherapy effects in GBM Rat model CNS1

O. Furman¹, D. Daniels², D. Guez², D. Last², S. Sharab², A. Talianski¹, Y. Mardor², L. Zach¹;

¹Sheba Medical Center, Neuro-Oncology Unit, Ramat Gan, Israel, ²Sheba Medical Center, Advanced Technology Center, Ramat Gan, Israel.

P11.23

Oncolytic adenovirus Delta-24-RGD exerts a potent anti-tumor effect in preclinical models of atypical teratoid/rhabdoid tumors

M. Garcia Moure^{1,2}, M. González Huariz^{1,2}, L. Marrodán^{1,2}, A. Patiño-García^{1,2}, **M. M. Alonso^{1,2}**;

¹University Hospital of Navarra, Pamplona, Spain, ²Health Research Institute of Navarra (IDISNA), Pamplona, Spain.

P11.24

CR13626, an oral tyrosine kinase inhibitor crossing the blood brain barrier, reduces tumour growth and prolongs survival in a mouse model of glioblastoma

C. Galimberti^{1,2}, M. Montagna¹, T. Piepoli¹, O. Letari¹, G. Caselli¹, R. Artusi¹, M. Colovic¹, S. Persiani¹, L. C. Rovati¹;

¹Rottapharm Biotech, Monza, Italy, ²University of Milano - Bicocca, Monza, Italy.

P11.25

Assessing electrical properties of cells as predictive marker for patient-specific TTFields response and optimal frequency

A. Kinzel¹, E. Zeev², K. Gotlib², C. Wenger¹, A. Naveh², Z. Bomzon², E. Kirson², U. Weinberg², Y. Palt²;

¹Novocure GmbH, Root, Switzerland, ²Novocure Ltd., Haifa, Israel.

P11.26

Genome-wide shRNA screen identifies candidate genes driving glioblastoma invasion

A. Schuster¹, V. Neirinckx¹, E. Klein¹, P. V. Nazarov¹, A. Oudin¹, A. Muller¹, F. Azuaje¹, C. Herold-Mende², B. Klink³, S. P. Niclou¹;

¹Luxembourg Institute of Health, Luxembourg, Luxembourg, ²University of Heidelberg, Heidelberg, Germany, ³Laboratoire National de Santé, Dudelange, Luxembourg.

P11.27

Drug screening of available anti-cancer drugs on patient-derived GBM cultures identifies candidate treatments for a subpopulation of GBM patients

I. Ntafoulis¹, T. Kers¹, M. van der Kaaij¹, R. Balvers¹, J. Hayes², J. van Rij¹, R. Tching³, A. Lindner⁴, J. Prehn⁴, A. Kremer^{1,3}, C. Dirven¹, S. Leenstra¹, M. Lamfers¹;

¹Dept of Neurosurgery, Brain Tumors Center, Erasmus MC, Rotterdam, Netherlands, ²Neurological Surgery, UCSF School of Medicine, San Francisco, CA, United States, ³Information Technology for Translational Medicine (ITTM), Luxembourg, Luxembourg, ⁴Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.

P11.28

Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) *in vivo*

A. F. Keßler¹, E. Salvador¹, D. Domröse¹, M. Burek², C. Tempel Brami³, T. Voloshin Sela³, M. Gilad³, R. Ernestus¹, M. Löhr¹, C. Förster², C. Hagemann¹;

¹University of Würzburg, Department of Neurosurgery, Tumorbiology Laboratory, Würzburg, Germany, ²University of Würzburg, Department of Anesthesia and Critical Care, Division Molecular Medicine, Würzburg, Germany, ³Novocure, Haifa, Israel.

P11.29

Development of ex vivo models for deeper insights into the biology and therapeutic targeting of tumor microtubule networks in gliomas

E. Jung¹, D. Domínguez Azorín², D. Hausmann², M. Mall³, P. Koch⁴, W. Wick¹, F. Winkler¹;

¹Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany, ²CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany, ³Cell Fate Engineering and Disease Modeling Group, German Cancer Research Center, Heidelberg, Germany, ⁴Central Institute of Mental Health (ZI), Mannheim, Germany.

P11.30

Special VEGF_{90kDa} form in exosome from GBM cells activates TAZ in endothelial cells to promote angiogenesis and contributes bevacizumab resistance

Z. Wang, y. Yuan, C. Xu, Y. Liu;

Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

P11.31

EB1-dependent survival of glioblastoma tumor-bearing mice after treatment with the novel checkpoint activator BAL101553 is associated with inhibition of cancer stem-like cell-mediated tumor angiogenesis and astrocytic differentiation

R. BERGES¹, A. Tchoghandjian¹, A. Serge¹, S. Honore¹, D. Figarella-Branger¹, F. Bachmann², H. Lane², D. Braguer¹;

¹Aix-Marseille Univ, Marseille, France, ²Basilea Pharmaceutica International Ltd, Basel, Switzerland.

P11.32

Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres

E. Kim, H. Oh, J. Shim, S. Kang;

Yonsei University College of Medicine, Seoul, Korea, Republic of.

P11.33

Characterization of a new patient-derived metastatic glioblastoma cell line and response to sodium selenite anticancer agent: *in vitro* results and preclinical data in mice

L. Larrouquere¹, S. Berthier¹, E. Col¹, C. Lefebvre¹, C. Cottet-Rousselle², B. Chovelon¹, C. Garrel¹, J. Boutonnat¹, P. Faure¹, F. Hazane-Puch¹;

¹CHU GRENOBLE ALPES, Grenoble, France, ²Laboratory of Fundamental and Applied Bioenergetics (LBFA), INSERM U 1055 and SFR Environmental and Systems Biology (BEeSy), University Grenoble Alpes, Grenoble, France, Grenoble, France.

P11.34

Bone Morphogenetic Protein 4 can sensitize glioblastoma cells to temozolomide

I. Verploegh, A. Conidi, M. Lamfers, C. Dirven, S. Leenstra, D. Huylebrock;

Erasmus MC, Rotterdam, Netherlands.

P11.35

Fluorine-18-labeled PET radiotracers for imaging tryptophan uptake and metabolism in brain tumors

O. Muzik^{1,2}, F. John^{2,3}, S. Mitta⁴, C. Juhasz^{2,1};

¹PET Center, Children's Hospital of Michigan, Detroit, MI, United States, ²Wayne State University, Detroit, MI, United States, ³University of Pecs, Pecs, Hungary, ⁴Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.

P11.36

Ribosomal hydroxylase Mina53 is required for Glioblastoma and is involved in regulation of translation rate and fidelity by regulating ribosomal biogenesis

D. Pandey¹, F. Mohammad², S. Weissmann², P. Hallenborg³, B. Blagoev³, K. Helir²;

¹Rikshospitalet, Oslo, Norway, ²Biotech Research and Innovation Centre, Copenhagen, Denmark, ³Institut for Biokemi og Molekylær Biologi, SDU, Odense, Denmark.

P11.37

Evaluating water content and electrical properties at 200 kHz in brain and GBM tumor tissue of three TTF fields patients with conventional imaging

Z. Bomzon¹, C. Wenger², H. K. Hershkovich¹, C. Tempel Brami¹, M. Giladi¹;

¹Novocure Ltd., Haifa, Israel, ²Novocure, Root D4, Switzerland.

P11.38

The Galectin-1 inhibitor OTX-008 has antiproliferative effects on human glioblastoma cells independent of MGMT-promotor status

H. Goettl¹, M. Kolodziej², J. Pons-Kühnemann³, F. Schwarm², C. Koch⁴, E. Uh^{2,5}, **M. Stein**^{2,5};

¹Justus-Liebig University Giessen, Giessen, Germany, ²Department of Neurosurgery, Justus-Liebig University Giessen, Giessen, Germany, ³Bureau of Statistics, Justus-Liebig University Giessen, Giessen, Germany, ⁴Experimental Anesthesiology Justus-Liebig University Giessen, Giessen, Germany, ⁵Center of Neurooncology, Justus-Liebig University Giessen, Giessen, Germany.

P11.39

Chloroquine as an anti-glioblastoma therapeutic: repurposing of an old drug

L. Roy, M. Poirier, D. Fortin;

FMSS, Université de Sherbrooke, Sherbrooke, QC, Canada.

P11.40**Development of an implantable multifunctional biodevice (GlioGel) in the treatment of recurrent glioblastoma**

L. Déry¹, G. Charest¹, M. Akbar², D. Fortin¹;

¹Université de Sherbrooke, Sherbrooke, QC, Canada, ²Université de Victoria, Victoria, BC, Canada.

P11.41**Comparison of fibroblast activation protein expression and localization in glioblastomas and brain metastases**

P. Busek¹, M. Zupal¹, B. Chmielova¹, Z. Vanickova¹, P. Hrabal², E. Krepela¹, A. Sedo¹;

¹Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Department of Pathology, Military University Hospital Prague, Prague, Czech Republic.

P11.42**Magnetic targeting of the granzyme B functionalized nanoparticles for therapy of glioblastoma**

M. Shevtsov^{1,2}, S. Stangl¹, Y. Marchenko³, L. Yakovleva³, V. Ryzhov⁴, B. Nikolaev³, O. Galibin⁵, E. Pitkin⁶, G. Multhoff¹;

¹Center for Translational Cancer Research Technische Universität München (TranslaTUM), Munich, Germany, ²Institute of Cytology of the Russian Academy of Sciences (RAS), St. Petersburg, Russian Federation, ³Research Institute of Highly Pure Biopreparations, St. Petersburg, Russian Federation, ⁴NRC "Kurchatov Institute", Petersburg Nuclear Physics Institute, Gatchina, Russian Federation, ⁵First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, ⁶Wharton School, University of Pennsylvania, Philadelphia, PA, United States.

P11.43**Deletions on Y chromosome are associated with shorter survival in glioblastoma**

M. Lysiak¹, A. Malmström^{1,2}, K. R. Roodakker³, E. Sandberg³, A. Dimberg⁴, M. Mudaisi⁵, C. Bratthäll⁶, M. Strandéus⁷, P. Milos⁸, M. Hallbeck^{1,9}, A. Smits^{3,10}, P. Söderkvist¹;

¹Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ²Department of Advanced Home Care, Linköping University, Linköping, Sweden, ³Department of Neuroscience, Neurology, Uppsala University, University Hospital, Uppsala, Sweden, ⁴Institute of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Department of Oncology, Linköping University, Linköping, Sweden, ⁶Department of Oncology, District Hospital, Kalmar, Sweden, ⁷Department of Oncology, Ryhov Hospital, Jönköping, Sweden, ⁸Department of Neurosurgery, Linköping University, Linköping, Sweden, ⁹Department of Clinical Pathology, Linköping University, Linköping, Sweden, ¹⁰Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

P11.44**Conception of a promising future therapy: Drug loaded-microbubbles against glioblastoma**

E. Schulz¹, V. Mawamba², V. Sturm¹, R. Ernestus¹, U. Schatzschneider², M. Löhr¹, C. Hagemann¹;

¹Tumorbiology Laboratory, Würzburg, Germany, ²Institute of Inorganic Chemistry, Würzburg, Germany.

P11.45**Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models**

C. von Achenbach¹, M. Weller¹, K. Kaulich², D. Gramatzki¹, A. Zacher², D. Fabbro³, G. Reifenberger², E. Szabó¹;

¹Laboratory of Molecular Neuro-Oncology, 8091 Zurich, Switzerland, ²Institute of Neuropathology, Düsseldorf, Germany, ³Piqur Therapeutics AG, Basel, Switzerland.

P11.46**Discovery of a new HDAC6 inhibitor for the treatment of glioblastoma**

J. Auzmendi-Iriarte¹, A. Saenz-Antoñanzas¹, J. Andermatten², A. Elua-Pinin², E. Aldaba³, Y. Vara³, A. Matheu¹;

¹Cellular Oncology group, Biodonostia, San Sebastián, Spain, ²Neurosurgery Department, Donostia University Hospital, San Sebastián, Spain, ³Quimatryx, San Sebastián, Spain.

P11.47**Generation, characterisation and drug screening of patient-derived IDH1-mutated glioma cell lines**

C. Verheul¹, T. V. Kers¹, A. Van Der Ploeg¹, M. Van Der Kaaij¹, M. Aghababazadeh¹, M. De Wit¹, Y. Hoogstrate¹, E. Struys², C. M. F. Dirven¹, S. Leenstra¹, P. J. French¹, M. L. M. Lamfers¹;

¹Erasmus Medical Center, Rotterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands.

P11.48**Dose-dependent effects of radiation exposure on the cell culture of glioblastoma G01, obtained from the patient with a long-term survival**

A. Belyashova¹, A. Golanov¹, G. Pavlova^{2,1}, E. Savchenko², N. Antipina¹, D. Panteleev^{2,1}, D. Shamadykova², G. Smirnov¹, A. Nikolaeva¹;

¹National Medical Research Center of Neurosurgery named after N.N. Burdenko, Moscow, Russian Federation, ²Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.

P11.49**An electrophysiological signature of glioma infiltration in the ex vivo human brain**

A. J. Kirby¹, J. P. Lavrador², C. Brogna^{2,1}, F. Vergan², C. Chandler², B. Zebian², I. Bodi^{3,1}, R. Bhangoo², K. Ashkan^{2,1}, G. T. Finnerty^{1,4};

¹Department of Basic and Clinical Neuroscience, Kings College London, London, United Kingdom, ²Department of Neurosurgery, King's College Hospital, London, United Kingdom, ³Department of Clinical Neuropathology, King's College Hospital, London, United Kingdom, ⁴Department of Neurology, King's College Hospital, London, United Kingdom.

P11.50

The dielectric properties of brain tumor tissue

M. A. Proescholdt¹, A. Lohmeier¹, E. Stoerr¹, P. Eberl¹, A. Brawanski¹, Z. Bomzon², H. S. Hershkovich²;

¹Department of Neurosurgery, Regensburg, Germany, ²NovoCure Ltd, Haifa, Israel.

P11.51

Repurposing the antipsychotic chlorpromazine for the treatment of glioblastoma multiforme

M. G. Paggi, C. Abbruzzese, S. Matteoni, P. Matarrese, D. Giannarelli, I. Sperduti, V. Villani, **A. Pace**;

Regina Elena National Cancer Institute, Rome, Italy.

P11.52

Reduced expression of proteolipid protein 2 increases ER-stress-induced apoptosis and autophagy in glioblastoma

Z. Feng^{1,2}, W. Zhou^{1,2}, J. Wang¹, B. Huang¹, A. Chen¹, D. Zhang¹, R. Bjerkvig^{2,3}, J. Wang^{1,2}, F. Thorsen², X. Li¹;

¹Qilu hospital of Shandong University, Jinan, China, ²Department of Biomedicine, University of Bergen, Bergen, Norway, ³Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.

P11.53

Genotype trumps phenotype: Oligodendroglioma and oligodendroglioma like tumors- A 1p19q fluorescence in situ hybridization based study at a tertiary referral centre in north India

A. Dewan, L. Kini, S. Sharma, M. Bhardwaj;

CORE Diagnostics, Gurugram, Haryana, India.

P11.54

Identification of PDGFRA and MYC(N) as somatic driver genes in Glioblastoma

A. D. Berzovsky^{1,2}, A. Transou², S. Irtenkau², L. Poisson², K. Hank Wu², T. Mikkelsen², A. deCarvalho^{1,2};

¹Wayne State University, Detroit, MI, United States, ²Henry Ford Health System, Detroit, MI, United States.

P11.55

Thymoquinone enhances the sensitivity of B16-F10 melanoma cell line to Gamma Knife radiosurgery

M. A. Hatiboglu^{1,2}, A. Kocyigit³, E. M. Guler³, K. Akdur³, I. Khan², A. Nalli^{1,2}, E. Karatas³, S. Tuzgen¹;

¹Department of Neurosurgery, Bezmialem Vakif University Medical School, Istanbul, Turkey, ²Department of Molecular Biology, Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, Istanbul, Turkey, ³Department of Biochemistry, Bezmialem Vakif University Medical School, Istanbul, Turkey.

P11.56

Oncolytic virus and tumor microenvironment modulators an alliance to fight glioblastoma

M. Puigdelloses, N. Martinez-Velez, M. Garcia-Moure, M. Gonzalez-Huarriz, I. Iñigo, **A. M. Marta**, J. Gallego Perez-Larraya;

University of Navarra, Pamplona, Spain.

P11.57

A 3D brain organoid coculture system delineates the invasive cell components in glioblastoma

W. Zhou^{1,2}, B. Klink³, G. Dittmar³, P. Nazarov³, E. M. Garcia³, M. Han², T. R. Lunava², J. V. Joesph², H. S. Saed², M. Bahador², J. Wang^{1,2}, R. Bjerkvig^{2,3};

¹Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Jinan, Shandong, China, ²K G Jebsen Brain Tumor Research Center, Department of Biomedicine, Bergen, Norway, ³Luxembourg Institute of Health, Luxembourg, Luxembourg.

P11.58

Astrocytic Environment Aid the Evolution of Immunosuppressive Environment in Glioblastoma

D. H. Heiland, V. M. Ravi, S. P. Behringer, O. Schnell;

Department of Neurosurgery, Freiburg, Germany.

P11.59

Integrin $\alpha 5$ heterogeneous expression in glioblastoma is related to glioma stem cell subpopulations

M. Dontenwill¹, M. Mercier¹, G. Gillmann¹, D. Reita¹, I. Lelong-Rebel¹, F. Noulet¹, A. Idbait², C. Herold-Mende³, D. Bagnard⁴, C. Spenlé⁴, S. Martin¹;

¹Laboratory of bioimaging and pathologies, UMR7021 CNRS, University of Strasbourg, Illkirch, France, ²Sorbonne University, INSERM, CNRS, UMRS 1127, ICM, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France, ³Division of Experimental Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany, ⁴INSERM U1119, University of Strasbourg, Illkirch, France.

P11.60

Neurosurgical delivery of the poly ADP ribose polymerase-1 inhibitor olaparib from a thermo-responsive biodegradable paste potentiates radiotherapy and prolongs survival

S. Smith¹, R. Serra², J. Rowlinson¹, N. Gorelick², G. Veal³, K. Shakesheff¹, H. Brem², R. Grundy¹, B. Tyler², **R. Rahman¹**;

¹University of Nottingham, Nottingham, United Kingdom, ²Johns Hopkins University, Baltimore, MD, United States, ³Newcastle University, Newcastle, United Kingdom.

P11.61

Development of a novel preclinical GBM model and therapeutic impact of IRE1 inhibition

P. Le Reste¹, R. Pineau², F. Jouan², J. Sama³, G. Jegou², J. Patterson⁴, E. Vauleon⁵, T. Avri², A. Pandit³, E. Chevet²;

¹Department of Neurosurgery, Rennes, France, ²INSERM U1242, Rennes, France, ³CURAM, Galway, Ireland, ⁴Fosun Orinove PharmaTech Inc, Rennes, France, ⁵CRLCC Eugene Marquis, Rennes, France.

P11.62

Brain distribution models to select polymer-delivered drugs for the intra-cavity treatment of malignant glioma

J. Rowlinson, P. McCrorie, S. Smith, D. Barrett, D. Kim, R. Grundy, D. Scurr, R. Rahman;

University of Nottingham, UK, Nottingham, United Kingdom.

P11.63

PI3K inhibition in conjunction with the ketogenic diet reduces growth and neuroinflammation in pediatric high-grade glioma

E. Noch, I. Yim, L. Cantley;

Weill Cornell Medicine, New York, NY, United States.

P11.64

Specialized neurooncological biorepository of the N.N. Burdenko National Medical Research Center for Neurosurgery: high-quality tumor bank for personalized medicine

D. Golbin¹, G. Pavlova^{1,2}, M. Shifrin¹, S. Shugay¹, T. Tsukanova¹, A. Korochkina¹, G. Danilov¹;

¹N.N. Burdenko National Medical Research Center for Neurosurgery, Moscow, Russian Federation, ²Institute of Gene Biology of Russian Academy of Sciences, Moscow, Russian Federation.

P11.65

Insights into the mechanisms of primary brain tumor invasion

A. Bikfalvi, T. Daubon, C. Billottet;

Laboratoire de l'Angiogenèse et du Microenvironnement des Cancers-INSERM U1029, Université Bordeaux, Bordeaux, France.

P12 Immunotherapy

P12.01

Local implantation of thermoresponsive interferon alpha-polypeptide conjugate combined with temozolomide for post-surgical glioblastoma chemoimmunotherapy

P. Liang^{1,2}, W. Zhuoran³, G. Weiping⁴, W. Guihua²;

¹Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China, ²Beijing Tsinghua Changgung Hospital, Beijing, China, ³Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China, ⁴Biomedical Engineering Department, Peking University, Beijing, China.

P12.02

Glioblastoma Multiforme immunological blockades and the implications of glioma cancer stem cells

L. D. Robilliard, C. MacDonald, C. E. Angel, G. J. Finlay, W. Joseph, E. S. Graham;

University of Auckland, Auckland, New Zealand.

P12.03

Bi-specific T cell engagers targeting IL13R α 2 activate tumor-infiltrating lymphocytes and improve survival in pre-clinical models of glioblastoma

M. Zannikou, K. C. Pituch, L. Ilut, **I. V. Balyasnikova**;

Northwestern University, Chicago, IL, United States.

P12.04

Synergistic effects of combination therapy of CAR-NK cells and anti-PD-1 antibody result in high efficacy against advanced stage orthotopic glioblastoma grafts in a syngeneic mouse model and induce protective anti-tumor immunity *in vivo*

F. Strassheimer¹, M. I. Strecker¹, C. Zhang^{2,3}, I. C. Mildenerberger¹, P. N. Harter^{3,4}, T. Tonr⁵, J. P. Steinbach^{1,3}, W. S. Wels^{2,3}, **M. C. Burger^{1,3}**;

¹Dr. Senckenberg Institute of Neurooncology, Goethe-University, Frankfurt, Germany, ²Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany, ³German Cancer Consortium (DKTK) and German Cancer Research Centre (DKFZ), Heidelberg, Germany, ⁴Edinger-Institute, Goethe University, Frankfurt, Germany, ⁵Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East and Medical Faculty Carl Gustav Carus, Dresden, Germany.

P12.05

Evaluating the compatibility of tumor treating electric fields with key antitumoral immune functions

G. Diamant, H. Simchony, T. Shiloach, A. Globerson-Levin, L. Gasri Plotnitsky, Z. Eshhar, N. Pencovich, **R. Grossman**, Z. Ram, I. Volovitz;

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

P12.06

Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas

A. SHARMA;

All India Institute of Medical Sciences, DELHI, India.

P12.07

Minimal bimodular G-quadruplex nano-construct as cryptic therapeutic DNA oligonucleotide to suppress glioblastoma cell functioning

A. Kopylov^{1,2}, O. Antipova², V. Legatova², N. Samoylenkova³, E. Savchenko³, A. Golovin^{1,4}, E. Zavyalova², G. Pavlova^{5,4};

¹Belozersky Institute Physical Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation, ²Chemistry Department, Lomonosov Moscow State University, Moscow, Russian Federation, ³Institute of Gene Biology, RAS, Moscow, Russian Federation, ⁴Sechenov First Moscow State Medical University, Institute of Molecular Medicine, Moscow, Russian Federation, ⁵Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russian Federation.

P12.08

Immunocytokines are a novel immunotherapeutic approach against glioblastoma

T. Weiss¹, E. Puca², M. Weller¹, D. Nerf², P. Roth¹;

¹University Hospital Zurich, Zurich, Switzerland, ²Swiss Federal Institute of Technology (ETH Zürich), Zurich, Switzerland.

P12.09

Multidimensional Personalized Response Assessment to Microglia Modulators in Glioblastoma Bioreactors

T. Shekarian¹, A. Wachnowicz¹, J. Flammer¹, C. Paganetti¹, T. Martins¹, M. Muraro¹, C. Schürch², G. Hutter¹;

¹Departement of Biomedecine, University Hospital Basel, Basel, Switzerland, ²Stanford University School of medicine, Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford, CA, United States.

P12.10

Treatment of pharmacoresistent epilepsy by combining stereotactic destruction and autologous mesenchymal stem cells

E. Slobina¹, T. Dokukina², F. Khlebokazov², N. Misyuk², M. Makhrov², P. Korolevich², I. Shamruk², S. Marchuk²;

¹Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation, ²National Scientific Center for Mental Health of Belarus, Minsk, Belarus.

P13 Omics in neuro-oncology

P13.01

TERT promoter methylation is significantly associated with TERT upregulation and tumor progression in pituitary adenomas

J. Adachi¹, Y. Miyake¹, T. Suzuki¹, K. Mishima¹, R. Araki², R. Nishikawa¹;

¹Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan, ²Community Health Science Center, Saitama Medical University, Iruma, Saitama, Japan.

P13.02

Conventional MRI radiomics in the diagnosis of early- and pseudo-progression

A. Bani Sadr, O. F. Eker, L. Berner, R. Ameli, M. Hermier, M. Barritault, D. Meyronet, J. Guyotat, E. Jouanneau, J. Honnorat, F. Ducray, Y. Berthezène;
Hospices Civils de Lyon, Bron, France.

P13.03

Identification of novel gene fusions in glioblastomas with chromothripsis

F. Ah-Pine¹, D. Casas², B. Boisselier^{1,2}, P. Guardiola¹, P. Menei¹, E. Garcion², A. Rousseau^{1,2};

¹CHU Angers, Angers, France, ²CRCINA, INSERM, Nantes-Angers, France.

P13.04

Transcriptional profiling differentiates spinal cord ependymal tumours from other glial tumours in children

A. A. Sobocińska¹, M. Niemira², A. Szałkowska², B. Wojtaś³, J. Trubicka⁴, W. Grajkowska⁴, E. Matyja¹, M. Łastowska^{1,4};

¹Department of Experimental and Clinical Pathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland, ²Clinical Research Centre, Medical University of Białystok, Białystok, Poland, ³Neurobiology Center, Nencki Institute of Experimental Biology, Warsaw, Poland, ⁴Department of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.

P13.05

Chemical Biopsy as an Alternative Sampling Method in Neurooncology

J. Bogusiewicz¹, P. Z. Goryńska¹, K. Jaroch¹, K. Goryński¹, D. Paczkowski², J. Furtak², M. Harat^{2,3}, B. Bojko¹;

¹Department of Pharmacodynamics and Molecular Pharmacology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland, ²Department of Neurosurgery, 10th Military Research Hospital, Bydgoszcz, Poland, ³Department of Public Health, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.

P13.06

Transcriptome-wide Mendelian randomization study to identify brain-specific causal genes influencing glioma

J. W. Robinson¹, J. Zheng¹, S. Tscavachidis², A. E. Howell¹, C. L. Relton¹, G. N. Armstrong², M. Bondy², R. M. Martin¹, K. M. Kurian¹;
¹University of Bristol, Bristol, United Kingdom, ²Baylor College of Medicine, Houston, TX, United States.

P13.07

Multi-omics as a tool for elucidating temozolomide resistance in glioblastoma multiforme

F. Fabro, E. Tóth, L. J. M. Dekker, T. M. Luider, T. M. Pierson, S. Leenstra;
Erasmus Medical Center, Rotterdam, Netherlands.

P13.08

1H-MRS metabolomics as a predictor of overall survival in glioma patients

J. Solivera¹, A. Fuentes Fayos¹, R. M. Luque¹, L. Barrios², J. M. Roda³, S. Cerdán⁴, M. L. Gandía-González²;
¹Instituto "Maimónides" de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofía, Córdoba, Spain, ²Department of Statistics CSIC, Madrid, Spain, ³Department of Neurosurgery, Hospital Universitario La Paz, Madrid, Spain, ⁴Institute of Biomedical Research "Alberto Sols" CSIC/UAM, Madrid, Spain.

P13.09

Genomic analysis of paired IDHwt glioblastoma (GB) reveals recurrent alterations of *MPDZ* at relapse after radiotherapy and temozolomide (RTCT)

B. Chanez, R. Appay, A. Guille, A. Lagarde, C. Bequet, C. Jiguet-Jiglaire, T. Graillon, H. Dufour, D. Figarella-Branger, O. Chinot, **E. Tabouret**;
Timone Hospital- APHM, Marseille, France.

P13.10

Glioblastoma within the subventricular zone associates with increased mesenchymal transition: an intratumoral gene expression analysis

S. Berendsen¹, D. Dalemans¹, K. Draaisma^{1,2}, P. A. Robe^{1,2}, T. J. Snijders¹;
¹University Medical Center Utrecht, Utrecht, Netherlands, ²University Hospital Liege, Liege, Belgium.

P13.11

Metabolomics and molecular profiling in glioma patients: an interactomic approach

A. C. Fuentes-Fayos^{1,2}, M. L. Gandía-González³, A. Cano-Rojas⁴, C. J. Blanco⁵, E. M. Negro-Morales⁶, Á. Toledano⁵, M. J. Ramos⁶, A. Cano-Sánchez⁶, R. M. Luque^{1,2}, R. M. Ortega-Salas⁷, J. M. Roda³, S. Cerdán⁸, M. L. García-Martín⁹, J. Solivera^{5,1};
¹Maimonides Institute of Biomedical Research of Cordoba (IMIBIC / Reina Sofía University Hospital (HURS), Córdoba, Spain, ²Department of Cell Biology, Physiology and Immunology, CIBER Physiopathology of Obesity and Nutrition (CIBERObn), University of Cordoba, Córdoba, Spain, ³Department of Neurosurgery, Hospital Universitario La Paz, Madrid, Spain, ⁴High-Performance Data Mining Lab, Department of Computer Science at the Virginia Commonwealth University, Richmond, VA, United States, ⁵Department of Neurosurgery, Reina Sofía University Hospital (HURS), Córdoba, Spain, ⁶Neuroradiology Department, Reina Sofía University Hospital (HURS), Córdoba, Spain, ⁷Pathology Department, Reina Sofía University Hospital, Córdoba, Spain, ⁸Instituto de Investigaciones Biomédicas Alberto Sols CSIC, Madrid, Spain, ⁹Centro Andaluz de Nanomedicina y Biotecnología (BIONAND), Málaga, Spain.

P13.12

Development and validation of a radiomic model for the preoperative prediction of transsphenoidal surgical response in patients with acromegaly

Y. Fan, M. Feng, R. Wang;
Peking Union Medical College Hospital, Beijing, China.

P13.13

Clinical factors involved in brain metastasis edema : results of a retrospective cohort and evaluation of the best edema descriptor

Y. Pin¹, M. Loo¹, W. Waissi¹, A. Paix¹, J. Todeschi¹, D. Antoni¹, F. Proust¹, **G. Ahle²**, G. Noël¹;
¹Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France, ²Centre de Lutte Contre le Cancer Paul Strauss, Strasbourg, France.

P13.14

Use of Foundation one CDx for molecular screening in patients with primary brain tumors: Gustave Roussy Experience

C. Baldini, W. Boulfoul, L. Lacroix, E. Rouleau, J. Scoazec, A. Varga, A. Hollebecque, V. Ribrag, J. Soria, C. Massard;
Gustave Roussy, Villejuif, France.

P13.15

DNA methylation abnormalities in non-promoter regulatory regions are associated with invasive behavior in pituitary tumors

M. Q. S. Mosella¹, T. S. Sabedo², T. M. Malta², J. Rock², M. Felicella², T. Aho², H. Noushmehr^{2,1}, **A. V. Castro²**;
¹University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil, ²Henry Ford Health System, Detroit, MI, United States.

P14 Clinical neuro-oncology

P14.01

Differential diagnosis of IDH mutant/IDH wildtype of glioma by using ¹¹C-methionine, ¹¹C-choline, and ¹⁸F-fluorodeoxyglucose positron emission tomography

H. Takei^{1,2}, J. Shinoda^{1,3}, S. Ikuta⁴, T. Maruyama⁴, Y. Muragaki⁴, T. Kawasaki^{1,2}, Y. Ikegame^{1,3}, M. Okada¹, T. Ito¹, Y. Asano^{1,3}, K. Yokoyama¹, N. Nakayama², H. Yano², T. Iwama²;

¹Chubu medical center for prolonged traumatic brain dysfunction, Kizawa Memorial Hospital, Minokamo City, Gifu Prefecture, Japan, ²Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu City, Gifu Prefecture, Japan, ³Department of Clinical Brain Science, Gifu University Graduate School of Medicine, Minokamo City, Gifu Prefecture, Japan, ⁴Department of Neurosurgery, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.

P14.02

Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment

S. Siller, M. Lauseker, A. Giese, J. Tonn, K. Niyazi, N. Thon, B. Suchorska, F. Kreth;
University Hospital, LMU Munich, Munich, Germany.

P14.03

Adult medulloblastoma: Influence of risk stratification and molecular subtypes on chemotherapy efficacy

O. Absalyamova¹, G. Kobiakov¹, G. Agabekyan¹, M. Ryzhova¹, N. Kobiakov², K. Lodygina¹, A. Poddubsky¹, A. Korshunov³;

¹N.N. Burdenko National Scientific and Practical Center for Neurosurgery, Moscow, Russian Federation, ²Lomonosov Moscow State University, Moscow, Russian Federation, ³Department of Neuropathology, Institute of Pathology Heidelberg University Hospital, Heidelberg, Germany.

P14.04

10 years of weekly web conference for brain tumor of adolescent/young adult (AYA) on behalf of ANOCEF, GO-AJA and SFCE societies

D. Frappaz¹, C. Bronnimann², C. Faure Conter³, E. Vauleon⁴, D. Meyronnet⁵, M. Sunyach⁶, P. Leblond⁶, R. Tanguy⁶, V. Laurence⁷, A. Bonneville-Levard⁶;

¹Centre Léon Bérard and IHOPe, Lyon, France, ²Chu, Bordeaux, France, ³IHOPe, Lyon, France, ⁴CHU, Rennes, France, ⁵CHU, Lyon, France, ⁶Centre Léon Bérard, Lyon, France, ⁷Institut Curie, Paris, France.

P14.05

Treatment of relapsing patients with intracranial germ cell tumors: the French experience

L. Callec¹, C. Patte², A. Lardy-Cleaud³, L. Vignon⁴, C. Alapetite⁵, P. Chastagner¹, C. Faure Conter⁶, **D. Frappaz**⁷;

¹CHU, Nancy, France, ²Gustave Roussy, Villejuif, France, ³Centre Léon Bérard, Lyon, France, ⁴INSERM, Paris, France, ⁵Institut Curie, Paris, France, ⁶IHOPe, Lyon, France, ⁷Centre Léon Bérard and IHOPe, Lyon, France.

P14.06

Phase II randomized trial of short course hypofractionated radiotherapy with or without temozolomide in elderly patients with Glioblastoma

R. Madan, S. Thakur, P. Salunke, C. Ahuja, D. Khosla, B. S. Yadav, R. Kapoor, N. Kumar;
Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

P14.07

Complete response under treatment with proton therapy followed by chemotherapy together with Tumor Treating Fields in a biopsied IDH wildtype glioblastoma patient

M. Stein¹, H. Dohmen², B. Woelk³, E. Uhl¹, M. Kolodziej⁴, A. Jensen⁵;

¹Center of Neurooncology, Justus-Liebig University Giessen, Giessen, Germany, ²Institute of Neuropathology, Justus-Liebig University Giessen, Giessen, Germany, ³Department of Neuroradiology, Justus-Liebig University Giessen, Giessen, Germany, ⁴Department of Neurosurgery, Justus-Liebig University Giessen, Giessen, Germany, ⁵Department of Radiation Oncology, Justus-Liebig University Giessen, Giessen, Germany.

P14.08

Bevacizumab treatment for the lesion emerging after the radiotherapy for malignant glioma

K. Miwa, T. Ito, K. Yokoyama, J. Shinoda;

Department of Neurosurgery, Kizawa Memorial Hospital, Minokamo, Japan.

P14.09

Initial global symptoms in glioblastoma are often misinterpreted and associated with shorter survival

H. Bruhn¹, C. Dahle¹, M. Vrethem¹, R. Henriksson², J. Lindh¹;

¹Department of Clinical and Experimental Medicine, Linköping, Sweden, ²Department of Radiation Sciences, Umeå, Sweden.

P14.10

Endoscopic skull base surgery for tumors invading internal carotid artery

S. Geng;

Beijing Tiantan Hospital, Beijing, China.

P14.12**The cost-effectiveness of tumor-treating fields in patients with newly diagnosed glioblastoma****X. Armoiry**^{1,2}, **P. Auguste**², **C. Dussart**³, **J. Guyotat**⁴, **M. Connock**²;¹Claude Bernard University Lyon 1, Lyon, France, ²University of Warwick, Coventry, United Kingdom, ³Claude Bernard University, Lyon, France, ⁴Hôpitaux de Lyon, Lyon, France.**P14.13****Incidence of pseudoprogression in high-grade IDH-mutant gliomas****A. SEYVE**, **S. Cartalat**, **D. Meyronet**, **A. D'hombres**, **M. Barritault**, **E. Jouanneau**, **M. Berhouma**, **J. Guyotat**, **J. Honorat**, **F. Ducray**;
Hospices Civils de Lyon, Lyon, France.**P14.14****Scalp invasion of diffuse large b-cell lymphoma without systemic involvement****A. E. Hasturk**, **E. E. Eyupoglu**, **G. Gel**, **C. Gokce**;

Oncology Education and Research Hospital, Department of Neurosurgery, Ankara, Turkey.

P14.15**Benefit of Bevacizumab for recurrent glioblastoma. Results of 81 patients from a single institution****O. Absalyamova**¹, **G. Kobiakov**¹, **G. Agabekyan**¹, **A. Poddubsky**¹, **A. Belyashova**¹, **K. Lodygina**¹, **A. Absalyamov**², **N. Kobiakov**²;¹N.N. Burdenko National Scientific and Practical Center for Neurosurgery, Moscow, Russian Federation, ²Lomonosov Moscow State University, Moscow, Russian Federation.**P14.16****Complete sustaining radiological response of a multi-recurrent disseminated adult medulloblastoma after antiangiogenic metronomic combined pediatric regimen MEMMAT: a case report****A. Duran-Peña**¹, **Y. Garcilazo-Reyes**¹, **D. Frappaz**², **L. Feuvret**³, **F. Bielle**⁴, **L. Capelle**⁵, **J. Savatovsky**⁶, **F. Laigle-Donadey**¹;¹AP-HP, Service de Neurologie 2-Mazarin, Hôpitaux Universitaires La Pitié-Salpêtrière-Charles Foix, PARIS, France, ²Service de Cancerologie Centre Léon Bérard, LYON, France, ³AP-HP, Service de Radiothérapie, CHU Pitié-salpêtrière Charles Foix, PARIS, France, ⁴AP-HP, Service de Neuropathologie CHU La Pitié Salpêtrière-Charles Foix, PARIS, France, ⁵AP-HP, Service de Neurochirurgie CHU La Pitié Salpêtrière-Charles Foix, PARIS, France, ⁶Fondation Ophthalmologique Rotschild, PARIS, France.**P14.17****Differentiation of treatment-related changes from tumor progression: A direct comparison between dynamic FET PET and ADC values obtained from DWI MRI****J. Werner**¹, **G. Stoffels**², **T. Lichtenstein**³, **J. Borggrefe**³, **P. Lohmann**², **G. Ceccon**¹, **G. R. Fink**^{1,2}, **K. Langer**^{2,4}, **C. Kabbasch**³, **N. Galldiks**^{1,2};¹Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ²Inst. of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany, ³Dept. of Neuroradiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ⁴Dept. of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.**P14.18****Prognostic value of serial dynamic O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET in patients with non-resectable malignant glioma undergoing chemoradiation****J. Rosen**¹, **G. Stoffels**², **P. Lohmann**², **E. K. Bauer**¹, **J. Werner**¹, **M. Rapp**³, **J. Felsberg**⁴, **G. R. Fink**^{1,2}, **K. Langer**^{2,5}, **N. Galldiks**^{1,2};¹Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany, ²Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany, ³Dept. of Neurosurgery, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Dept. of Neuropathology, University Hospital Duesseldorf, Duesseldorf, Germany, ⁵Dept. of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.**P14.19****The inverse paradigm of IDH-wildtype glioblastoma is fundamental to overcome the two causes of resistance and develop novel effective therapies****E. Brognaro**;

Department of Neurosurgery, S. Maria della Misericordia Hospital, Rovigo, Italy.

P14.20**Anxiety level in a prospective cohort of newly diagnosed glioblastoma patients: preliminary results from the IMAGE study****D. Maillet**^{1,2}, **P. Narme**³, **V. Menard**¹, **M. Larrieu**¹, **K. Sahel**¹, **C. Belin**¹, **A. Carpentier**¹;¹Service de Neurologie, Hôpital Saint-Louis (AP-HP), Paris, France, ²Laboratoire PSITEC, EA 4072, UFR de Psychologie, Université de Lille, Villeneuve d'Ascq, France, ³Laboratoire Mémoire Cerveau et Cognition (EA7536), Institut de Psychologie, Université de Paris, Boulogne-Billancourt, France.**P14.21****Tehila Kaisman-Elbaz MD/PhD****T. Kaisman-Elbaz**^{1,2}, **Y. Elbaz**³, **V. Merkin**¹, **L. Dym**², **A. Noy**², **M. Atar-Vardi**⁴, **R. Bari**⁴, **S. Turiel**⁴, **K. Lavrenkov**^{5,2}, **I. Melamed**¹;¹Neurosurgery department, Soroka University Medical Center, Beer Sheva, Israel, ²Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel, ³Physics Department, Nuclear Research Center, Negev, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Beer Sheva, Israel, ⁵Institute of Oncology, Soroka University Medical Center, Beer Sheva, Israel.

P14.22**Long-term survival of treatment of HGG using PDT**

A. Rynda, V. Olyushin, D. Rostovtsev, Y. Zaborodskaya;

Polenov Russian Research Institute of Neurosurgery, Saint-Petersburg, Russian Federation.

P14.23**Risk of venous thromboembolism (VTE) in grade II-IV gliomas as a function of molecular subtype**

M. Diaz¹, J. Jo², D. Schiff¹;

¹University of Virginia Medical Center, Charlottesville, VA, United States, ²Vidant Medical Center, Greenville, NC, United States.

P14.24**Bevacizumab treatment in atypical disseminated choroid plexus papilloma in adult patients**

F. Colò¹, L. Larrouquere², R. Rivoirard³, H. Loiseau⁴, A. Lortholary⁵, A. Mervoyer⁶, I. Catry-Thomas⁷, **D. Frappaz**²;

¹Medical school University of Trieste, Trieste, Italy, ²Centre Léon Bérard et IHOP, Lyon, France, ³Lucien Neuwirth Cancer Institut, Saint Priest en Jarez, France, ⁴Bordeaux University Hospital, Bordeaux, France, ⁵Hopital privé du Confluent, Nantes, France, ⁶Institut de Cancérologie de l'Ouest, Nantes, France, ⁷Hôpital Saint André CHU, Bordeaux, France.

P14.25**Venous thromboembolic events in patients with brain metastases: the PICOS score**

F. Wolpert¹, B. Grossenbacher¹, A. Lareida¹, P. Roth¹, M. C. Neider², N. Andratschke³, E. Le Rhun^{1,4}, M. Weller¹;

¹Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland, ²Department of Neurosurgery, University Hospital and University of Zurich, Zurich, Switzerland, ³Department of Radiation Oncology, University Hospital and University of Zurich, Zurich, Switzerland, ⁴Neuro-oncology, Department of Neurosurgery, University Hospital Lille, Salengro Hospital, Rue Emile Laine, Lille, France.

P14.26**Autoimmune disease-associated primary CNS lymphoma: Meta-analysis and review of literature**

L. D. Kaulen¹, J. M. Baehring²;

¹Yale School of Medicine, Dept. of Neurology, New Haven, CT, United States, ²Yale School of Medicine, Dept. of Neurology and Neurosurgery, New Haven, CT, United States.

P14.27**The significance of multicentric noncontrast-enhancing lesions distant from surgically resected glioblastoma: Case series of 3 patients**

J. Hwang¹, H. An¹, S. Yoon¹, K. Park²;

¹Dept of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea, Republic of, ²Dept of Neurosurgery, Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of.

P14.28**First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma**

A. F. Keßler, J. Weiland, T. Linsenmann, R. Ernestus, C. Hagemann, M. Löhr;

University Hospital Würzburg, Department of Neurosurgery, Würzburg, Germany.

P14.29**Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET**

E. K. Bauer¹, G. Stoffels², T. Blau³, G. Reifenberger^{4,5}, J. M. Werner¹, P. Lohmann², M. Rapp⁶, G. R. Fink^{1,2}, K. Langen^{2,7}, N. Galldiks^{1,2};

¹Dept. of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ²Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany, ³Dept. of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ⁴Dept. of Neuropathology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ⁵Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne and Duesseldorf, Aachen, Bonn, Cologne and Duesseldorf, Germany, ⁶Dept. of Neurosurgery, Heinrich Heine University Duesseldorf, Duesseldorf, Germany, ⁷Dept. of Nuclear Medicine, University of Aachen, Aachen, Germany.

P14.30**Treatment outcomes of newly-diagnosed glioblastoma multiforme (GBM) by O6-methylguanine DNA methyltransferase promoter (MGMT) status: a multi-country study**

A. Z. Fu^{1,2}, J. P. Hall³, A. Bailey³, J. Kemp³, G. J. Thompson⁴, C. Lee¹;

¹Bristol-Myers Squibb, Lawrenceville, NJ, United States, ²Department of Oncology, Georgetown University Medical Center, Washington, DC, United States, ³Adelphi Real World, Manchester, United Kingdom, ⁴Bristol-Myers Squibb, Uxbridge, United Kingdom.

P14.31**CMV reactivation in a cohort of newly-diagnosed glioblastoma patients treated with temozolomide chemoradiotherapy. A single center analysis**

R. URSU^{1,2}, J. Doridam^{3,4}, E. Chaugne³, H. Zannou³, C. Belin^{1,2}, S. Cuzzubbo^{1,2}, L. Sirven-Villaros^{1,2}, S. Bricler^{5,4}, C. Levy-Piedbois⁶, **A. Carpentier**^{1,2};

¹Department of Neurology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France, ²University Paris Diderot, Sorbonne Paris Cité, Paris, France, ³Department of Neurology, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France, ⁴Université Paris 13, UFR de Santé, Médecine et Biologie Humaine, Bobigny, France, ⁵Department of Microbiologie Clinique, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France, ⁶Institut de Radiothérapie des Hautes Energies, Bobigny, France.

P14.32

Spatial discrepancies between FET PET and conventional MRI in patients with newly diagnosed glioblastoma

P. Lohmann¹, P. Stavrinou², K. Lipke¹, E. K. Bauer³, G. Ceccon³, J. Werner³, G. R. Fink^{1,3}, N. J. Shah^{1,4}, K. Langen^{1,5}, N. Galldiks^{1,3};
¹Institute of Neuroscience and Medicine (INM-3,-4), Research Center Juelich, Juelich, Germany, ²Department of Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ³Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany, ⁴Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany, ⁵Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.

P14.33

Adult brainstem gliomas in neurofibromatosis type 1 (NF1)

J. Guillamo¹, A. Wang², F. Ducray³, S. Barbarot⁴, O. Chino⁵, D. Frappaz⁶, L. Bauchet⁷, P. Wolkenstein⁸, F. Laigle-Donadey⁹;
¹CHU Nimes, Nimes, France, ²Hopital Foch, Suresnes, France, ³CHU Lyon, HCL, Bron, France, ⁴CHU Nantes, Nantes, France, ⁵AP HM, La Timone, Marseille, France, ⁶CLCC Leon Berard, Lyon, France, ⁷CHU Montpellier, Montpellier, France, ⁸CHU Henri Mondor, AP HP, Creteil, France, ⁹CHU Pitie-Salpetriere, AP HP, Paris, France.

P14.34

Priority of comet tail sign in the planning of stereotactic irradiation for the treatment of brain metastases

K. Mitsuya;

Shizuoka cancer centre, Shizuoka, Japan.

P14.35

The modern management of brain metastases

N. D. Wallace, P. J. Kelly;

Cork University Hospital, Cork, Ireland.

P14.36

Treatment patterns by O6-methylguanine DNA methyltransferase promoter (MGMT) status in newly-diagnosed glioblastoma multiforme (GBM): a multi-country chart review study

A. Z. Fu^{1,2}, G. J. Thompson³, J. P. Hall⁴, A. Bailey⁴, J. Kemp⁴, C. Lee¹;

¹Bristol-Myers Squibb, Lawrenceville, NJ, United States, ²Department of Oncology, Georgetown University Medical Center, Washington, DC, United States, ³Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁴Adelphi Real World, Manchester, United Kingdom.

P14.37

Depression in patients with primary brain tumors: Relation to clinical variables and tumor characteristics

F. John^{1,2}, G. R. Barger^{1,3}, S. Mittal^{1,4}, C. Juhasz^{1,5};

¹Wayne State University, Detroit, MI, United States, ²University of Pecs, Pecs, Hungary, ³Karmanos Cancer Institute, Detroit, MI, United States, ⁴Virginia Tech Carilion School of Medicine, Roanoke, VA, United States, ⁵PET Center, Children's Hospital of Michigan, Detroit, MI, United States.

P14.38

Clinical experience with tumor treating fields (TTFields) treatment for posterior fossa tumors

A. Taliensky^{1,2}, T. Vagner^{1,2}, E. Jan¹, L. Zach^{1,2};

¹Oncology Institute, Chaim Sheba Medical Center, Ramat-Gan, Israel, ²Tel Aviv University Medical School, Tel Aviv, Israel.

P14.39

How far should it be removal beyond the Gd-enhanced edge in Glioblastoma cases? -Preoperative removal range identification using Methionine-PET and Thallium-SPECT fusion image-

N. Nakayama¹, H. Yano¹, H. Take², K. Miwa², J. Shinoda², T. Iwama¹;

¹Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan, ²Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, Minokamo City, Gifu, Japan.

P14.40

Incidence and risk factors identification for lung cancer brain metastasis

H. Fariña, M. Rodríguez-Salazar, M. Rodríguez-Yanes, J. Plata-Bello;

Hospital Universitario de Canarias, La Laguna, Spain.

P14.41

Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial

J. Furtner¹, E. Genbrugge², T. Gørlia², M. Bendszus³, M. Nowosielski⁴, V. Gollinopoulos², M. Weller⁵, M. J. van den Bent⁶, W. Wick⁷, M. Preusser⁸;

¹Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ²European Organization for Research and Treatment of Cancer, Brussels, Belgium, ³University Medical Center and German Cancer Research Center, Heidelberg, Germany, ⁴Department of Neurology, Medical University Innsbruck, Innsbruck, Austria, ⁵University Hospital and University of Zurich, Zurich, Switzerland, ⁶Department of Neurology/Neuro-Oncology, Erasmus MC - Cancer Institute, Rotterdam, Netherlands, ⁷Neurology Clinic, University of Heidelberg, Clinical Cooperation Unit (CCU) Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany, ⁸Department of Medicine I, Medical University of Vienna, Vienna, Austria.

P14.42

Diagnostic challenges of infratentorial hemangioblastomas: improvement of current radiological classification scheme

I. Jung, E. Kim, J. Moon, S. Kang, J. Chang;

Department of Neurosurgery, Brain Tumor Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Seoul, Korea, Republic of.

P14.43

Histone H3F3A and HIST1H3B K27M mutations in pediatric high-grade gliomas: the Florentine experience

M. Guidi;

Meyer Children's Hospital, Firenze, Italy.

P14.44

Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study

T. Roh¹, S. Kang², C. Hong², J. Chang²;

¹Ajou University, Suwon, Korea, Republic of, ²Yonsei University, Seoul, Korea, Republic of.

P14.45

Primary diffuse large B-cell CNS lymphoma over 80 years: an analysis of 110 patients from the french Oculo-Cerebral Lymphoma (LOC) network

A. MAAREK¹, D. Maucort-Boulch¹, C. Houillier², K. Hoang-Xuan², C. Soussain³, H. Ghesquière¹;

¹Hôpital Lyon Sud, Pierre-Bénite, France, ²Hôpital Pitié-Salpêtrière, Paris, France, ³CLCC Hôpital René Huguenin - Institut Curie, Saint-Cloud, France.

P14.46

SUBEPENDYMAL GIANT CELLS ASTROCYTOMA (SEGA) IN TUBEROUS SCLEROSIS COMPLEX (TSC): A SERIES OF 31 PATIENTS

F. GIORDANO, C. MOSCHEO, M. LENGE, F. MARI, M. GRANDONI, A. BUCCOLIERO, I. SARDI, L. GENITORI, M. Guidi;

Meyer Pediatric Hospital, Firenze, Italy.

P14.47

Tissue immune markers for central nervous system germinoma

A. K. CHAN¹, Z. F. Sh², K. W. Lo¹, H. K. Ng¹, C. C. Lau³;

¹Department of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Neurosurgery, Hua Shan Hospital, Fudan University, Shanghai, China, ³University of Connecticut School of Medicine, Storrs, CT, United States.

P14.48

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copynumber alterations and stratified clinical risks

A. K. CHAN¹, K. K. Li¹, Z. F. Sh², H. K. Ng¹;

¹Department of Anatomical and Cellular Pathology, Faculty of Medicine, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, ²Department of Neurosurgery, Hua Shan Hospital, Fudan University, Shanghai, China.

P14.49

Primary central nervous system lymphoma presenting as dementia: do not forget IL10 in CSF analysis

A. Blain¹, A. Brinet¹, M. Berthel¹, A. Camoyret¹, C. Gaultier¹, L. Droy-Dupré, MD¹, H. Oesterlé, MD¹, R. Hurstel¹, A. Debliquis², M. Costopoulos³, M. Le Garff-Tavernier³, F. Sellal¹, G. Ahle¹;

¹Hôpitaux Civils de Colmar, Colmar, France, ²Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France, ³Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

P14.50

Clinicopathological spectrum of intracranial germ cell tumors: an Indian tertiary cancer center experience

A. Sahay, G. Chinnaswamy, V. Bhat, V. Patil, T. Gupta, J. G. Shastri, A. Moyiadi, P. Shetty, E. Sridhar;

Tata Memorial Centre, Mumbai, India.

P14.51

Brain mapping for mentalizing in GBM patient

D. Chung, W. Yoon;

Incheon St. Mary's Hospital, Incheon, Korea, Republic of.

P14.52

Differential methylation of a single CpG site in the CD95 ligand promoter affects gene activity and correlates with invasiveness of glioma cells

C. Merz¹, J. Sykora¹, A. Krendyukov¹, B. Wiestler², C. Gieffers¹, W. Wick³;

¹Apogenix AG, 69120 Heidelberg, Germany, ²TUM Universitätsklinik, 81675 München, Germany, ³Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen, 69120 Heidelberg, Germany.

P14.53

Deconstructing pathologically increased MEG network clustering in glioma patients

S. D. Kulik, J. Derks, T. Numan, A. Hillebrand, P. C. de Witt Hamer, M. Klein, J. J. G. Geurts, J. C. Reijneveld, C. J. Stam, M. M. Schoonheim, L. Douw;
VUmc, Amsterdam, Netherlands.

P14.54

Association of EGFR Expression and Copy Number with Outcome in Depatux-m (ABT-414) Randomized Phase II Study of the EORTC Brain Tumor Group

M. J. van den Bent¹, T. Gorlia², Y. Sun³, R. Kular⁴, J. Looman³, E. E. Bain³, L. Robberts-Rapp³, P. J. Ansell³, V. Gollinopoulos², P. French¹;
¹Erasmus MC Cancer Institute, Rotterdam, Netherlands, ²European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium, ³AbbVie Inc., North Chicago, IL, United States, ⁴Abbott Molecular Inc., Des Plaines, IL, United States.

P14.55

FOXP2 as a prognostic biomarker in glioblastoma

J. Plata-Bello, H. Fariña, I. Betancor, Y. Quintero, E. Salido, V. Garcia-Marin;
Hospital Universitario de Canarias, La Laguna, Spain.

P14.56

Recurrent Glioblastomas: Should we operate a second and even a third time

M. Yahia-Cherif, O. De Witte, C. Mélot, F. Lefranc;
Université Libre de Bruxelles (ULB). Hôpital Erasme, Brussels, Belgium.

P14.57

Association of tryptophan metabolism and depression in patients with primary brain tumors

C. Juhasz^{1,2}, F. John^{1,3}, S. K. Michelhaugh¹, O. Muzik^{1,2}, G. R. Barger^{1,4}, S. Mittal^{1,5};
¹Wayne State University, Detroit, MI, United States, ²PET Center, Children's Hospital of Michigan, Detroit, MI, United States, ³University of Pecs, Pecs, Hungary, ⁴Karmanos Cancer Institute, Detroit, MI, United States, ⁵Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.

P14.58

Extending adjuvant temozolomide longer than six cycles doesn't add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL

C. Balana¹, J. Sepulveda², **E. Pineda³**, M. Vaz⁴, C. Mesia⁵, J. Fuster⁶, R. Girones⁷, J. Muñoz-Langa⁷, M. Navarro⁸, M. Alonso⁹, M. Gil Gil⁶, A. Herrero¹⁰, A. Estival¹, O. Gallego¹¹, S. Peralta¹², C. Olier¹³, P. Pérez-Segura¹⁴, M. Covela¹⁵, M. Martínez García¹⁶, M. Domenech¹, C. Carrato¹⁷, C. Sanz¹⁷, J. Velarde¹, A. Berrocal¹⁸, R. Luque¹⁹, R. De las Peñas²⁰, S. Del Barco²¹;
¹Institut Catala Oncologia Badalona, Badalona, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Hospital Ramon y Cajal, Madrid, Spain, ⁵Institut Catala Oncologia Hospital Duran y Reynalds, Hospitalet de Llobregat, Spain, ⁶Hospital Universitari Son Espases, Palma de Mallorca, Spain, ⁷Hospital Universitari i Politècnic la Fe, Valencia, Spain, ⁸Hospital Universitario de Salamanca, Salamanca, Spain, ⁹Hospital Universitario la Virgen del Rocío, Sevilla, Spain, ¹⁰Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹¹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹²Hospital Universitari Sant Joan de Reus, Reus, Spain, ¹³Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain, ¹⁴Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo, Spain, ¹⁶Hospital Parc de Salut Mar, Barcelona, Spain, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital General Universitari de Valencia, Valencia, Spain, ¹⁹Hospital Universitario Virgen de las Nieves, Granada, Spain, ²⁰Hospital Provincial de Castellon, Castellon, Spain, ²¹Institut Catala Oncologia Hospital Universitari Josep Trueta, Girona, Spain.

P14.59

Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFIELDS in WHO Grade III Glioma

A. F. Keßler¹, R. Ritz²;
¹University Hospital Würzburg, Department of Neurosurgery, Würzburg, Germany, ²Klinik für Neurochirurgie, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany.

P14.60

FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFIELDS) in a patient with progressive high-grade glioma

A. F. Keßler, J. Weiland, T. Linsenmann, R. Ernestus, C. Hagemann, M. Löhr;
University Hospital Würzburg, Department of Neurosurgery, Würzburg, Germany.

P14.61

Tumor Treating Fields (TTFIELDS) combined with lomustine (CCNU) and temozolomide (TMZ) in newly diagnosed glioblastoma (GBM) patients - a bi-centric analysis

L. Lazaridis^{1,2}, N. Schäfer³, T. Schmidt^{1,2}, A. Stoppek^{1,2}, J. Weller³, T. Tzaridis³, B. Scheffler⁴, D. Pierscianek^{5,2}, C. Kleinschnitz⁶, M. Stuschke^{7,2}, U. Sure^{5,2}, U. Herrlinger³, S. Kebir^{1,2}, M. Glas^{1,2};
¹Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany, ³Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Bonn, Germany, ⁴DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany, ⁵Department of Neurosurgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁶Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁷Department of Radiotherapy, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

P14.62

Safety and adverse event profile post-market surveillance analysis of Tumor Treating Fields (TTFIELDS) in EMEA

T. Schmidt^{1,2}, S. Kebir^{1,2}, L. Lazaridis^{1,2}, A. Stoppek^{1,2}, M. Glas^{1,2};
¹Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

P14.63

The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care (TIGER: TTFields in Germany in routine clinical care)

O. Bähr¹, G. Tabatabaie², R. Fietkau³, R. Goldbrunner⁴, M. G. Glas^{5,6};

¹Neurologische Klinik, Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany, ²Interdisciplinary Division of Neurooncology, University Hospital Tübingen, Tübingen, Germany, ³Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany, ⁴Center for Neurosurgery, University Hospital Cologne, Köln, Germany, ⁵Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁶West German Cancer Center (WTZ), University Hospital Essen, University Duisburg-Essen, Essen, Germany.

P14.64

Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results

A. Silvani, E. Anghileri, G. Simonetti, M. Eoli, G. Finocchiaro, B. Pollo, M. Farinotti, L. Fariselli, P. Gaviani;
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

P14.65

Anaplastic pleomorphic xanthoastrocytoma: literature review& case report

G. Agabekyan¹, G. Kobayakov¹, K. Lodygina¹, N. Kobayakov², O. Absalyamova¹, M. Ryzhova¹, M. Inozemceva¹, A. Poddubsky¹;

¹National Medical Research Centre for Neurosurgery n.a. N.N. Burdenko, Moscow, Russian Federation, ²Moscow State University n.a. M.V. Lomonosov, Moscow, Russian Federation.

P14.66

TTFields dose distribution and tumor growth patterns confirm clinical activity of TTFields: MRI analysis of the randomized phase 3 EF-14 trial

S. Kebir¹, M. T. Ballo², S. Jeyapalan³, S. A. Toms⁴, A. Hottinger⁵, E. Pollom⁶, M. Glas¹;

¹Division of Clinical Neurooncology, Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, ²West Cancer Center, West Cancer Center & Research Institute, Memphis, TN, United States, ³Tufts Medical Center, Boston, MA, United States, ⁴Warren Alpert Medical School, Providence, RI, United States, ⁵Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁶Stanford University, Stanford, CA, United States.

P14.67

Somatostatin receptor targeted radioligand therapy in head and neck paraganglioma

M. Mütter¹, W. Rolfe², L. Stegger², B. Zinnhardt², M. Schäfers², M. Weckesser², K. Rahbar², W. Stummer¹;

¹University Hospital Münster, Dept. of Neurosurgery, Münster, Germany, ²University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany.

P14.68

Life expectancy in biopsied GBM patients: a single-centre experience

O. Kalita^{1,2}, Z. Sporikova², M. Halaj^{1,2}, K. Cwientka¹, M. Vaverka¹, L. Hrabalek¹, R. Trojanec¹, M. Hajdich^{1,2}, J. Drabek², J. Vrbkova²;

¹University Hospital Olomouc, Olomouc, Czech Republic, ²Palacky University in Olomouc, Olomouc, Czech Republic.

P14.69

Evaluation of electric field intensity delivered by Tumor-Treating Fields therapy to PET-defined metabolic volumes in recurrent glioblastomas

S. Mittal^{1,2}, F. John^{1,3}, A. Naveh⁴, Z. Bomzon⁴, G. R. Barger^{1,5}, C. Juhasz^{1,6};

¹Wayne State University, Detroit, MI, United States, ²Virginia Tech Carilion School of Medicine, Roanoke, VA, United States, ³University of Pecs, Pecs, Hungary, ⁴Novocure Ltd., Haifa, Israel, ⁵Karmanos Cancer Institute, Detroit, MI, United States, ⁶PET Center, Children's Hospital of Michigan, Detroit, MI, United States.

P14.70

Systemic therapy for brain metastases in elderly patients with lung cancer: A systematic review

Y. Nakasu¹, K. Mitsuya², S. Nakasu³;

¹Department of Neurosurgery, Shiga University of Medical Science, Ohtsu, Japan, ²Division of Neurosurgery, Shizuoka Cancer Centre, Nagaizumi, Japan, ³Department of Neurosurgery, Kusatsu General Hospital, Kusatsu, Japan.

P14.71

Tumor Treating Fields combined with radiotherapy and temozolomide for newly diagnosed glioblastoma: final safety and efficacy results from a pilot study

R. Grossman, F. Bokstein, D. Blumenthal, C. Ben Harush, D. Limon, Z. Ram;

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

P14.72

Multicentric glioblastoma - A retrospective study of imaging characteristics, treatment approach, pattern of relapse and survival

A. Benouaich Amiel¹, V. Khasminsky², O. Gal³, S. Fichman⁴, T. Weiss⁵, T. Siegal¹, S. Yust-Katz⁶;

¹rabin medical center davidoff oncology, Petah tikva, Israel, ²rabin medical center Department of Neuro Radiology, petah tikva, Israel, ³rabin medical center davidoff oncology Department of radiotherapy, Petah tikva, Israel, ⁴rabin medical center Neuro Pathology, Department of Pathology, petah tikva, Israel, ⁵rabin medical center davidoff oncology Department of radiotherapy, petah tikva, Israel, ⁶rabin medical center davidoff oncology, petah tikva, Israel.

P14.73**Toxicity and outcomes of reduced-dose whole brain radiotherapy as consolidation treatment for patients with CNS lymphoma in real life setting**

P. Lesueur¹, G. Dama², K. Hoang-Xuan³, V. Rolland⁴, A. Schmitt⁵, O. Chinot⁶, M. Fabbro⁷, P. Agapé⁸, C. Chabrot⁹, S. Chebrek¹⁰, L. Feuvret³, D. Stefan¹, C. Soussain¹¹, C. Houillier³;

¹Centre François Baclesse, Caen, France, ²CHU de Caen, Caen, France, ³La Pitié Salpêtrière (AP-HP), Paris, France, ⁴CH de Perpignan, Perpignan, France, ⁵Institut bergonié, Bordeaux, France, ⁶Hôpital de la Timône, Marseille, France, ⁷Institut régional du Cancer de Montpellier, Montpellier, France, ⁸Institut de cancérologie de l'Ouest, Nantes, France, ⁹CHU de Clermont Ferrand, Clermont Ferrand, France, ¹⁰CH d'Avignon, Avignon, France, ¹¹Institut Curie, Saint Cloud, France.

P14.74**Remarkable response to Combined BRAF and MEK Inhibitors in two Adults with leptomeningeal carcinomatosis secondary to Pleomorphic Xantastrocytoma grade II with BRAFV600E mutation**

M. Eoli, B. Pollo, A. Silvani, R. Paterra, A. Erbetta, E. Anghileri, P. Gaviani, G. Finocchiaro;
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Milan, Italy.

P14.75**Active beam scanning proton therapy radiosurgery: early outcomes**

D. Amelio, D. Scaroni, R. Righetto, F. Fellin, I. Giacomelli, A. Turkaj, M. Schwarz, M. Amichetti;
Proton Therapy Center - Trento Hospital, Trento, Italy.

P14.76**Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study**

L. Garnier¹, C. Dehais², E. Curtit¹, E. Tabouret³, C. Ramirez⁴, E. Vauleon⁵, V. Bourg⁶, M. Boone⁷, D. Figarella-Branger⁸, F. Ducray⁹, POLA Network;

¹Department of Medical Oncology, University Hospital of Besançon, Besançon, France, ²Department of Neuro-Oncology, AP-HP, Paris, France, ³Department of Neuro-Oncology, AP-HM, Marseille, France, ⁴Department of Neuro-Oncology, University Hospital of Lille, Lille, France, ⁵Department of Medical Oncology, University Hospital of Rennes, Rennes, France, ⁶Department of Neuro-Oncology, University Hospital of Nice, Nice, France, ⁷Department of Neuro-Oncology, University Hospital of Amiens, Amiens, France, ⁸Department of Pathology, AP-HM, Marseille, Marseille, France, ⁹Department of Neuro-Oncology, Hospices Civils de Lyon, Lyon, Lyon, France.

P14.77**Reduced dose craniospinal irradiation (CSI) is feasible for standard risk adult medulloblastoma (MBL) patients similarly to pediatric population**

M. Massimino¹, M. Sunyach², L. Gandola¹, E. Pecori¹, F. Spreafico¹, A. Bonneville Levard², V. Biassoni¹, E. Schiavello¹, B. Diletto¹, R. Stefini³, D. Frappaz²;

¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, ²Centre Léon Bérard, LYON, France, ³Neurosurgery Unit, Legnano Hospital, Legnano, Italy.

P14.78**Hypofractionated stereotactic radiotherapy as a salvage therapy for recurrent high-grade gliomas: Single-center experience**

T. Reynaud¹, A. Bertaut², W. Farah³, D. Thibou¹, G. Crehange¹, G. Truc¹, N. Vulquin¹;

¹Department of Radiotherapy, Georges François Leclerc Center, Dijon, France, ²Department of Epidemiology, Georges François Leclerc Center, Dijon, France, ³Department of Neurosurgery, CHU, Dijon, France.

P14.79**Randomized phase II trial of Tumor Treating Fields plus radiation therapy plus temozolomide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma**

D. Limon, F. Bokstein, D. Blumenthal, C. Ben Harush, Z. Ram, R. Grossman;

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

P14.80**ADVANCES IN RADIOTHERAPY FOR BRAIN TUMORS (BENIGN, MALIGNANT AND PEDIATRICS TUMORS)**

M. Theodorou;

Bank of Cyprus oncology Center, Nicosia, Cyprus.

P14.81**Importance of early spectral variations during a longitudinal 60-month follow-up MRI and 1H-MRS in 135 treated glioblastoma patients**

S. BOUSSIDA, A. HEINTZ, Z. SAIDAK, M. LEFRANC, A. GALMICHE, J. CHOMBAR, J. PELTIER, B. CHAUFFERT, M. BOONE, J. CONSTANS;
CHU Amiens-Picardie, Amiens, France.

P14.82**Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study**

J. Zhang;

Sanbo Brain Hospital, Capital Medical University, Beijing, China.

P14.83**Adjuvant chemotherapy after severe myelotoxicity during temozolomide chemoradiation in gliomas. It is feasible? The talian Multicentric Study (AINO)**

V. Villani¹, A. Fabi¹, P. Gavian², R. Rudà³, G. Lombardi⁴, G. Simonetti², A. Silvan², E. Pronello³, G. Minniti⁵, **A. Pace⁶**;
¹IFO, roma, Italy, ²UO NEURO-ONCOLOGIA FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Milano, Italy, ³Department of Neuro-Oncology University of Turin and City of Health and Science Hospital, Torino, Italy, ⁴Department of Experimental and Clinical Oncology Medical Oncology 1, Veneto Institute of Oncology-IRCCS, Padova, Italy, ⁵UPMC San Pietro, roma, Italy, ⁶IFO, Rome, Italy.

P14.84**Intraarterial chemotherapy and osmotic blood-brain barrier modification in the treatment of primary CNS lymphoma**

D. Fortin, G. Gahide, C. Iorio-Morin;
 Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.

P14.85**Brain metastasis from Hodgkin's Lymphoma: case report and literature review**

F. Bruno¹, E. Pronello¹, S. Bortolani¹, R. Palmiero¹, A. Melcarne², A. Chiappella³, C. Mantovani⁴, R. Soffietti¹, R. Rudà¹;
¹Dept. of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy, ²Dept. of Neurosurgery, University and City of Health and Science Hospital, Turin, Italy, ³Dept. of Haematology, University and City of Health and Science Hospital, Turin, Italy, ⁴Dept. of Radiotherapy, University and City of Health and Science Hospital, Turin, Italy.

P14.86**Bevacizumab-associated intracerebral hemorrhage in patients with CNS malignancy: A single-center retrospective cohort study**

N. Clarke, M. Ruff;
 Mayo Clinic, Rochester, MN, United States.

P14.87**Leptomeningeal dissemination in high grade glioma: Correlation of MRI, cytology and standard CSF indices**

H. Durand¹, F. Lamy¹, T. Parratte¹, A. Brinet¹, A. Blain¹, F. Lamy¹, C. Gaultier, MD¹, L. Droy-Dupré¹, S. Leblanc, MD¹, H. Oesterlé, MD¹, S. Olteanu¹, D. Atlani¹, J. Voirin¹, K. Mokhtar², **G. Ahle¹**;
¹Hôpitaux Civils de Colmar, Colmar, France, ²Hôpital Pitié-Salpêtrière, Paris, France.

P14.88**Comparison of SNaPshot PCR and digital droplet PCR for the identification of TERT promoter in non-diagnostic biopsies from glioma patients**

D. Poncet, T. Picart, J. Guyotat, E. Jouanneau, B. Joubert, A. Vasiljevic, J. Honnorat, D. Meyronet, F. Ducray, **M. Barrिताult**;
 Hospices Civils de Lyon, Lyon, France.

P14.89**What happens after 15 years? A clinical picture of a cohort of survivors of CNS tumors treated with whole-brain irradiation in a National Cancer Center**

V. L. Espírito Santo¹, J. Passos², T. Pimentel², J. Nunes², I. Costa², D. Salgado²;
¹Centro Hospitalar Trás-os-Montes e Alto Douro, Vila Real, Portugal, ²Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal.

P14.90**Interleukin 6 is a useful marker for pseudotumoral inflammatory CNS lesions suspicious of lymphoma**

A. Ungureanu¹, M. Costopoulos², T. Parratte¹, A. Brinet¹, H. Durand¹, C. Gaultier¹, T. Postert³, R. Hurstel¹, I. Alamome¹, F. Sella¹, M. Le Garff-Tavernier², **G. Ahle¹**;
¹Hôpitaux Civils de Colmar, Colmar, France, ²Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³St. Vincenz-Krankenhaus, Paderborn, Germany.

P14.91**Study glycolytic metabolism in 1H-MRS monovoxel in the most aggressive part of 62 glioblastomas before and after 18 months of treatment**

A. HEINTZ, S. Boussida, Z. Saida, J. Chombar, M. Lefranc, C. Desenclos, A. Galmiche, B. Chauffert, M. Boone, **J. Constans**;
 CHU Amiens Picardie, Amiens, France.

P14.92**Study of Glutaminergic and Glutamatergic Metabolism in 1H-MRS Monovoxel in the Most Aggressive Part of 62 Glioblastoma Before and After 18 months Treatment**

A. HEINTZ, J. Chombar, S. Boussida, Z. Saidak, M. Lefranc, N. Deval, A. Coutte, B. Chauffert, M. Boone, **J. Constans**;
 CHU Amiens Picardie, Amiens, France.

P14.93**The utility of the brain 18-FDG-PET and perfusion magnetic resonance imaging in the radionecrosis differential diagnosis**

N. Mongay¹, N. Vidal¹, A. Lucas¹, M. Macià¹, G. Plans¹, A. Fernandez-Coello¹, C. Majos¹, L. Rodriguez-Bel², M. Alemany¹, J. Bruna¹;
¹Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-ICO, L'Hospitalet, Spain, ²Department of Nuclear Medicine, Hospital Universitari de Bellvitge, L'Hospitalet, Spain.

P14.94**Mitochondrial DNA copy number in new onset and recurrent glioblastoma and its effect on radiation resistance and patient survival****P. Sravya¹, V. P. Nimbalkar¹, N. N. Kanuri¹, S. Rao¹, A. Arivazhagan¹, S. Somanna¹, P. Kondaiiah², V. Santosh¹;**¹National Institute of Mental Health and Neurosciences, Bangalore, India, ²Indian Institute of Science, Bangalore, India.**P14.95****Is the pathological-grade relevant in “IDH-wild type, TERT-mutant” diffuse-gliomas? An analysis in 147 patients****A. E. Danyeli, C. B. Akyerli, A. Dinçer, E. Coşgun, U. Abacıoğlu, M. Pamir, K. Özduvan;**

Acibadem Mehmet Ali Aydınlar University, School of Medicine, Istanbul, Turkey.

P14.96**Gliomatosis cerebri imaging pattern: a treatment-independent marker for worse overall survival in WHO grade II and III gliomas****I. Divé^{1,2}, E. Steidl^{3,2}, M. Wagner³, M. C. Burger^{1,2}, K. Franz⁴, P. N. Harter⁵, O. Bähr^{1,2}, E. Fokas⁶, U. Herrlinger⁷, J. P. Steinbach^{1,2};**¹Dr. Senckenberg Institute of Neurooncology, Frankfurt am Main, Germany, ²University Cancer Center Frankfurt (UCT), Frankfurt am Main, Germany,³Institute of Neuroradiology, University Hospital Frankfurt, Frankfurt am Main, Germany, ⁴Department of Neurosurgery, University Hospital Frankfurt,Frankfurt am Main, Germany, ⁵Institute of Neurology (Edinger-Institut), University Hospital Frankfurt, Frankfurt am Main, Germany, ⁶Department ofRadiooncology, University Hospital Frankfurt, Frankfurt am Main, Germany, ⁷Department of Neurology, University Hospital Bonn, Bonn, Germany.**P14.97****High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer****P. Mir Seyed Nazari¹, C. Ay¹, A. Steindl², B. Gatterbauer³, J. M. Frischer³, K. Dieckmann⁴, G. Widhalm³, J. A. Hainfellner⁵, I. Pabinger¹, M. Preusser², A. Berghoff²;**¹Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria, ²Division ofOncology, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria, ³Department of Neurosurgery, Medical University of Vienna,Comprehensive Cancer Center, Vienna, Austria, ⁴Department of Radiotherapy, Medical University of Vienna, Comprehensive Cancer Center, Vienna,Austria, ⁵Institute of Neurology, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.**P14.98****Improving the targeting of Gamma-Knife radiosurgery for recurrent high-grade gliomas (WHO grades III and IV) with ¹¹C-Methionine PET/CT****E. Chaskis, G. Van Simaey, C. Martens, O. De Witte, S. Goldman, F. Lefranc;**

Hôpital Erasme, Brussels, Belgium.

P14.99**Clinical and biologic features predictive of survival after relapse of childhood medulloblastoma****S. Huybrechts¹, A. Chive², A. Tauziède-Espariat³, C. Rossoni⁴, E. Indersie⁵, P. Varlet³, S. Puget², R. Abbas⁴, O. Ayrault⁵, L. Guerrini-Rousseau⁴, J. Grill⁴, D. Valteau-Couanet⁴, C. Dufour⁴;**¹Hospital Center of Luxembourg, Luxembourg, Luxembourg, ²Necker Hospital, Paris, France, ³Sainte Anne Hospital, Paris, France, ⁴Gustave RoussyCancer Center, Villejuif, France, ⁵Institut Curie, Orsay, France.**P14.100****Measurements of glioblastoma response to recurrence using spectroscopic measurements and MRI volumetry****J. Chombar, A. Heintz, J. Constans;**

CHU AMIENS, Salouel, France.

P14.101**Glioblastoma survival outcomes related to cortical/neural stem cells regions****T. Kazda^{1,2}, R. Jancalek¹, R. Belanova², P. Pospisil², P. Burkon², L. Hynkova², P. Slampa², R. Lakomy²;**¹Faculty of Medicine, Masaryk University, Brno, Czech Republic, ²Masaryk Memorial Cancer Institute, Brno, Czech Republic.**P14.102****Cerebellar atrophy patterns in paraneoplastic cerebellar degeneraiton and spinocerebellar ataxia 1 (SCA1)****C. Vialatte de Péville¹, D. Psimaras¹, I. Adanyegu², F. Graus³, A. Dürr², J. Honnorat⁴, J. Delattre¹, A. Alentorn¹;**¹AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Sorbonne Université, UPMC Univ, Paris, France, ²AP-HP, Groupe HospitalierPitié-Salpêtrière, Department of Genetics, Sorbonne Université, Paris, France, ³AP-HP, GDepartment of Neurology, Hospital Clinic, University ofBarcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴roupe Hospitalier Pitié-Salpêtrière, Service deNeurologie 2, Sorbonne Université, UPMC Univ, Barcelona, Spain, ⁵AP-HP, French Reference Center on Paraneoplastic Neurological Syndromes,

Hospices Civils de Lyon, and Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon - Université Claude Bernard Lyon 1, Lyon,

France, Lyon, France.

P14.103**Patterns of diffuse glioma progression****G. L. Kobayakov, M.D.¹, A. Belyashova, M.D.¹, Y. Trunin, M.D.¹, O. Absalyamova, MD.¹, K. Lodygina, M.D.¹, N. Kobiakov, Student²;**¹Burdenko Neurosurgical Institute, Moscow, Russian Federation, ²Lomonosov Moscow State University Faculty of Medicine, Moscow, Russian

Federation.

P14.104**The outcomes of conservatively observed asymptomatic nonfunctioning pituitary adenomas with optic nerve compression****K. Hwang¹, Y. Kim², C. Kim¹, J. Han¹;**¹Seoul National University Bundang hospital, Seongnam-si, Korea, Republic of, ²Seoul National University hospital, Seoul, Korea, Republic of.

P14.105

High incidence of brain metastases in lung cancer patients at the time of primary diagnosis

E. Kobyakova, M.D.¹, E. Nechipay, M.D.¹, D. Sashin, M.D.¹, N. Kobiakov, Student², G. L. Kobyakov, M.D.³;

¹N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation, ²Lomonosov Moscow State University, Moscow, Russian Federation,

³Burdenko Neurosurgical Institute, Moscow, Russian Federation.

P14.106

One-year survival of radiotherapy vs conservative therapy in patients with metastatic brain disease in Cipto Mangunkusumo General Hospital 2014-2016

T. Aninditha¹, P. Y. Pratama¹, D. Imran¹, R. A. Aman¹, R. A. Werdhani¹, H. R. Sofyan¹, J. Odilo², T. A. S. Ranakusuma¹;

¹Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, ²Hermira Sukabumi Hospital, Sukabumi, Indonesia.

P14.107

Rapid early progression of glioblastoma is not related to cortical/neural stem cells regions

R. Jancalek^{1,2}, T. Kazda^{1,3}, R. Belanova³, P. Pospisil³, P. Burkon³, L. Hynkova³, P. Slampa³, R. Lakomy³;

¹Faculty of Medicine, Masaryk University, Brno, Czech Republic, ²St. Anne's University Hospital, Brno, Czech Republic, ³Masaryk Memorial Cancer Institute, Brno, Czech Republic.

P14.108

Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma

K. Seystahl¹, B. Hentsche², S. Loew³, D. Gramatzki¹, J. Felsberg⁴, U. Herrlinger⁵, M. Westphal⁶, G. Schackert⁷, N. Thor⁸, U. Schlegel⁹, M. Tatagiba¹⁰, T. Pietsch¹¹, G. Reifenberger⁴, M. Löffler², W. Wick³, M. Weller¹;

¹Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland, ²Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany, ³Department of Neurology and Neurooncology Program, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany, ⁴Department of Neuropathology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ⁵Department of Neurology, Division of Clinical Neuro-oncology, University of Bonn Medical Center, Bonn, Germany, ⁶Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Hamburg, Germany, ⁷Department of Neurosurgery, Carl Gustav Carus University Hospital, Technical University of Dresden, Dresden, Germany, ⁸Department of Neurosurgery, University of Munich LMU, Munich, Germany, ⁹Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr-Universität Bochum, Bochum, Germany, ¹⁰Department of Neurosurgery, Eberhard-Karls-University, University Hospital Tübingen, Tübingen, Germany, ¹¹Department of Neuropathology, University of Bonn, Bonn, Germany.

P14.109

Standard error of measurement (SEM) and intraclass coefficient (ICC) in volumetric assessment of postoperative residual tumor volume in glioblastoma

G. Hallaert, H. Pinson, D. Van Roost, J. Kalala, V. Vandriessche, T. Boterberg;

Ghent University Hospital, Gent, Belgium.

P14.110

Primary leptomeningeal melanocytic tumors - clinical course and molecular pathological aspects of an underestimated entity -

H. Dohmen^{1,2}, A. Jensen³, K. Schoeller⁴, E. Uh^{2,4}, T. Acker^{1,5}, M. Stein^{2,4};

¹Institute of Neuropathology, Justus-Liebig University Giessen, Giessen, Germany, ²Center of Neurooncology, Justus-Liebig University Giessen, Giessen, Germany, ³Department of Radiation Oncology, Justus-Liebig University Giessen, Giessen, Germany, ⁴Department of Neurosurgery, Justus-Liebig University Giessen, Giessen, Germany, ⁵Center of Neurooncology, Justus-Liebig University Giessen, Giessen, Germany, Giessen, Germany.

P14.111

Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: case report and review of the literature

J. F. Megyesi, D. R. Macdonald;

University of Western Ontario, London, ON, Canada.

P14.112

Long-term application of TTFIELDS in glioblastoma: a multiple-case study

A. Lawson McLean, R. Kalff, J. Walter;

Jena University Hospital, Jena, Germany.

P14.113

The role of maintenance high-dose methotrexate chemotherapy in elderly primary CNS lymphoma patients with complete response to induction immunochemotherapy

K. Mishima, M. Shirahata, J. Adachi, T. Suzuki, T. Fujimaki, R. Nishikawa;

Saitama Medical University, Yamane, Hidaka-shi, Saitama, Japan.

P14.114

Tumor treating fields in glioblastoma clinical practice guidelines: a European and North American landscape analysis

A. Lawson McLean, R. Kalff, J. Walter;

Jena University Hospital, Jena, Germany.

P14.115

A Neurologist's Foray into Gamma Knife: Lessons Learned from the first 100 cases:

G. H. J. Stevens, S. T. Chao, E. S. Murphy, J. H. Suh, J. Yu, G. Neyman;
Taussig Cancer Center, Cleveland, OH, United States.

P14.116

Lack of correlation between incidental ipsilateral subventricular zone radiation dose and overall survival in glioblastoma patients

G. Hallaert¹, H. Pinson¹, D. Vanhauwaert², L. Staelens², C. Vandebroecke³, D. Van Roost¹, J. Kalala¹, T. Boterberg¹;
¹Ghent University Hospital, Gent, Belgium, ²AZ Delta, Roeselare, Belgium, ³AZ St. Lucas, Gent, Belgium.

P14.117

Cost efficient test algorithm for molecular subgrouping of medulloblastomas for day-to-day practice in resource limited countries

K. Kaur, P. Jha, P. Pathak, V. Suri, M. C. Sharma, A. Garg, A. Suri, C. Sarkar;
All India Institute of Medical Sciences, New Delhi, New Delhi, India.

P14.118

Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study

Y. J. GARCILAZO¹, C. Soussain², E. Tabouret³, G. Ahle⁴, A. Schmitt⁵, A. Waultier⁶, M. Blonski⁷, A. Liou-Schischmanoff⁸, K. Hoang-Xuan¹, C. Houillier⁹;
¹Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ²Service d' Hématologie, Institut Curie, Site Saint Cloud, France, ³Aix-Marseille Univ, CNRS, INP, AP-HM, Service de Neuro- Oncologie, CHU de la Timone, Marseille, France, ⁴Service de Neurologie, Hospices civils de Colmar, Colmar, France, ⁵Service d' Hématologie, Institut Bergonié, Bordeaux, France, ⁶Service d' Hématologie, CHU de Nîmes, Nîmes, France, ⁷Service de Neurologie, CHU de Nancy, Nancy, France, ⁸Service Pharmacie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ⁹Sorbonne Université, IHU, ICM, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

P14.119

Clinical-radiological description of a retrospective series of patients diagnosed with stroke due to hypercoagulability associated with cancer

I. Esparragosa, R. Valenti-Azcarate, D. Moreno-Ajona, C. Toledano-Illan, P. Irimia Sieira, E. Martinez-Vila, J. Gallego Perez de Larraya;
Department of Neurology, Pamplona, Spain.

P14.120

Phase II study of weekly carboplatin in pretreated adult malignant gliomas

V. Villani¹, **A. Pace²**, A. Vidiri¹, A. Tanzilli¹, F. Sperati¹, I. Terrenato¹, M. Carosi¹, B. Casini¹, M. Maschio¹, T. koudriavtseva¹, F. Cognetti¹, A. Fabi¹;
¹IFO, roma, Italy, ²IFO, Rome, Italy.

P14.121

Use of corticosteroids in glioblastoma patients A single institution experience

U. Smrdel, M. Skoblar Vidmar;
Institute of Oncology Ljubljana, Slovenia, Ljubljana, Slovenia.

P14.122

Integrin $\alpha 5$ is a poor prognostic factor in patients with glioblastoma treated by the Stupp protocol

N. Etienne-Selloum^{1,2}, J. Prades³, D. Bello Roufai³, F. El Azumi¹, M. Boone³, H. Sevestre⁴, S. Trude⁵, A. Coutte⁶, C. Desenclos⁷, J. Constans⁸, B. Chauffert³, M. Dontenwill¹;
¹UMR 7021 CNRS/Unistra, Laboratoire de Bioimagerie et Pathologies, Faculté de pharmacie, Illkirch-Graffenstaden, France, ²Service de Pharmacie, Centre de Lutte contre le Cancer Paul Strauss, Strasbourg, France, ³Service d'oncologie médicale, CHU Amiens-Picardie, Amiens, France, ⁴Service d'anatomie et cytologie pathologique, CHU Amiens-Picardie, Amiens, France, ⁵Laboratoire d'oncobiologie moléculaire, CHU Amiens-Picardie, Amiens, France, ⁶Service de radiothérapie, CHU Amiens Picardie, Amiens, France, ⁷Service de neurochirurgie, CHU Amiens-Picardie, Amiens, France, ⁸Service de radiologie et imagerie médicale, CHU Amiens-Picardie, Amiens, France.

P14.123

Neurological complications related to checkpoints inhibitors

I. Esparragosa, R. Valenti-Azcarate, D. Moreno-Ajona, J. Gallego Perez de Larraya;
Department of Neurology, Pamplona, Spain.

P14.124

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

P. Roth¹, J. Reijneveld², T. Gorlia³, F. Dhermain⁴, F. De Vos⁵, M. Vanlancker³, C. O'Callaghan⁶, E. Le Rhun⁷, M. van den Bent⁸, W. Mason⁹, M. Weller¹;
¹Department of Neurology, University Hospital Zurich, Zurich, Switzerland, ²Universiteit Amsterdam, Amsterdam, Netherlands, ³EORTC, Brussels, Belgium, ⁴Institut Gustave Roussy, Villejuif, France, ⁵University Medical Center Utrecht Cancer Center, Utrecht, Netherlands, ⁶Canadian Cancer Trials Group, Kingston, ON, Canada, ⁷University Hospital Lille, Lille, France, ⁸Daniel den Hoed Cancer Center, Rotterdam, Netherlands, ⁹Princess Margaret Hospital, Toronto, ON, Canada.

P14.125**Retrospective analysis of long-term response to bevacizumab in combination with irinotecan for recurrent glioblastoma : identification of prognostic factors**

C. Besson¹, M. Morisse², H. Brut¹, W. Waiss³, G. Noël³, B. Chauffer², D. Prébay¹, R. Schott⁴, **N. Etienne-Selloum**^{5,1};

¹Service de Pharmacie, Centre de Lutte contre le Cancer Paul Strauss, Strasbourg, France, ²Service d'oncologie médicale, CHU Amiens-Picardie, Amiens, France, ³Service de radiothérapie, Centre de Lutte contre le Cancer Paul Strauss, Strasbourg, France, ⁴Service d'oncologie médicale, Centre de Lutte contre le Cancer Paul Strauss, Strasbourg, France, ⁵UMR 7021 CNRS/Unistra, Laboratoire de Bioimagerie et Pathologies, Faculté de pharmacie, Illkirch-Graffenstaden, France.

P14.126**radiation-induced optic neuropathy**

A. Thomas¹, C. Birzu², L. Feuvret³, G. Noël¹, K. Hoang-Xuan², J. Savatosky⁴, D. Ricard⁶, D. Psimaras²;

¹Radiotherapy department, Centre Paul Strauss, Unicancer, F-67065, Strasbourg, France, Strasbourg, France, ²Neurology department, Pitie-Salpetriere hospital, Paris, France, Paris, France, ³Radiotherapy department, Pitie-Salpetriere hospital, Paris, France, Paris, France, ⁴Department of Neuroradiology, Fondation Rothschild Hospital, Paris, France, Paris, France, ⁵Department of Neurology, Service de Santé des Armées, HIA de Percy, 101 avenue Henri Barbusse, 92140 Clamart, France, Clamart, France.

P14.127**From next generation sequencing and comparative genomic hybridization to personalised medicine for adult primary brain tumors : the profiler trial**

A. Bonneville-Jevard¹, D. FRAPPAZ¹, D. PISSALOUX¹, Q. WANG¹, D. PEROL¹, J. BLAY¹, D. MEYRONET²;

¹Centre Léon Bérard, Lyon, France, ²Hospices civils de Lyon, Lyon, France.

P14.128

Lack of development of Pneumocystis Jirovecii Pneumonia in a cohort of 103 Italian glioblastoma patients not receiving prophylaxis during post-surgical chemoradiotherapy

N. Rifino^{1,2}, A. Rigamonti¹, F. Guida¹, C. Bonato¹, G. De Nobili¹, G. Spina¹, A. Salmaggi¹;

¹A. Manzoni Hospital, Lecco, Italy, ²University of Milano-Bicocca, Milan, Italy.

P14.129

Predicting glioblastoma invasion using multiparametric MRI and a bi-level machine learning approach

C. Li¹, P. Liu¹, **Y. Wei**¹, Y. Li², C. Schönlieb¹, S. J. Price¹;

¹University of Cambridge, Cambridge, United Kingdom, ²Fudan University, Shanghai, China.

AUTHOR INDEX

A

Abacioğlu, Ufuk: P14.95
Abbas, Rachid: P14.99
Abbasova, Elena: P03.14
Abbruzzese, Claudia: P11.51
Abdel Karim, Khaled: **P03.06**, P03.07, P03.08
Abdollahi, Amir: P11.07
Abdullaeva, Sevda: P03.14
Absalyamov, Artyom: P14.15
Absalyamova, Oksana: **P14.03**, P14.15, P14.65, P14.103
Acker, Till: P14.110
Adachi, Jun-ichi: **P13.01**, P14.113
Adams, Claire L.: P09.07
Adanyegu, Isaac: P14.102
Adeberg, Sebastian: P05.07
Agabekyan, Goar: P14.03, P14.15, **P14.65**
Agapé, Philippe: P14.73
Aghababazadeh, Masoomeh: P11.47
Ahle, Guido: **P13.13**, P14.118, **P14.49**, **P14.87**, **P14.90**
Ahn, Hong: P10.01
Aho, Todd: P13.15
Ah-Pine, Franck: **P13.03**
Ahuja, Chirag: P14.06
Akbari, Mohsen: P11.40
Akdur, Kerime: P11.55
Akyerli, Cemaliye B.: P14.95
Alamome, Isabelle: P14.90
Alapetite, Claire: P14.05
Aldaba, Eneko: P11.46
Alemany, Montserrat: P10.04, P14.93
Alentorn, Agusti: **P14.102**
Alfasi, Tali: P04.06
Alonso, Marta M.: **P06.01**, P08.04, **P11.23**
Alonso, Miriam: P14.58
Aman, Renindra A.: P14.106
Ameli, Roxana: P04.18, P13.02
Amelio, Dante: **P14.75**
Amichetti, Maurizio: P14.75
Amiel, Alexandra: P05.04, P09.06
An, Hong: P14.27
Anastopoulou, GG G.: P10.04
Andermatten, Joaquin: P11.46
Andratschke, Nicolaus: P14.25
Angel, Catherine E.: P12.02
Anggraeni, Dya: P09.01
Anghileri, Elena: P14.64, P14.74
Aninditha, Tiara: **P14.106**
Ansell, Peter J.: P14.54
Ansell, Peter: P11.08
Antipina, Natalia: P11.48
Antipova, Olga: P12.07
Antonenko, Fedor: P03.14
Antoni, Delphine: P13.13
Appay, Romain: P13.09
Araki, Ryuichiro: P13.01
Argyriou, Andreas: P14.04
Arivazhagan, Arimappagan: P14.94
Armoiry, Xavier: **P14.12**
Armstrong, Georgina N.: P13.06
Artusi, Roberto: P11.24
Asano, Yoshitaka: P14.01
Ashkan, Keyoumars: P11.49
Asmaro, Karam: P01.02
Atar-Vardi, Maya: P14.21
Atlani, David: P14.87
Auguste, Peter: P14.12
Auzmendi-Iriarte, Jaione: **P11.46**
Avril, Tony: P11.61
Ay, Cihan: P14.97
Ayrault, Olivier: P14.99
Azevedo, Ana: P03.13
Azuaje, Francisco: P11.26

B

Bachmann, Felix: P11.31
Baehring, Joachim M.: P14.26
Bagnard, Dominique: P11.59
Bahador, Marzieh: P11.57
Bähr, Oliver: P14.63, P14.96
Bailey, Abigail: P14.30, P14.36
Bain, Earle E.: P11.08, P14.54
Bairey, Osnat: P05.04
Baiz, Daniele: P09.07
Balana, Carme: P14.58
Baldi, Isabelle: P09.08
Baldini, Capucine: **P13.14**
Ballo, Matthew T.: P14.66
Balvers, Rutger: P11.27
Balyasnikova, Irina V.: **P12.03**
Bani Sadr, Alexandre: **P13.02**
Barba, Carmen: P04.08
Barbarot, Sebastien: P14.33
Barger, Geoffrey R.: P14.37, P14.57, P14.69
Bari, Romi: P14.21
Barreto Zambrano, Tanny Daniela: P03.05
Barrett, David: P11.62
Barrios, Laura: P13.08
Barrिताult, Marc: P13.02, P14.13, **P14.88**
Bartels, Frederik: P11.07
Bassiri, Kayleigh: P09.07
Battiste, James D.: P05.06
Bauchet, Luc: P14.33
Bauer, Elena K.: P14.18, **P14.29**, P14.32
Behringer, Simon P.: P11.58
Bejarano, Leire: P11.17
Belanova, Renata: P14.101, P14.107
Belin, Catherine: P14.20, P14.31
Belin, Lisa: P05.05
Bello Roufai, Diana: P14.122
Bello, Lorenzo: P04.09, P05.08
Belyashova, Alexandra: **P11.48**, P14.15, P14.103
Ben Harush, Carmit: P14.71, P14.79
Bendszus, Martin: P14.41
Benouaich Amiel, Alexandra: P14.72
Bequet, Céline: P13.09
Berberich, Anne: **P11.07**
Berendsen, Sharon: **P13.10**
Berezovsky, Artem D.: **P11.54**
Berge, Jérôme: P09.08
Berger, Asaf: P04.06
Berger, Mitchel S.: P08.01
Berges, Raphael: **P11.06**, **P11.31**
Berghoff, Anna-Sophie: P14.97
Berhouma, Moncef: P14.13
Bernier, Lise-Prune: P04.18, P13.02
Bernhardt, Denise: P05.07
Bernier, Marie-Odile: P08.05
Berrocal, Alfonso: P14.58
Bertaut, Aurélie: P14.78
Berthel, Marie-Camille: P14.49
Berthezène, Yves: P13.02
Berthier, Sylvie: P11.33
Berzero, Giulia: **P04.10**, P10.06
Besson, Charlotte: P14.125
Betancor, Isabel: P14.55
Bhan, Arti: P01.02
Bhangoo, Ranjeev: P11.49
Bhardwaj, Mohit: P11.53
Bhat, Vasudev: P14.50
Biassoni, Veronica: P14.77
Bielle, Franck: P14.16
Bihin, Benoit: P03.02, P03.03
Bikfalvi, Andreas: **P11.65**
Billottet, Clotilde: P11.65

Birzu, Cristina Alina: **P10.06**, P14.126
 Bjerkvig, Rolf: P11.52, P11.57
 Blagoev, Blagoy: P11.36
 Blain, Antoine: P14.49, P14.87
 Blanco, Critóbal J.: P13.11
 Blanco-Acevedo, Cristóbal: P11.17
 Blasco, María A.: P11.17
 Blau, Tobias: P14.29
 Blay, Jean-Yves: P14.127
 Bley, Shira: P08.02
 Blonski, Marie: P14.118
 Blumenthal, Deborah: P14.71, P14.79
 Bodi, Istvan: P11.49
 Bogusiewicz, Joanna: **P13.05**
 Boisselier, Blandine: P13.03
 Bojko, Barbara: P13.05
 Bokstein, Felix: P14.71, P14.79
 Bomzon, Zeev: P11.18, P11.21, P11.25, **P11.37**, P11.50, P14.69
 Bonato, Claudio: P14.128
 Bondy, Melissa: P13.06
 Bonneville-Levard, Alice: P14.04, P14.77, **P14.127**
 Boone, Mathieu: P14.122, P14.76, P14.81, P14.91, P14.92
 Borggreffe, Jan: P14.17
 Bortolani, Sara: P14.85
 Boterberg, Tom: P14.109, P14.116
 Bouchoux, Guillaume: P05.05
 Boulfoul, Wafa: P13.14
 Bourg, Veronique: P14.76
 Boussida, Salem: P14.81, P14.91, P14.92
 Boutonnat, Jean: P11.33
 Braguer, Diane: P11.06, P11.31
 Bratthäll, Charlotte: P11.43
 Brawanski, Alexander: P03.11, P03.12, P11.50
 Brehar, Felix M.: P04.17
 Brell, Marta: P03.10
 Brem, Henry: P11.60
 Brichler, Segolene: P14.31
 Brinet, Abdelmalek: P14.49, P14.87, P14.90
 Brito, Cheila: **P03.13**
 Brogna, Christian: P11.49
 Brognaro, Enrico: **P14.19**
 Brokinkel, Benjamin: P09.05
 Bronnimann, Charlotte: **P04.12**, P14.04
 Brooks, Anna: P10.02, P10.03
 Bruhn, Helena: **P14.09**
 Bruna, Jordi: P10.04, P14.93
 Bruno, Francesco: P04.09, **P14.85**
 Brut, Hugo: P14.125
 Buccoliero, Anna Maria: P04.08, P14.46
 Buerki, Robin A.: P08.01
 Burek, Malgorzata: P11.28
 Burger, Michael C.: **P12.04**, P14.96
 Burkon, Petr: P14.101, P14.107
 Busek, Petr: **P11.41**
 Butowski, Nicholas A.: P08.01

C
 Cai, Hai-ping: P11.01
 Calatozzolo, Chiara: **P09.03**
 Calin, Violeta L.: P04.17
 Callec, Laetitia: P14.05
 Camacho López, Cristina: P03.05
 Camoyret, Aurore: P14.49
 Cannavale, Gaetano: P11.19
 Canney, Michael: P05.05
 Cano-Rojas, Alberto: P13.11
 Cano-Sánchez, Antonio: P13.11
 Cantley, Lewis: P11.63
 Capelle, Laurent: P14.16
 Cappellen, David: P04.12
 Carosi, Mariantonia: P14.120

Carpentier, Alexandre: P05.05
 Carpentier, Antoine: **P14.20**, **P14.31**
 Carpentier, Catherine: P04.12
 Carra, Federica: P08.03
 Carrato, Cristina: P14.58
 Cartalat, Stéphanie: P04.18, P14.13
 Casas, Déborah: P13.03
 Caselli, Gianfranco: P11.24
 Casini, Beatrice: P14.120
 Castaño, Justo P.: P11.17
 Castro Cuevas, Cristina: P03.05
 Castro, Ana V.: **P01.02**, **P13.15**
 Catry-Thomas, Isabelle: P14.24
 Ceccon, Garry: P14.17, P14.32
 Cen, Ziwen: P11.01
 Censullo, Maria Luigia: **P04.08**, **P08.03**
 Cerdán, Sebastián: P13.08, P13.11
 Cetica, Valentina: P04.08
 Chabardès, Stéphan: P11.02
 Chabrot, Cécile: P14.73
 Chai, Yi: P04.13
 Chan, Aden K.: **P14.47**, **P14.48**
 Chandler, Christopher: P11.49
 Chanez, Brice: P13.09
 Chang, Jong Hee: P14.42, P14.44
 Chang, Qing: **P01.01**
 Chang, Susan M.: P08.01
 Chao, Samuel T.: P14.115
 Chapelon, Jean-Yves: P05.05
 Charest, Gabriel: P11.40
 Chaskis, Elly: **P14.98**
 Chastagner, Pascal: P14.05
 Chauffert, Bruno: P14.122, P14.125, P14.81, P14.91, P14.92
 Chaugne, Emeline: P14.31
 Chebrek, Safia: P14.73
 Chen, Anjing: P11.52
 Chen, Fu-rong: P11.01
 Chen, Yin-sheng: P03.09
 Chen, Zhong-ping: **P03.09**, P11.01
 Cheng, Caroline: P11.12
 Chevet, Eric: P11.61
 Chevigné, Andy: P11.09
 Chiappella, Annalisa: P14.85
 Chinnaswamy, Girish: P14.50
 Chinot, Olivier: P13.09, P14.33, P14.73
 Chirifi, Ihsan: P11.12
 Chitale, Dhananjay: P01.02
 Chivet, Anais: P14.99
 Chmielova, Barbora: P11.41
 Choi, Du-Yong: P02.01
 Chombar, Jean-Philippe: **P14.100**, P14.81, P14.91, P14.92
 Chovelon, Benoit: P11.33
 Chung, Dong-Sup: **P14.51**
 Ciceri, Fabio: P05.02
 Clarke, Jennifer R.: P08.01
 Clarke, Nathan: **P14.86**
 Clement, Paul: P11.08
 Cloughesy, Timothy: P05.06
 Cognetti, Francesco: P14.120
 Cohen, Rachel: P08.02
 Col, Edwige: P11.33
 Colò, Francesca: P14.24
 Colovic, Milena: P11.24
 Comanescu, Brandus: P04.17
 Conidi, Andrea: P11.34
 Conill Llobet, Carles: P03.05
 Connock, Martin: P14.12
 Constans, Jean Marc: P14.100, P14.122, **P14.81**, **P14.91**, **P14.92**
 Conti Nibali, Marco: P04.09
 Cortés Mateus, Karen Sttephannía: **P03.05**
 Cortnum, Søren O. S.: P05.03

Coşgun, Erdal: P14.95
Costa, Ilda: P14.89
Costa, Mathias: P04.06
Costopoulos, Myrto: P14.49, P14.90
Cottet-Rousselle, Cécile: P11.33
Coutte, Alexandre: P14.92, P14.122
Covela, Marta: P14.58
Crehange, Gilles: P14.78
Curtit, Elsa: P14.76
Cuzzubbo, Stefania: P14.31
Cwiertka, Karel: P14.68

D

Dahle, Charlotte: P14.09
Daisne, Jean F.: P03.02, P03.03
Dalemans, Diana: P13.10
Damaj, Gandhi: P14.73
Daniels, Dianne: P11.22
Danilov, Gleb: P11.64
Danyeli, Ayca E.: P14.95
Darlix, Amélie: **P04.02, P04.14**
Daubon, Thomas: P11.65
De Gregorio, Veronica: P04.08
de Groot, John: P05.06
de Heer, Iris: P11.08
De las Peñas, Ramon: P14.58
De Nobili, Giuseppe: P14.128
De Vos, Filip: P14.124
De Wit, Maurice: P11.47
de Witt Hamer, Philip C.: P14.53
De Witte, Olivier: P14.56, P14.98
Debliquis, Agathe: P14.49
Debus, Jürgen: P05.07
deCarvalho, Ana: P01.02, P11.54
Dehais, Caroline: P04.12, P14.76
Dekker, Lennard J. M.: P13.07
Del Barco, Sonia: P14.58
Delattre, Jean-Yves: P04.10, P04.12, P05.05, P14.102
Deleval, N.: P14.92
Derks, Jolanda: P14.53
Déry, Laurence: **P11.40**
Derzane, Estela: P09.06
Desenclos, Christine: P14.91, P14.122
Desseaux, Carole: P05.05
Dewan, Aditi: **P11.53**
Dhermain, Frederic: P14.124
D'hombres, Anne: P14.13
Di Meco, Francesco: P09.03
Di Stefano, Anna Luisa: P04.10
Diamant, Gil: P12.05
Diansari, Yunni: **P05.01, P09.01**
Diaz, Maria: **P14.23**
Dieckmann, Karin: P14.97
Dik, Wim: P11.10, P11.11
Diletto, Barbara: P14.77
Dimberg, Anna: P11.43
DiMeco, Francesco: P05.02
Dinçer, Alp: P14.95
Dipasquale, Angelo: P05.08
Dirven, Clemens: P11.27, P11.34, P11.47
Dittmar, Gunnar: P11.57
Divé, Iris: **P14.96**
Doenitz, Christian: P03.11, P03.12
Dohmen, Hildegard: P14.07, P14.110
Dokukina, Tatyana: P12.10
Domenech, Marta: P14.58
Domínguez Azorín, Daniel: P11.29
Domröse, Dominik: P11.28
Dong, Zhen: P11.07
Dontenwill, Monique: **P11.59, P14.122**
Doridam, Jennifer: P14.31
Douw, Linda: P14.53

Draaisma, Kaspar: P13.10
Drabek, Jiri: P14.68
Dragunow, Michael: P10.02, P10.03
Droy-Dupré, Laure: P14.49, P14.87
Dubbink, Hendrik J.: P04.11
Ducray, François: P04.12, P04.18, P13.02, P14.13, P14.33, P14.76, P14.88
Duffau, Hugues: P04.02, P04.14
Dufour, Christelle: P14.99
Dufour, Henry: P13.09
Dunn, Jemma: P09.07
Durand, Hélène: P14.87, P14.90
Durand, Thomas: P08.05
Duran-Peña, Alberto: **P14.16**
Dürr, Alexandra: P14.102
Dussart, Claude: P14.12
Dykina, Alina: P03.14
Dym, Lianne: P14.21

E

Eberl, Petra: P11.50
Eimer, Sandrine: P04.12
Eker, Omer F.: P13.02
El Azumi, Fatma: P14.122
El Shafie, Rami: P05.07
Elbaz, Yonatan: P14.21
El-Shehaby, Amr M.: P03.06, P03.07, P03.08
Elua-Pinin, Alex: P11.46
Emad Eldin, Reem M.: P03.06, **P03.07, P03.08**
Engelhardt, Julien: **P09.08**
Eoli, Marica: P05.02, P11.08, P14.64, **P14.74**
Erbetta, Alessandra: P14.74
Ercolano, Emanuela: P09.07
Ernestus, Ralf-Ingo: P11.28, P11.44, P14.28, P14.60
Escudero López, Elisabet: P03.05
Eshhar, Zelig: P12.05
Esparragosa, Ines: P08.04, **P14.119, P14.123**
Espirito Santo, Vera L.: **P14.89**
Esteves, Susana: P03.13
Estival, Anna: P14.58
Etienne-Selloum, Nelly: **P14.122, P14.125**
Eyupoglu, Eylem E.: P14.14

F

Fabbro, Doriano: P11.45
Fabbro, Michel: P04.02, P14.73
Fabi, Alessandra: P14.120, P14.83
Fabro, Federica: **P13.07**
Fan, Yang-Hua: **P13.12**
Farah, Walid: P14.78
Farina, Francesca: P05.02
Fariña, Helga: P14.40, P14.55
Farina, Silvia: P08.03
Farinotti, Mariangela: P14.64
Fariselli, Laura: P14.64
Faull, Richard: P10.03
Faure Conter, Cécile: P14.04, P14.05
Faure, Patrice: P11.33
Felicella, Michelle: P13.15
Felistia, Yuli: P05.01
Fellin, Francesco: P14.75
Felsberg, Jörg: P14.18, P14.108
Feng, Ming: P13.12
Feng, Zichao: **P11.52**
Ferec, Claude: P04.12
Ferluga, Sara: P09.07
Fernandez-Coello, Alejandro: P14.93
Feuvret, Loic: P08.05, P14.16, P14.73, P14.126
Fichman, Suzana: P14.72
Fietkau, Rainer: P14.63
Figarella-Branger, Dominique: P04.12, P11.31, P13.09, P14.76

Fink, Gereon R.: P14.17, P14.18, P14.29, P14.32
 Finlay, Graeme J.: P12.02
 Finnerty, Gerald T.: P11.49
 Finocchiaro, Gaetano: **P05.02**, P14.64, P14.74
 Flammer, Julia: P12.09
 Flueh, Charlotte: **P10.05**
 Fokas, Emmanouil: P14.96
 Fonte, Carla: P08.03
 Förster, Carola: P11.28
 Fortin, David: P11.39, P11.40, **P14.84**
 Fraisse, Julien: P04.02
 Franceschi, Enrico: P11.08
 Franchino, Federica: P04.09
 Franz, Kea: P14.96
 Frappaz, Didier: **P14.04**, **P14.05**, P14.127, P14.16, **P14.24**,
 P14.33, **P14.77**
 French, Pim J.: P04.11, **P11.08**, P11.47, P14.54
 Frénel, Jean-Sébastien: P04.12, P11.08
 Frischer, Josa: P14.97
 Fritah, Sabrina: P11.09
 Fu, Alex Z.: **P14.30**, **P14.36**
 Fuad, M.: P03.01
 Fuentes-Fayos, Antonio C.: **P11.17**, P13.08, **P13.11**
 Fueyo, Juan: P06.01
 Fujimaki, Takamitsu: P14.113
 Fulbert, Clémentine: **P11.02**
 Furman, Orit: P08.02, **P11.22**
 Furtak, Jacek: P13.05
 Furtner, Julia: **P14.41**
 Fuster, José: P03.10, P14.58

G

Gahide, Gerald: P14.84
 Gal, O: P14.72
 Galibin, Oleg: P11.42
 Galimberti, Chiara: **P11.24**
 Galldiks, Norbert: P04.07, P14.17, P14.18, P14.29, P14.32
 Gállego Pérez-Larraya, Jaime: **P08.04**, P11.56, P14.119,
 P14.123
 Gallego, Jaime: P06.01
 Gallego, Oscar: P14.58
 Galmiche, A.: P14.91
 Galmiche, Antoine: P14.81
 Gandía-González, María L.: P13.08, P13.11
 Gandola, Lorenza: P14.77
 Garcia Moure, Marc: P11.23
 Garcia, Elena M.: P11.57
 García-Marin, Victor: P14.55
 García-Martín, María L.: P13.11
 García-Moure, Marc: P06.01, P11.56
 Garcilazo, Ytel J.: **P14.118**
 Garcilazo-Reyes, Ytel: P14.16
 Garcion, Emmanuel: P13.03
 Garg, Ajay: P04.19, P11.05, P14.117
 Gargalionis, Antonis N.: P04.15
 Garner, James: P05.06
 Garnier, Louis: **P14.76**
 Garrel, Catherine: P11.33
 Garrido Alcantud, Susana: P03.05
 Gasri Plotnitsky, Lital: P12.05
 Gatterbauer, Brigitte: P14.97
 Gaude, Christophe: P11.02
 Gaultier, Claude: P14.49, P14.87, P14.90
 Gaviani, Paola: P14.64, P14.74, P14.83
 Gel, Gülce: P14.14
 Genbrugge, Els: P14.41
 Geng, Sumin: **P14.10**
 Genitori, Lorenzo: P04.08, P08.03, P14.46
 Gentner, Bernhard: P05.02
 Geurts, Jeroen J. G.: P14.53
 Gheeyoung, Choe: P11.03
 Ghesquière, Hervé: P14.45
 Ghiringhelli, François: P07.02
 Giacomelli, Irene: P14.75
 Giannarelli, Diana: P11.51
 Gieffers, Christian: P14.52
 Giese, Armin: P14.02
 Giglio, Sabrina: P04.08
 Gil Gil, Miguel J: P14.58
 Giladi, Moshe: P11.20, P11.28, P11.37
 Gillmann, Gauthier: P11.59
 Gimbert, Edouard: P09.08
 Giordano, Flavio: P08.03, P14.46
 Giordano, Laura: P05.08
 Girgenti, Vita: P09.03
 Girones, Regina: P14.58
 Giunti, Laura: P04.08
 Glas, Martin: P14.61, P14.62, **P14.63**, P14.66
 Globerson-Levin, Anat: P12.05
 Godefroy, Olivier: P08.05
 Goett, Hanna: P11.38
 Gokce, Cemal: P14.14
 Golanov, Andrey: P11.48
 Golbin, Denis: **P11.64**
 Goldbrunner, Roland: P14.63
 Goldlust, Samuel A.: P05.06
 Goldman, Serge: P14.98
 Golfopoulos, Vassilis: P14.41, P14.54
 Golovin, Andrey: P12.07
 Gomez-Manzano, Candelaria: P06.01
 González Huariz, Marisol: P11.23
 González Sánchez, Josep: P03.05
 González, Victor: **P03.10**
 Gonzalez-Huariz, Marisol: P11.56
 Gorelick, Noah: P11.60
 Gorgan, Mircea R.: P04.17
 Gorlia, Thierry: P11.08, P14.124, P14.41, P14.54
 Goryńska, Paulina Z.: P13.05
 Goryński, Krzysztof: P13.05
 Gotlib, Karnit: P11.20, P11.25
 Gozé, Catherine: P04.02, P04.14
 Graham, E S.: P12.02
 Graillon, Thomas: P13.09
 Grajkowska, Wiesława: P13.04
 Gramatzki, Dorothee: P11.45, P14.108
 Grandoni, Manuela: P14.46
 Graus Ribas, Francesc: P03.05
 Graus, Francesc: P14.102
 Grill, Jacques: P14.99
 Grossenbacher, Bettina: P14.25
 Grossman, Rachel: **P04.06**, **P12.05**, **P14.71**, **P14.79**
 Grundy, Richard: P11.60, P11.62
 Guardiola, Philippe: P13.03
 Guerrini, Renzo: P04.08
 Guerrini-Rousseau, Lea: P14.99
 Guez, David: P11.22
 Guida, Francesco: P14.128
 Guidi, Milena: P04.08, P08.03, **P14.43**, **P14.46**
 Guihuai, Wang: P12.01
 Guillamo, Jean-Sebastien: **P14.33**
 Guille, Arnaud: P13.09
 Guldberg, Trine L.: P05.03
 Guler, Eray M.: P11.55
 Guo, Cheng-cheng: P03.09
 Gupta, Tejpal: P14.50
 Gurion, Ronit: P05.04
 Gurung, Niteeka: P11.05
 Gustin, Thierry: P03.02, P03.03
 Guyotat, Jacques: P04.18, P13.02, P14.12, P14.13, P14.88

H

Hagemann, Carsten: P11.28, P11.44, P14.28, P14.60
 Hainfellner, Johannes: P14.97
 Haj, Amer: P03.11, P03.12

Hajduch, Marian: P14.68
 Halaj, Matej: P14.68
 Hall, Jennifer P.: P14.30, P14.36
 Hallaert, Giorgio: **P14.109, P14.116**
 Hallbeck, Martin: P11.43
 Hallenborg, Phillip: P11.36
 Han, Jung Ho: P14.104
 Han, Mingzhi: P11.57
 Hanemann, Clemens O.: **P09.07**
 Hank Wu, Kuan-Han: P11.54
 Hansen, Frederik L.: P05.03
 Harat, Marek: P13.05
 Harter, Patrick N.: P12.04, P14.96
 Hartoyo, Abraham: P03.04
 Harun, Yusril: P05.01
 Hasturk, Askin E.: **P14.14**
 Hatiboglu, Mustafa A.: **P11.55**
 Hau, Ann-Christin: P11.09
 Hausmann, David: P11.29
 Hayes, Josie: P11.27
 Hazane-Puch, Florence: P11.33
 Heiland, Dieter H.: **P11.58**
 Heintz, Adrien: P14.100, P14.81, P14.91, P14.92
 Held-Feindt, Janka: P10.05
 Helin, Kristian: P11.36
 Henriksson, Roger: P14.09
 Hentschel, Bettina: P14.108
 Hermier, Marc: P13.02
 Hernandez-Tamames, Juan A.: P04.11
 Herold-Mende, Christel: P11.26, P11.59
 Herrero, Ana: P14.58
 Herrlinger, Ulrich: P14.108, P14.61, P14.96
 Hershkovich, Hadas S.: P11.50
 Hershkovich, Hadas Sara Kinzel.: P11.37
 Hillebrand, Arjan: P14.53
 Hilton, David A.: P09.07
 Hoang- Xuan, Khê: P04.10, P08.05, **P14.45**, P14.73, P14.118, P14.126
 Hollebecque, Antoine: P13.14
 Höne, Simon J.: **P05.07**
 Hong, Chang-Ki: P14.44
 Honig, Asaf: P09.06
 Honnorat, Jérôme: P04.18, P10.06, P13.02, P14.13, P14.88, P14.102
 Honoré, Stéphane: P11.06, P11.31
 Hoogstrate, Youri: P11.47
 Hottinger, Andreas: P14.66
 Houillier, Caroline: P14.118, P14.45, P14.73
 Howell, Amy E.: P13.06
 Hrabal, Petr: P11.41
 Hrabalek, Lumir: P14.68
 Hu, Libo: P04.13
 Huang, Bin: P11.52
 Huckle, Nanina: P11.07
 Hufnagel, Robin: P10.05
 Huizer, Karin: P11.11, P11.12
 Hurstel, Remy: P14.49, P14.90
 Hutter, Gregor: P12.09
 Huybrechts, Sophie: **P14.99**
 Huylebroeck, Danny: P11.34
 Hwang, Jeong-Hyun: P10.01, **P14.27**
 Hwang, Kihwan: **P14.104**
 Hynkova, Ludmila: P14.101, P14.107

I

Ibáñez, Javier: P03.10
 Idbaih, Ahmed: **P05.05**, P11.59
 Idoate, Miguel Angel: P08.04
 Ikegame, Yuka: P14.01
 Ikuta, Soko: P14.01
 Ilie, Alis: P07.02
 Ilut, Liliana: P12.03

Imran, Darma: P14.106
 Incekara, Fatih: P04.11
 Indersie, Emilie: P14.99
 Iñigo, Ignacio: P11.56
 Iñigo-Marco, Ignacio: P06.01
 Inozemceva, Maria: P14.65
 Iorio-Morin, Christian: P14.84
 Irimia Sieira, Pablo: P14.119
 Irtenkauf, Susan: P11.54
 Ito, Takeshi: P14.01, P14.08
 Iwama, Toru: P14.01, P14.39

J

Jacob, Julian: P08.05
 Jäkel, Cornelia: P05.07
 Jan, Elisheva: P08.02, P14.38
 Jancalek, Radim: P14.101, **P14.107**
 Jaroch, Karol: P13.05
 Jaume, Lea: P10.06
 Jegou, Gwenaële: P11.61
 Jensen, Alexandra: P14.07, P14.110
 Jeyapalan, Suriya: P14.66
 Jha, Prerana: P14.117
 Jiguet-Jiglaire, Carine: P13.09
 Jiménez-Vacas, Juan M.: P11.17
 Jo, Jasmin: P14.23
 Joesph, Justin V.: P11.57
 John, Flora: P11.35, P14.37, P14.57, P14.69
 Joseph, Wayne: P12.02
 Jouan, Florence: P11.61
 Jouanneau, Emmanuel: P13.02, P14.13, P14.88
 Joubert, Bastien: P14.88
 Juhasz, Csaba: P11.35, **P14.37, P14.57**, P14.69
 Jung, Erik: **P11.29**
 Jung, Inho: **P14.42**

K

Kabbasch, Christoph: P14.17
 Kaisman-Elbaz, Tehila: **P14.21**
 Kalala, Jean-Pierre: P14.109, P14.116
 Kalf, Rolf: P14.112, P14.114
 Kalita, Ondrej: **P14.68**
 Kalkanis, Steven: P01.02
 Kalofonos, H P.: P10.04
 Kamarlis, Reno: P04.04
 Kamel, Randa: **P04.03**
 Kamp, Marcel: P04.07
 Kang, Seok-Gu: P11.32, P14.42, P14.44
 Kanner, Andrew: P09.06
 Kanuri, Nandaki N.: P14.94
 Kapoor, Rakesh: P14.06
 Karatas, Ersin: P11.55
 Karindang, Nursaenah: P09.01
 Kashinian, Alon: P04.06
 Kaulen, Leon D.: **P14.26**
 Kaulich, Kerstin: P11.45
 Kaur, Kavneet: **P04.19, P14.117**
 Kawasaki, Tomohiro: P14.01
 Kazda, Tomas: **P14.101**, P14.107
 Ke, Chao: P03.09
 Kebir, Sied: P14.61, P14.62, **P14.66**
 Kedia, Sweta: P11.05
 Keinan, Lital: P09.06
 Kelly, Justin: P08.06
 Kelly, Paul J.: P14.35
 Kemp, Jessalyn: P14.30, P14.36
 Keric, Naureen: P03.04
 Kers, Trisha: P11.27, P11.47
 Keßler, Almuth F.: **P11.28, P14.28, P14.59, P14.60**
 Kessler, Tobias: P11.07
 Khalil, Pietter: P03.06
 Khan, Imran: P11.55

Khasminsky, Vadim: P14.72
 Khlebokazov, Fedor: P12.10
 Khosla, Divya: P14.06
 Kieser, Meinhard: P05.07
 Kietz, Silke: **P06.02**
 Kim, Chae-Yong: P14.104
 Kim, Dong-Hyun: P11.62
 Kim, Eui Hyun: **P11.32**, P14.42
 Kim, Jong-Tae: P02.01
 Kim, Woohyun: **P11.16**
 Kim, Yong Hwy: P14.104
 Kini, Lata: P11.53
 Kinzel, Adrian: **P11.18**, **P11.20**, **P11.21**, **P11.25**
 Kirby, Alastair J.: **P11.49**
 Kirson, Eilon: P11.20, P11.25
 Ki-Su, Park: **P10.01**
 Klein, Eliane: P11.26
 Klein, Martin: P14.53
 Kleinschnitz, Christoph: P14.61
 Klink, Barbara: P11.26, P11.57
 Klonou, Alexia: **P04.15**
 Kobiakov, Grigory: P14.03, **P14.15**
 Kobiakov, Nikolai: P14.03, P14.15, P14.103, P14.105
 Kobyakov, Grigory L.: P14.65, **P14.103**, **P14.105**
 Kobyakov, Nikolay: P14.65
 Kobyakova, Ekaterina: P14.105
 Koch, Christian: P11.38
 Koch, Philipp: P11.29
 Koch-Paszkowski, Joanna: P11.13
 Kocyigit, Abdurrahim: P11.55
 Koerts, Guus: P03.02, P03.03
 Kolodziej, Malgorzata: P11.38, P14.07
 Kondaiah, Paturu: P14.94
 Kopylov, Alexey: **P12.07**
 Korkolopoulou, Pinelopi: P04.15
 Korn, Akiva: P04.06
 Korochkina, Antonina: P11.64
 Korolevich, Pavel: P12.10
 Korshøj, Anders R.: P05.03
 Korshunov, Andrey: P14.03
 Koudriavtseva, Tatiana: P14.120
 Kremer, Andreas: P11.27
 Krendyukov, Andriy: P14.52
 Krepela, Evzen: P11.41
 Kreth, Friedrich-Wilhelm: P14.02
 Krisam, Johannes: P05.07
 Krist, Bart: P11.12
 Kros, Johan M.: P04.11, P11.08, **P11.10**, **P11.11**, **P11.12**
 Kular, Rupinder: P14.54
 Kulik, Shanna D.: **P14.53**
 Kumar, Narendra: P14.06
 Kurian, Kathreena M.: P09.07, P13.06
 Kurz, Elena: P03.04

L
 Lacomme, Stéphanie: P04.12
 Lacroix, Ludovic: P13.14
 Lafon, Cyril: P05.05
 Lagarde, Arnaud: P13.09
 Laigle-Donadey, Florence: P14.16, P14.33
 Lakomy, Radek: P14.101, P14.107
 Lamfers, Martine: P11.27, P11.34, P11.47
 Lamy, Florian: P14.87, P14.87
 Lane, Heidi: P11.31
 Lang, Kristin: P05.07
 Langen, Karl-Josef: P04.07, P14.17, P14.18, P14.29, P14.32
 Lardy-Cleaud, Audrey: P14.05
 Lareida, Anna: P14.25
 Larrieu, Marianne: P14.20
 Larrieu-Ciron, Delphine: P04.12
 Larrouquere, Louis: **P11.33**, P14.24
 Laspidea, Virginia: P06.01

Last, David: P11.22
 Łastowska, Maria: P13.04
 Lau, Ching C.: P14.47
 Laurence, Valérie: P14.04
 Laurent, François: P09.08
 Lauseker, Michael: P14.02
 Laviv, Yossi: P09.06
 Lavrador, Jose P.: P11.49
 Lavrenkov, Konstantin: P14.21
 Lavy-Shahaf, Gitit: P11.20
 Lawson McLean, Aaron: **P14.112**, **P14.114**
 Lazaridis, Lazaros: **P14.61**, P14.62
 Le Garff-Tavernier, Magali: P14.49, P14.90
 Le Reste, Pierre-Jean: **P11.61**
 Le Rhun, Emilie: P14.124, P14.25
 Leblanc, Suzanne: P14.87
 Leblond, Pierre: P14.04
 Lee, Cindy: P14.30, P14.36
 Lee, Ian: P01.02
 Lee, Kyu Sang: **P11.03**
 Leenen, Pieter: P11.10
 Leenstra, Sieger: P11.27, P11.34, P11.47, P13.07
 Lefebvre, Christine: P11.33
 Lefranc, Florence: P14.56, P14.98
 Lefranc, Michel: P14.81, P14.91, P14.92
 Legatova, Valeriya: P12.07
 Legnani, Federico: P05.02
 Lelong-Rebel, Isabelle: P11.59
 Lemke, Dieter: P11.07
 Lenge, Matteo: P14.46
 Lesueur, Paul: **P14.73**
 Letari, Ornella: P11.24
 Levy-Piedbois, Christine: P14.31
 Li, Chao: P14.129
 Li, Depei: P03.09
 Li, Kay K.: P14.48
 Li, Na: P01.01
 Li, Xingang: P11.52
 Li, Yuxin: P14.129
 Liang, Ping: **P04.13**, **P12.01**
 Lichtenstein, Thorsten: P14.17
 Lichtenthaeler, Katharina: P03.04
 Limon, Dror: P14.71, P14.79
 Lindh, Jonas: P14.09
 Lindner, Andreas: P11.27
 Linsenmann, Thomas: P14.28, P14.60
 Liou-Schischmanoff, Amélie: P14.118
 Lipke, Katharina: P14.32
 Lisievici, Mihai: P04.17
 Liu, Pan: P14.129
 Liu, Wei: P04.13
 Liu, Ying: P11.30
 Lloret Puerto, Alba: P03.05
 Lo, Kwok W.: P14.47
 Lodygina, Kristina: P14.03, P14.103, P14.15, P14.65
 Loew, Sarah: P14.108
 Löffler, Markus: P14.108
 Lohmann, Philipp: P14.17, P14.18, P14.29, **P14.32**
 Lohmeier, Annette: P11.50
 Löhr, Mario: P11.28, P11.44, P14.28, P14.60
 Loiseau, Hugues: P09.08, P14.24
 Lombardi, Giuseppe: P14.83
 Loo, Maxime: P13.13
 Looman, Jim: P11.08, P14.54
 Lorenzi, Elena: P05.08
 Lortholary, Alain: P14.24
 Loussouarn, Delphine: P04.12
 Lucas, Anna: P14.93
 Luiders, Theo M.: P13.07
 Lukacova, Slavka: P05.03
 Lunavat, Taral R.: P11.57
 Luque, Raquel: P14.58

Luque, Raúl M.: P11.17, P13.08, P13.11
Lysiak, Malgorzata: **P11.43**

M

Maarek, Alizee: P14.45
Macapagal, Jena: **P10.03**
Maccario, Hélène: P11.06
MacDonald, Christa: P12.02
Macdonald, David R.: P14.111
Macià, Miquel: P14.93
Madan, Renu: **P14.06**
Mafra, Manuela: P03.13
Maillet, Didier: P14.20
Majos, Carles: P14.93
Makhrov, Michael: P12.10
Mall, Moritz: P11.29
Malmström, Annika: P11.43
Malta, Tathiane M.: P01.02, P13.15
Mantovani, Cristina: P14.85
Marchenko, Yaroslav: P11.42
Marchuk, Sergei: P12.10
Mardor, Yael: P11.22
Mari, Francesco: P14.46
Marie, Yannick: P04.10
Marisdina, Selly: P05.01
Marques, Rute: P11.10
Marrodán, Lucía: P11.23
Marta, Alonso M.: **P11.56**
Martens, Corentin: P14.98
Martin, Richard M.: P13.06
Martin, Sophie: P11.59
Martinez García, Maria: P14.58
Martinez-Velez, Naiara: P11.56
Martinez-Vila, Eduardo: P14.119
Martins, Carmo: P03.13
Martins, Tomas: P12.09
Maruyama, Takashi: P14.01
Maschio, Marta: P14.120
Mason, Warren: P14.124
Massard, Christophe: P13.14
Massimino, Maura: P14.77
Matarrese, Paola: P11.51
Matheu, Ander: P11.46
Matteoni, Silvia: P11.51
Matyja, Ewa: P11.14, P13.04
Maucort-Boulch, Delphine: P14.45
Mawamba, Viviane: P11.44
Mazzanti, Michele: **P11.19**
Mazzoleni, Stefania: P05.02
McCrorie, Phoebe: P11.62
McDonald, Kerrie: P04.16
Mee, Edward: P10.03
Megyesi, Joseph F.: **P14.111**
Mei, Davide: P04.08
Melamed, Israel: P14.21
Melcarne, Antonio: P14.85
Mélot, Christian: P14.56
Menard, Virgine: P14.20
Ménégaud, Louise: P07.02
Menei, Philippe: P13.03
Mercier, Marie-Cécile: P11.59
Merkin, Vladimir: P14.21
Mervoyer, Augustin: P14.24
Merz, Christian: **P14.52**
Mesia, Carlos: P14.58
Meyronet, David: P13.02, P14.04, P14.13, P14.88, P14.127
Michelhaugh, Sharon K.: P14.57
Mihailescu, Mona: P04.17
Mikic, Nikola: **P05.03**
Mikkelsen, Thomas: P01.02, P11.54
Mildenberger, Iris C.: P12.04
Milos, Peter: P11.43

Minniti, Giuseppe: P14.83
Mir Seyed Nazari, Pegah: **P14.97**
Mishima, Kazuhiko: P13.01, **P14.113**
Misyuk, Nicolay: P12.10
Mitsuya, Koichi: **P14.34**, P14.70
Mittal, Sandeep: P11.35, P14.37, P14.57, **P14.69**
Miwa, Kazuhiro: **P14.08**, P14.39
Miyake, Yohei: P13.01
Mo, Francesca: P04.09
Mohammad, Faizaan: P11.36
Moisescu, Mihaela G.: P04.17
Mokhtari, Karima: P04.10, P14.87
Mollà Armada, Meritxell: P03.05
Mongay, Neus: **P14.93**
Montagna, Mario: P11.24
Moon, Ju Hyung: P14.42
Moreno-Ajona, David: P14.119, P14.123
Morfouace, Marie: P11.08
Morisse, Mony Chenda: P14.125
Moscheo, Carla: P14.46
Mosella, Maritza Q. S.: P01.02, P13.15
Mou, Yonggao: P03.09
Mouchamps, Micheline: P03.02, P03.03
Mousli, Alia: **P03.02**, **P03.03**
Moyiadi, Aliasgar: P14.50
Mudaisi, Munila: P11.43
Mueller, Mareike: **P04.07**
Mühlberger, Andreas: P03.11
Mukherjee, Abir: P01.02
Muller, Arnaud: P11.26
Multhoff, Gabriele: P11.42
Muñoz Guglielmetti, Diego Alejandro: P03.05
Muñoz-Langa, José: P14.58
Munster, Mijal: P11.20
Muragaki, Yoshihiro: P14.01
Muraro, Manuele: P12.09
Murphy, Erin S.: P14.115
Murray, Louise: P11.13
Mustafa, Dana: P11.10, P11.11, P11.12
Müther, Michael: **P09.05**, **P14.67**
Muzik, Otto: **P11.35**, P14.57

N

Nabeel, Ahmed: P03.06, P03.07, P03.08
Nadal, Ernest: P10.04
Nakasu, Satoshi: **P09.04**, P14.70
Nakasu, Yoko: P09.04, **P14.70**
Nakayama, Noriyuki: P14.01, **P14.39**
Naldini, Luigi: P05.02
Nalli, Arife: P11.55
Nambirajan, Aruna: **P11.05**
Narme, Pauline: P14.20
Navarria, Pierina: P05.08
Navarro, Miguel: P14.58
Naveh, Ariel: P11.18, P11.21
Naveh, Ariel: P11.25, P14.69
Nazarov, Petr: P11.26, P11.57
Ndiaye, Mané: **P07.02**
Nechipay, Emily: P14.105
Negro-Moral, Eva M.: P13.11
Neidert, Marian C.: P14.25
Neirincx, Virginie: **P11.09**, P11.26
Nelson, Kevin: P01.02
Neri, Dario: P12.08
Neyman, Gennady: P14.115
Ng, Ho K.: P14.47, P14.48
Ni, Xiang-rong: **P11.01**
Niclou, Simone P.: P11.09, P11.26
Niemira, Magdalena: P13.04
Nikolaev, Boris: P11.42
Nikolaeva, Anna: P11.48
Nimbalkar, Vidya P.: P14.94

Nishikawa, Ryo: P13.01, P14.113
Niyazi, Karim-Maximilian: P14.02
Noch, Evan: **P11.63**
Noël, Georges: P08.05, P13.13, P14.125, P14.126
Noor, Humaira: **P04.16**
Noulet, Fanny: P11.59
Noushmehr, Houtan: P01.02, P13.15
Nowosielski, Martha: P14.41
Noy, Ariel: P14.21
Ntafoulis, Ioannis: **P11.27**
Numan, Tianne: P14.53
Nunes, João: P14.89
Nunes, Marie-Laure: P09.08

O

Oberheim-Bush, Nancy A. E.: P08.01
O'Callaghan, Chris: P14.124
Odiolo, Jonathan: P14.106
Oesterlé, Hélène: P14.49, P14.87
Oh, Hyeong Cheol: P11.32
Okada, Makoto: P14.01
Okuma, Masahiro: **P09.02**
Oleaga Zufiria, Laura: P03.05
Olier, Clara: P14.58
Olivero, Alan: P05.06
Olteanu, Stefan: P14.87
Olyushin, Victor: P14.22
Ortega-Salas, Rosa M.: P13.11
Osés González, Gabriela: P03.05
Ostrowski, Robert: P11.14
Ottobri, Luisa: P11.13
Oudin, Anais: P11.26
Özduman, Koray: **P14.95**

P

Pabinger, Ingrid: P14.97
Pace, Andrea: **P11.51, P14.120, P14.83**
Paczkowski, Dariusz: P13.05
Paganetti, Chiara: P12.09
Paggi, Marco G.: P11.51
Paix, Adrien: P13.13
Palmiero, Rosa: P14.85
Palti, Yoram: P11.20, P11.25
Pamir, M Necmettin: P14.95
Pandey, Deo Prakash: **P11.36**
Pandit, Abhay: P11.61
Pantel, Tobias: P03.04
Panteleev, Dmitri: P11.04, P11.48
Papavassiliou, A. G.: P04.15
Pardey Bracho, Gilda: P04.18
Park, Jong-Hyeok: **P02.01**
Park, Ki-Su: P14.27
Park, Thomas I. H.: P10.03
Park, Thomas: P10.02
Parratte, Timothée: P14.87, P14.90
Passos, João: P14.89
Patanè, Monica: P09.03
Pattera, Rosina: P14.74
Pathak, Pankaj: P14.117
Patil, Vijay: P14.50
Patiño-García, Ana: P06.01, P11.23
Patte, Catherine: P14.05
Patterson, John: P11.61
Pavlova, Galina: **P11.04**, P11.48, P11.64, P12.07
Pavlova, Svetlana: P11.04
Pecori, Emilia: P14.77
Pedrosa Eguílaz, Leire: P03.05
Pedrosa, Rute: P11.10
Pellerino, Alessia: **P04.09**
Peltier, Johan: P14.81
Pencovich, Niv: P12.05
Peralta, Sergi: P14.58

Perez, Thomas: P11.06
Pérez-Segura, Pedro: P14.58
Perol, David: P14.127
Persiani, Stefano: P11.24
Persico, Pasquale: P05.08
Pessina, Federico: P05.08
Petrescu, George E. D.: **P04.17**
Picart, Thiébaud: **P04.18**, P14.88
Piepoli, Tiziana: P11.24
Pierscianek, Daniela: P14.61
Pierson, Tessa M.: P13.07
Pietsch, Torsten: P14.108
Pilot, Thomas: P07.02
Pimentel, Teresa: P14.89
Pin, Yvan: P13.13
Pineau, Raphael: P11.61
Pineda, Estela: P03.05, **P14.58**
Pinson, Harry: P14.109, P14.116
Piperi, Christina: P04.15
Pissaloux, Daniel: P14.127
Pitkin, Emil: P11.42
Pituch, Katarzyna C.: P12.03
Piulats, J M.: P10.04
Plans, Gerard: P14.93
Plata-Bello, Julio: **P14.40, P14.55**
Platten, Michael: P11.07
Poddubsky, Artem: P14.65
Poddubsky, Artyom: P14.03, P14.15
Poetsch, Laura: P04.12
Poirier, Marie-Belle: P11.39
Poisson, Laila: P01.02, P11.54
Pojo, Marta: P03.13
Pollo, Bianca: P05.02, P09.03, P14.64, P14.74
Pollom, Erqi: P14.66
Poloni, Riccardo: P11.19
Poncet, Delphine: P14.88
Pons-Kühnemann, Jörn: P11.38
Porat, Yaara: P11.20
Pospisil, Petr: P14.101, P14.107
Postert, Thomas: P14.90
Potapov, Alexander: P11.04
Pouchieu, Camille: P09.08
Prades, Julien: P14.122
Pratama, Putra Y.: P14.106
Prébay, Danielle: P14.125
Prehn, Jochen: P11.27
Preusser, Matthias: P14.41, P14.97
Price, Stephen J.: P14.129
Proescholdt, Christina: **P08.06**
Proescholdt, Martin A.: **P03.11, P03.12, P11.50**
Pronello, Edoardo: P04.09, P14.83, P14.85
Proust, François: P13.13
Psimaras, Dimitri: P08.05, P10.06, P14.102, P14.126
Puca, Emanuele: P12.08
Pucko, Emanuela: **P11.14**
Puget, Stephanie: P14.99
Puigdelloses, Montse: P06.01, P08.04, P11.56
Pujol Farre, Teresa: P03.05
Pusch, Sonja: P11.07
Pyromali, Ioanna: P11.19

Q

Qu, Yue: P11.01
Quintero, Yamilet: P14.55

R

Rahbar, Kambiz: P09.05, P14.67
Rahbek, Christian: P05.03
Rahman, Ruman: **P11.60**, P11.62
Ram, Zvi: P04.06, P12.05, P14.71, P14.79
Ramirez, Carole: P14.76
Ramos, Manuel J.: P13.11

Rampini, Dimitri: P11.19
 Ramshad-Lassen, Yasmin: P05.03
 Ranakusuma, Teguh A. Suharno.: P14.106
 Rao, Shilpa: P14.94
 Rapkins, Robert: P04.16
 Rapp, Marion: P04.07, P14.18, P14.29
 Ratel, David: P11.02
 Ravi, Vidhya M.: P11.58
 Rébé, Cédric: P07.02
 Reda, Wael A.: P03.06, P03.07, P03.08
 Reifenberger, Guido: P11.45, P14.108, P14.29
 Reijneveld, Jaap C.: P14.53, P14.124
 Reita, Damien: P11.59
 Relton, Caroline L.: P13.06
 Renovanz, Mirjam: **P03.04**
 Revishchin, Alexander: P11.04
 Reynaud, Thomas: **P14.78**
 Ribeiro, Monica: **P08.05**
 Ribrag, Vincent: P13.14
 Ricard, Damien: P08.05, P14.126
 Richter, Christoph: P03.04
 Rieken, Stefan: P05.07
 Rifino, Nicola: **P14.128**
 Rigamonti, Andrea: P14.128
 Rigau, Valérie: P04.02, P04.14
 Righetto, Roberto: P14.75
 Ringel, Florian: P03.04
 Ritz, Rainer: P14.59
 Rivoirard, Romain: P14.24
 Rizzo, Ambra: P09.03
 Robberts-Rapp, Lisa: P14.54
 Robe, Pierre A.: P13.10
 Robilliard, Laverne D.: **P12.02**
 Robin, Adam: P01.02
 Robinson, Jamie W.: **P13.06**
 Rock, Jack: P01.02, P13.15
 Roda, José M.: P13.08, P13.11
 Rodriguez Almaraz, Jesus E.: **P08.01**
 Rodriguez-Bel, Laura: P14.93
 Rodríguez-Salazar, Marisol: P14.40
 Rodríguez-Yanes, Marina: P14.40
 Roh, Tae Hoon: **P14.44**
 Roll, Wolfgang: P09.05, P14.67
 Rolland, Virginie: P14.73
 Ronchi, Susanna: P04.10
 Roodakker, Kenney R.: P11.43
 Roque, Lúcia: P03.13
 Rosen, Jurij: **P14.18**
 Rosenblum, Mark: P01.02
 Rossoni, Caroline: P14.99
 Rostomashvili, Sophio: P10.06
 Rostovtsev, Dmitrii: P14.22
 Roth, Patrick: P12.08, **P14.124**, P14.25
 Rouleau, Etienne: P13.14
 Rousseau, Audrey: P13.03
 Rousseau, Martina: P08.03
 Roussel, Martine: P08.05
 Rovati, Lucio C.: P11.24
 Rowlinson, Jonathan: P11.60, **P11.62**
 Roy, Laurent-Olivier: **P11.39**
 Rudà, Roberta: P04.09, P14.83, P14.85
 Ruff, Michael: P14.86
 Russo, Carlo: P05.02
 Rydén, Isabelle: **P04.01**
 Rynda, Artemii: **P14.22**
 Ryzhov, Vyacheslav: P11.42
 Ryzhova, Maria: P14.65
 Ryzhova, Marina: P14.03

Sacchetti, Andrea: P11.11
 Saed, Halala S.: P11.57
 Saenz-Antoñanzas, Ander: P11.46
 Sáez Beltrán, Jordi: P03.05
 Sahay, Ayushi: **P14.50**
 Sahel, Kamilya: P14.20
 Sai, Ke: P03.09
 Saida, Z.: P14.91
 Saidak, Zuzana: P14.81, P14.92
 Saladino, Andrea: P09.03
 Salgado, Duarte: P14.89
 Salido, Eduardo: P14.55
 Salmaggi, Andrea: P14.128
 Salunke, Pravin: P14.06
 Salvador, Ellaine: P11.28
 Salvatore, Daniela: **P11.13**
 Samal, Juhi: P11.61
 Samoylenkova, Nadezhda: P12.07
 Sánchez-Sánchez, Rafael: P11.17
 Sandberg, Elisabeth: P11.43
 San-Galli, François: P09.08
 Sanson, Marc: P04.10, P04.12
 Santoro, Armando: P05.08
 Santosh, Vani: P14.94
 Sanz, Carolina: P14.58
 Sardi, Iacopo: P04.08, P08.03, P14.46
 Sarkar, Chitra: P04.19, P11.05, P14.117
 Sashidharan, Anju: P11.05
 Sashin, Denis: P14.105
 Savatosky, Julian: P14.126, P14.16
 Savchenko, Ekaterina: P11.04, P11.48, P12.07
 Savopol, Tudor: P04.17
 Scarsbrook, Andy: P11.13
 Scartoni, Daniele: P14.75
 Schackert, Gabriele: P14.108
 Schäfer, Niklas: P14.61
 Schäfers, Michael: P09.05, P14.67
 Schatzschneider, Ulrich: P11.44
 Schebesch, Karl-Michael: P03.12
 Scheffler, Björn: P14.61
 Schiavello, Elisabetta: P14.77
 Schiff, David: P14.23
 Schimitt, Anna: P14.118
 Schlegel, Uwe: P14.108
 Schmidmeier, Melissa: P03.11
 Schmidt, Mirko H. H.: P11.09
 Schmidt, Teresa: P14.61, **P14.62**
 Schmitt, Anna: P14.73
 Schmitt, Daniela: P05.07
 Schneider, Jurgen: P11.13
 Schneiderman, Rosa: P11.20
 Schnell, Oliver: P11.58
 Schoeller, Karsten: P14.110
 Scholz-Kreisel, Peter: P03.04
 Schönlieb, Carola-Bibiane: P14.129
 Schoonheim, Menno M.: P14.53
 Schott, Roland: P14.125
 Schouten, Joost W.: P04.11
 Schrijver, Benjamin: P11.10
 Schulz, Ellina: **P11.44**
 Schürch, Christian Martijn: P12.09
 Schuster, Anne: P11.09, **P11.26**
 Schwarm, Frank: P11.38
 Schwarz, Marco: P14.75
 Schweder, Patrick: P10.03
 Sciacca, Francesca L.: P09.03
 Scoazec, Jean-Yves: P13.14
 Scorsetti, Marta: P05.08
 Scurr, David: P11.62
 Sedo, Aleksis: P11.41
 Seizeur, Romuald: P04.12
 Sellal, François: P14.49, P14.90

S
 Sabedot, Thais S.: P01.02, P13.15
 Sabel, Michael: P04.07

Sepulveda, Juan Manuel: P11.08, P14.58
 Serafimova, Marga: P04.06
 Serge, Arnault: P11.31
 Serra, Riccardo: P11.60
 Severinsen, Kåre E.: P05.03
 Sevestre, Henri: P14.122
 Seystahl, Katharina: **P14.108**
 Seyve, Antoine: **P14.13**
 Sgouros, Spyros: P04.15
 Shah, Nadim J.: P14.32
 Shakesheff, Kevin: P11.60
 Shamadykova, Dzhirgala: P11.48
 Shamruk, Irina: P12.10
 Sharabi, Shirley: P11.22
 Sharma, Agrima: P11.05, **P12.06**
 Sharma, Mehar C.: P04.19, P14.117
 Sharma, Meher: P11.05
 Sharma, Shivani: P11.53
 Sharma, Vikram: P09.07
 Shastri, Jayant G.: P14.50
 Shaw, Gary: P11.13
 Shekarian, Tala: **P12.09**
 Shetty, Prakash: P14.50
 Shevtsov, Maxim: **P11.42**
 Shi, Ji: **P04.05**
 Shi, Zhi F.: P14.47, P14.48
 Shifrin, Mikhail: P11.64
 Shiloach, Tamar: P12.05
 Shim, Jin-Kyoung: P11.32
 Shin, Myung-Hoon: P02.01
 Shinoda, Jun: P14.01, P14.08, P14.39
 Shirahata, Mitsuaki: P14.113
 Short, Susan: P11.13
 Shugay, Svetlana: P11.64
 Sidibe, Nelly: P03.14
 Siegal, Tali: **P05.04, P09.06, P14.72**
 Siegfried, Aurore: P04.12
 Siller, Sebastian: **P14.02**
 Silvani, Antonio: **P14.64**, P14.74, P14.83
 Simchony, Hadar: P12.05
 Simó, Marta: P10.04
 Simonelli, Matteo: **P05.08**
 Simonetti, Giorgia: P14.64, P14.83
 Simpson, Jeremy: P05.06
 Sirven-Villaros, Lila: P14.31
 Skoblar Vidmar, Marija: P14.121
 Slampa, Pavel: P14.101, P14.107
 Slobina, Elena: **P03.14, P12.10**
 Smirnov, Georiy: P11.48
 Smith, Stuart: P11.60, P11.62
 Smits, Anja: P11.43
 Smits, Marion: P04.11
 Smrdel, Uros: **P14.121**
 Smyslov, Alexei: P03.14
 Snijders, Tom J.: P13.10
 Snyder, James: P01.02
 Sobocińska, Anna A.: **P13.04**
 Söderkvist, Peter: P11.43
 Soffiatti, Riccardo: P04.09, P14.85
 Sofyan, Henry R.: P14.106
 Solivera, Juan: P11.17, **P13.08**, P13.11
 Somanna, Sampath: P14.94
 Sørensen, Jens C. H.: P05.03
 Soria, Jean-Charles: P13.14
 Soussain, Carole: P14.118, P14.45, P14.73
 Spena, Giannantonio: P14.128
 Spenlé, Caroline: P11.59
 Sperati, Francesca: P14.120
 Sperduti, Isabella: P11.51
 Sporikova, Zuzana: P14.68
 Spreafico, Filippo: P14.77
 Sravya, Palavalasa: **P14.94**

Sridhar, Epari: P14.50
 Staelens, Lorenzo: P14.116
 Stam, Cornelis J.: P14.53
 Stangl, Stefan: P11.42
 Stavrinou, Pantelis: P14.32
 Stefan, Dinu: P14.73
 Stefini, Roberto: P14.77
 Stegger, Lars: P14.67
 Steidl, Eike: P14.96
 Stein, Marco: P06.02, **P11.38, P14.07, P14.110**
 Steinbach, Joachim P.: P12.04, P14.96
 Steindl, Ariane: P14.97
 Stevens, Glen H. J.: **P14.115**
 Stoerr, Eva-Maria: P11.50
 Stoffels, Gabriele: P04.07, P14.17, P14.18, P14.29
 Stoppek, Ann-Kathrin: P14.61, P14.62
 Strandéus, Michael: P11.43
 Strassheimer, Florian: P12.04
 Strecker, Maja I.: P12.04
 Struys, Eduard: P11.47
 Stummer, Walter: P09.05, P14.67
 Sturm, Volker: P11.44
 Stuschke, Martin: P14.61
 Suchorska, Bogdana: P14.02
 Suci Rahayu, Nona: P03.01, P04.04
 Suh, John H.: P14.115
 Sulpice, Eric: P11.02
 Sun, Yan: P14.54
 Sunyach, Marie-Pierre: P14.04, P14.77
 Sure, Ulrich: P14.61
 Suri, Ashish: P04.19, P14.117
 Suri, Vaishali: P04.19, P11.05, P14.117
 Susanti, Elsa: **P03.01, P04.04**
 Suzuki, Tomonari: P13.01, P14.113
 Swanson, Molly: P10.02
 Sykora, Jaromir: P14.52
 Synowitz, Michael: P10.05
 Szabó, Emese: P11.45
 Szalkowska, Anna: P13.04

T
 Tabarin, Antoine: P09.08
 Tabatabai, Ghazaleh: P14.63
 Tabouret, Emeline: **P13.09**, P14.118, P14.76
 Takei, Hiroaki: **P14.01**, P14.39
 Taliansky, Alisa: P08.02, P11.22, **P14.38**
 Tang, Zili: P11.07
 Tanguy, Renan: P14.04
 Tanzilli, Antonio: P14.120
 Tarba, Nicolae: P04.17
 Tatagiba, Marcos: P14.108
 Tauziède-Espariat, Arnault: P14.99
 Tawadros, Sameh: P03.06, P03.07, P03.08
 Taylor, Jennie W.: P08.01
 Tching, Romain: P11.27
 Tchoghandjian, Aurelie: P11.31
 Teh, Irvin: P11.13
 Tempel Brami, Catherine: P11.28, P11.37
 Terrenato, Irene: P14.120
 Thakur, Subhash: P14.06
 Themistocleous, Marios: P04.15
 Theodorou, Marilena: **P14.80**
 Thibouw, David: P14.78
 Thielscher, Axel: P05.03
 Thomas, Alice: **P14.126**
 Thomas, Laure: P04.18
 Thompson, Gwilym J.: P14.30, P14.36
 Thon, Niklas: P14.02, P14.108
 Thorsen, Frits: P11.52
 Todeschi, Julien: P13.13
 Toledano, Álvaro: P13.11
 Toledano-Illan, Carlos: P14.119

Toms, Steven A.: P14.66
Tonn, Joerg-Christian: P14.02
Tonn, Torsten: P12.04
Tóth, Emma: P13.07
Transou, Andrea: P11.54
Trojanec, Radek: P14.68
Trubicka, Joanna: P13.04
Truc, Gilles: P14.78
Trudel, Stéphanie: P14.122
Trunin, Yury: P14.103
Tscavachidis, Spirion: P13.06
Tsukanova, Tatiana: P11.64
Turiel, Sivan: P14.21
Turkaj, Ana: P14.75
Tuzgen, Saffet: P11.55
Twig, Gilad: P09.06
Tyler, Betty: P11.60
Tzarfati, Garry: P04.06
Tzaridis, Theophilos-Dimitrios: P14.61

U

Uhl, Eberhard: P11.38, P14.07, P14.110
Ungureanu, Aurelian: P14.90
Unterberg, Andreas: P05.07
Ursu, Renata: P14.31

V

Vagner, Tali: P14.38
Valduvico Ruíz, Izaskun: P03.05
Valenti-Azcarate, Rafael: P14.119, P14.123
Valteau-Couanet, Dominique: P14.99
van den Bent, Martin J.: **P04.11**, P11.08, P14.41, **P14.54**, P14.124
Van den Berge, Dirk: P04.03
van der Kaaij, Marielle: P11.27, P11.47
Van Der Ploeg, Alicia: P11.47
van Eijck, Casper: P11.10
van Rij, Jort: P11.27
Van Roost, Dirk: P14.109, P14.116
Van Simaeys, Gaetan: P14.98
Vandenbroecke, Caroline: P14.116
Vandriessche, Veroniek: P14.109
Vanhouwaert, Dimitri: P14.116
Vanickova, Zdislava: P11.41
Vanlancker, Maureen: P14.124
Vara, Yosu: P11.46
Varga, Andreea: P13.14
Varlet, Pascale: P14.99
Vasiljevic, Alexandre: P14.88
Vasilyev, Vladimir: P03.14
Vauleon, Elodie: P11.61, P14.04, P14.76
Vaverka, Miroslav: P14.68
Vaz, Maria Angeles: P14.58
Vázquez-Borrego, Mari C.: P11.17
Veal, Gareth: P11.60
Velarde, Jose Maria: P14.58
Velasco, Roser: **P10.04**
Verduci, Ivan: P11.19
Vergani, Francesco: P11.49
Verger Fransoy, Eugenia: P03.05
Verheul, Cassandra: **P11.47**
Verploegh, Iris: **P11.34**
Vialatte de Pémile, Clément: P14.102
Vidal, Noemí: P14.93
Vidiri, Antonello: P14.120
Vignes, Jean-Rdolophe: P09.08
Vignon, L: P14.05
Vignot, Alexandre: P05.05
Villa, Chiara: P04.10
Villani, Veronica: P11.51, P14.120, P14.83
Vincent, Arnaud J. P. E.: P04.11
Voirin, Jimmy: P14.87

Voloshin Sela, Tali: P11.28
Volovitz, Ilan: P12.05
von Achenbach, Caroline: P11.45
von Oettingen, Gorm: P05.03
Vrbkova, Jana: P14.68
Vrethem, Magnus: P14.09
Vulquin, Noémie: P14.78

W

Wachnowicz, Anna Theresa: P12.09
Wagner, Marlies: P14.96
Wagner, Tali: **P08.02**
Waissi, Waisse: P13.13, P14.125
Walbert, Tobias: P01.02
Walenkamp, Annemiek: P11.08
Wallace, Neil D.: **P14.35**
Walter, Jan: P14.112, P14.114
Wang, Adrien: P14.33
Wang, Jian: P03.09, P11.52, P11.57
Wang, Jing: P11.01
Wang, Jiwei: P11.52
Wang, Qing: P14.127
Wang, Renzhi: P13.12
Wang, Zhengmin: **P11.30**
Warnert, Esther A. H.: P04.11
Waultier, Agathe: P14.118
Weckesser, Matthias: P14.67
Wei, Yiran: **P14.129**
Weiland, Judith: P14.28, P14.60
Weinberg, Uri: P11.20, P11.25
Weiping, Gao: P12.01
Weiss, Tamara: P14.72
Weiss, Tobias: **P12.08**
Weissmann, Simon: P11.36
Weller, Johannes: P14.61
Weller, Michael: P11.08, **P11.45**, P12.08, P14.25, P14.41, P14.108, P14.124
Wells, Michael: P01.02
Wels, Winfried S.: P12.04
Wen, Patrick Y.: **P05.06**
Wenger, Cornelia: P11.25, P11.37
Werdhani, Retno A.: P14.106
Werner, Jan-Michael: **P14.17**, P14.18, P14.29, P14.32
Westphal, Manfred: P14.108
Wick, Wolfgang: P11.07, P11.29, P14.41, P14.52, P14.108
Widhalm, Georg: P14.97
Wiestler, Benedikt: P11.07, P14.52
Winkler, Frank: P11.07, P11.29
Woelk, Bernhard: P14.07
Wojtaś, Bartosz: P13.04
Wolkenstein, Pierre: P14.33
Wolpert, Fabian: **P14.25**
Woolf, Zoe: **P10.02**
Wright, John: P11.13
Wu, Jianing: **P11.15**
Wu, Shao-xiong: P03.09

X

Xia, Yun-fei: P03.09
Xu, Chenyue: P11.30

Y

Yadav, Budhi S.: P14.06
Yahia-Cherif, Mehdi: **P14.56**
Yakovleva, Ludmila: P11.42
Yang, Qun-ying: P03.09
Yano, Hirohito: P14.01, P14.39
Yesharim, Ofir: P11.18, P11.21
Yim, Isaiah: P11.63
Yokogami, Kiyotaka: **P07.01**
Yokoyama, Kazutoshi: P14.01, P14.08
Yoon, Sang Youl: P10.01, P14.27

Yoon, Wan-Soo: P14.51
Yu, Jennifer: P14.115
Yu, Yan-jiao: P11.01, P11.01
Yu, Zhi-hui: P11.01
Yuan, yifan: P11.30
Yust-Katz, Shlomit: P05.04, P09.06, P14.72

Z

Zabrodszkaya, Yulia: P14.22
Zach, Leor: P08.02, P11.22
Zach, Lior: P14.38
Zacher, Angela: P11.45
Zakharova, Ludmila: P11.04
Zannikou, Markella: P12.03
Zannou, Honorat: P14.31
Zavyalova, Elena: P12.07

Zebian, Bassel: P11.49
Zeevi, Einav: P11.20, P11.25
Zeng, Jing: P03.09
Zhang, Congcong: P12.04
Zhang, Di: P11.52
Zhang, Jun-Ping: **P14.82**
Zhang, xiang-hen: P03.09
Zhang, Yuqi: P04.13
Zheng, Jie: P13.06
Zhou, Wenjing: P11.52, **P11.57**
Zhu, Changbin: P11.12
Zhu, Liang-Yi: P01.01
Zhuoran, Wang: P12.01
Zielinska, Maria: P11.14
Zinnhardt, Bastian: P09.05, P14.67
Zubal, Michal: P11.41